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Abstract
Nowadays, screening uses the method of X-ray mammography for the early 
diagnosis of breast cancer. However, as a screening method, X-ray mammography 
has its limitations, such as age, periodicity of screening, ‘dense’ mammary gland 
and dynamic survey (repeated radiation). In order to overpass these limitations, 
more advanced alternative methods of breast examination should be used, which 
would be as effective as the ‘golden standard.’ Characteristics of electroimpedance 
diagnostics are given. The aim of screening is to detect breast cancer including early 
breast cancer (tumor size below 1 cm) and to form a survey of high-risk group. In 
order to reach these aims, the following actions need to be undertaken: search for 
areas with anomalous conductivity, detection of distorted mammographic scheme 
and evaluation of age-related electrical conductivity. The application of a scale for 
age-related breast conductivity with defined percentile limits allows to organize a 
survey group. Electrical properties of a cancerous tumor differ significantly from 
those of the surrounding tissues. Statistics of anomalous conductivity in cases of 
breast cancer is given. The disease development connected with the destruction of 
epithelial basement membrane is linked with various phenomena occurring in the 
tumor and the surrounding tissues. Statistics of disrupted mammographic scheme 
in cases of cancer is given.
Keywords: electroimpedance mammography, breast cancer, survey group, mammary 
gland structure, age-related electrical conductivity, anomalous conductivity, 
distorted mammographic scheme
1. Introduction: problems of breast cancer screening
In 1968 James Maxwell Glover Wilson and Gunnar Jungner supported by the 
World Health Organization published a research named [1]. In 1972 the American 
Cancer Society together with the National Cancer Institute developed the Breast 
Cancer Detection Demonstration Project, aimed to perform X-ray mammography 
breast cancer screening for more than quarter of a million of American women.
Since then, X-ray mammography has become not only the main screening 
method but also the ‘gold’ standard in diagnostics. It is important to distinguish the 
difference between screening tests and early diagnostics. Early diagnostics implies 
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detection of tumors in patients without symptoms [2]. Nowadays, screening uses 
X-ray mammography as the method of early diagnostics of breast cancer. However, 
used as a screening method, X-ray mammography has its limitations and draw-
backs. We’ll name some problems of the main screening method.
Age. Women aged below 40 usually do not undergo breast cancer screening 
since sensitivity of mammography is low in this population due to the high density 
of breast tissue [3]. It was discovered that mammographic screening under the age 
of 50 is not only less effective than in the elder age but is also related to higher radia-
tion risks [4]. Shifting of screening to the age range below 40 is undesirable since 
it will lead to the increase of patients’ radiation exposure. Age limitations for X-ray 
mammography are closely related to breast cancer morbidity.
Morbidity. According to the data of the Health and Social Care Information 
Centre [5], despite screening programs, breast cancer morbidity does not decrease; 
it remained on the same level for all age groups for 10 years since 2004–2005 till 
2014–2015 (Table 1). For the sake of solving the problem of morbidity, it would 
seem only natural to shift the screening framework down along the age scale. But 
age limitations do not allow for that.
Operational characteristics (sensitivity and specificity). Screening survey 
is a survey with low prevalence. As a rule, a low-prevalence survey is a preven-
tive checkup. Screening survey is characterized by unrestricted sampling, usually 
estimated in many thousands, by low prevalence, standardized procedure, signifi-
cant predominance of healthy patients over patients with pathologies, impossibility 
to use a reference method and histological verification of diagnosis due to a large 
number of healthy patients, significant predominance of early stage of disease 
among the affected patients and impossibility to apply operational characteristics, 
i.e. sensitivity and specificity. It is impossible to get operational characteristics and 
incidence data from the screening survey data. Operational characteristics can be 
received from the examination of patients with symptoms.
Table 2 shows operational characteristics of X-ray mammography received dur-
ing a 6-year period from a large group of patients with symptoms [6].
Sensitivity of X-ray mammography used for breast cancer diagnostics above 
80%, which would satisfy screening requirements, is observed only in the 70–79, 
80–89 and 90+ age groups.
Breast density. Breast cancer is often similar to X-ray density of fibroglandular 
tissue, which makes it difficult to distinguish these tissue types due to the masking 
effect of dense glandular tissue [7]. It explains the unreliability of X-ray mammog-
raphy for cancer diagnostics in women with high-density glandular parenchyma, 
with fibrocystic disease. Women with high mammographic density have higher 
Table 1. 
Women with cancer detected by age group.
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risk of breast cancer occurrence [8]. It has been proved that high mammographic 
density can be related to quadruple increase of breast cancer risk [9, 10].
Formation of survey or risk group. According to the definition of the World 
Health Organization, ‘there should be a recognizable latent or early symptomatic 
stage. The natural history of the condition, including the early stage, should be 
adequately understood.’ With the help of screening, it becomes possible to form 
breast cancer risk groups. Since ductal carcinoma takes origin from epithelial cells, 
areas with fibroglandular tissues and large amount of cells are highly susceptible to 
the increased epithelial proliferation [11]. It is the quantitative estimation of the state 
of fibroglandular tissue that should be used as the selection criterion allowing to 
differentiate the norm and the pathology. Patients with the amount of fibroglandular 
tissue abnormal for their age should become a part of the surveillance group. The 
existing screening methods do not allow to form breast cancer surveillance groups.
Repetitive examinations. Screening is a dynamic process. Recall of a patient 
for the screening program may cause anxiety or serious worries about potential 
illness, the so-called Ulysses syndrome, and lead to repeated radiation exposure 
[12]. In this connection, it is sensible to use safe screening methods that allow for 
multiple repetitive examinations. Frequency of examinations especially among 
high-risk group patients and in cases of hormone replacement therapy is chosen on 
an individual basis depending on the pathology detected.
Radiation exposure. Glandular tissue in the breast is most susceptible to 
radiation exposure compared to fat, skin and areola since immature cells are more 
vulnerable to ionizing radiation exposure [13]. And since ductal carcinoma takes 
origin from epithelial cells, it leaves one perplexed why X-ray mammography is 
used in breast cancer screening programs. Mammography has increased risks of 
radiation-induced breast cancer. Supposedly, low radiation dose is riskier than 
higher radiation dose [14, 15].
Rupture risk. The mammography procedure carries a risk of rupture of encap-
sulated cancer tumor, which may occur during the compression of breast tissue, 
and it may lead to metastases. Modern mammography equipment uses 42 pounds 
of pressure [16]. It may suffice for the disintegration of capsule and formation of 
metastases.
Mammography technique. According to the criteria of disease screening, 
the diagnostic method should be accessible and acceptable for the population [1]. 
Mammography technique can be evaluated through the analysis of the dose applied, 
the quality and size of the ray and the specific compression of breast. It has been 
established that the radiation dose and growth of breast cancer incidence are related 
[13]. Direct calculations of radiation dose (mGy) for a specific mammary gland are 
impossible. The difficulty lies in the knowledge of the structure of a specific mam-
mary gland, which is necessary for the calculation of the conversion ratio. For this 
Table 2. 
The number of patients attending the symptomatic breast clinic, by age and final diagnosis of either having 
breast cancer or not having breast cancer.
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reason, an average dose is used, which depends on the thickness of the breast. In 
modern mammographs, the exposition is selected automatically based on the thick-
ness of the compressed breast. Specific compression of the breast is the baseline for 
a good-quality image. Errors that may occur in the calculation of breast thickness 
during the compression of breast are related to the compression panel that may get 
bended and deformed.
These data show the necessity to implement additional effective screening 
programs for young women including screening with the application of alternative 
technology in order to lengthen the preclinical detection stage, which would lead to 
the decrease of breast cancer mortality rate [17]. In order to overcome the existing 
limitations, it is necessary to use modern alternative methods of breast examination 
that would be equal to the ‘gold’ standard in its effectiveness. Electrical impedance 
mammography is a diagnostic method satisfying the criteria set by the World Health 
Organization for screening for diseases. MEIK v.5.6, electrical impedance mammo-
graph developed and manufactured by PKF ‘Sim-technika,’ Russia, uses advanced 
technologies of imaging and processing of electrical impedance images of breast. It 
is a noninvasive technology of image creation, it uses 3D-tomography system, it is a 
form of ‘soft-field’ tomography, it applies ‘non-local’ method of tomographic image 
creation and cross-sectional approach to data collection, it uses back-projection 
method as the algorithm of image reconstruction, and finally it allows to receive 
quantitative diagnostic information. The electrical properties of biological tissue as of 
colloid-dispersed system in an alternating electric field depend on the concentration 
and behavior of the chemical components of the tissue. The electric properties of a 
tumor differ significantly from those of the surrounding tissues. The aim of screening 
is to detect breast cancer including early breast cancer (tumor size below 1 cm) and to 
form a survey or high-risk group. In order to reach these aims, the following actions 
need to be undertaken: search for areas with abnormal conductivity, detection of dis-
torted mammographic scheme and evaluation of age-related electrical conductivity.
2. Formation of survey group
Breast cancer risk factors. A notion exists of risk factors for breast cancer 
development. High breast density is one of the strongest risk factors for breast 
cancer development. Many of the stated risk factors for breast cancer influence 
breast density in the long run through hormones. Women with high breast density 
have higher concentration of estrogen in blood serum than women with lower 
breast density, and the risk of breast cancer for them is twice as high compared to 
the low level of circulating estrogens [18]. For women with extremely high breast 
density, the relative risk of breast cancer is four to eight times higher than high 
breast density or about two times higher than medium breast density [19]. Relative 
risk of breast cancer for women with extremely high breast density is 6.0 [with 95% 
confidence interval, 2.8–12.9], and it is the third risk factor after the patient’s sex 
and age [20]. Search for risk factors, diagnostics and preventive measures for high 
breast density forms a new field of research.
High breast density. Breast density is inversely proportional to the content of 
adipose tissue and directly proportional to the content of epithelial and fibrous 
tissue [21]. With advancing age, breast density decreases, and the breast tissue ‘ages’ 
[21]. Serial mammography showed that the initial breast density influences the 
change of density through life: age-related decrease of high density is stronger than 
the density decrease in cases of lower density [22]. It was found that there exists a 
relation between high breast density and hormonal status. The specific features of 
reproductive anamnesis, menstruation anamnesis, menopausal status, excessive 
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weight and exogenous and endogenous hormones influence breast density. Women 
with high breast density have higher concentration of estrogen in blood serum 
than women with lower breast density. Estrogen replacement therapy in pre- and 
postmenopausal period increases breast density [23–25]. Therefore, ‘breast density’ 
marker has higher potential as to being used for the prevention of breast cancer [26].
Methods of breast density estimation. Detecting women with high density of 
breast is the primary objective for screenings. Today there is no set ‘gold’ standard 
for the estimation of breast density. There are several methods for the assessment of 
breast density. Visual methods are based on the qualitative analysis of breast paren-
chyma, such as in Wolf’s, Tabàr’s, Boyde’s and BI-RADS classifications. The aim of 
semiautomatic estimation is to measure breast density. There exist automated systems 
for the estimation of the area of breast density. Volumetric methods allow to evaluate 
the actual volume of fibroglandular tissue. It should be noted that various methods of 
breast density measurement use only X-ray systems. There is a sharp need for addi-
tional screening of women with high breast density [27]. Due to the growing interest 
toward estimation of breast density, new diagnostic methods appear.
Electrical impedance estimation of breast structure. Biological tissue is 
presented as a colloidal dispersion system. The structure of breast has a number of 
tissues that fulfill different functions (epithelial tissues, connective tissues, nervous 
tissue, blood and lymph) and fill the anatomical structures. The electrical properties 
of tissues are the direct consequence of the tissue structure. The electrical impedance 
mammograph MEIK v.5.6. with current force 0.5 mA and frequency of 50 kHz allows 
to evaluate breast structure. The fundamental difference of electrical impedance 
scanning from other tomography methods is that besides visual evaluation of the 
image, the electrical impedance mammography provides quantitative informa-
tion, i.e. the numerical estimation of its anatomical and histological structure. This 
unique information is used for diagnostic purposes. All other factors equal, the 
electrical conductivity will depend on the concentration of ions and the amount of 
cellular elements, and it will decrease as the concentration grows [28]. The electrical 
conductivity index [IC], which is received during electric impedance scanning, is a 
quantitative characteristic of breast structure. Low index of electrical conductivity is 
typical for the breast containing a large amount of cellular elements and high con-
centration of ions, which corresponds to acinar-ductal type of breast structure. High 
electrical conductivity index is typical for the breast containing a large amount of fat 
lobules and connective tissue and low concentration of ions, which corresponds to 
amorphous structure of the breast. One thousand six hundred thirty-two processed 
images received from electromammographic examinations of healthy women helped 
to evaluate, percentile method applied, the structure of breast from the point of view 
of electrical impedance mammography. Table 3 shows percentile limits for different 
types of breast structure in electrical impedance mammography.
Therefore, the electrical conductivity index can be used for the evaluation of 
breast structure from the point of view of electrical impedance mammography. It is 
a known fact that the structure of breast defines the breast density. For this reason, 
the defined ranges of electrical conductivity correspond to different types of ‘den-
sity’ of breast. Table 4 shows the structure of the breast according to the electrical 
impedance mammography and types of density according to American College of 
Radiology [ACR] classification. ‘Dense’ breast, i.e. the so-called acinar-ductal type, 
is characterized by low electrical conductivity index. High electrical conductivity 
index is common for amorphous type of breast [consisting mostly of adipose and 
connective tissue]. The image shows examples of electrical impedance mammograms 
of patients from different age groups with different structure of breast: a 25-year-old 
patient with acinar-ductal type (Figure 1) and extreme breast density and 63-year-
old patient with amorphous structure and low breast density (Figure 2).
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to evaluate breast structure. The fundamental difference of electrical impedance 
scanning from other tomography methods is that besides visual evaluation of the 
image, the electrical impedance mammography provides quantitative informa-
tion, i.e. the numerical estimation of its anatomical and histological structure. This 
unique information is used for diagnostic purposes. All other factors equal, the 
electrical conductivity will depend on the concentration of ions and the amount of 
cellular elements, and it will decrease as the concentration grows [28]. The electrical 
conductivity index [IC], which is received during electric impedance scanning, is a 
quantitative characteristic of breast structure. Low index of electrical conductivity is 
typical for the breast containing a large amount of cellular elements and high con-
centration of ions, which corresponds to acinar-ductal type of breast structure. High 
electrical conductivity index is typical for the breast containing a large amount of fat 
lobules and connective tissue and low concentration of ions, which corresponds to 
amorphous structure of the breast. One thousand six hundred thirty-two processed 
images received from electromammographic examinations of healthy women helped 
to evaluate, percentile method applied, the structure of breast from the point of view 
of electrical impedance mammography. Table 3 shows percentile limits for different 
types of breast structure in electrical impedance mammography.
Therefore, the electrical conductivity index can be used for the evaluation of 
breast structure from the point of view of electrical impedance mammography. It is 
a known fact that the structure of breast defines the breast density. For this reason, 
the defined ranges of electrical conductivity correspond to different types of ‘den-
sity’ of breast. Table 4 shows the structure of the breast according to the electrical 
impedance mammography and types of density according to American College of 
Radiology [ACR] classification. ‘Dense’ breast, i.e. the so-called acinar-ductal type, 
is characterized by low electrical conductivity index. High electrical conductivity 
index is common for amorphous type of breast [consisting mostly of adipose and 
connective tissue]. The image shows examples of electrical impedance mammograms 
of patients from different age groups with different structure of breast: a 25-year-old 
patient with acinar-ductal type (Figure 1) and extreme breast density and 63-year-
old patient with amorphous structure and low breast density (Figure 2).
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On the Figure 2 you can find examples of electrical impedance mammograms 
of the same age group but with different breast structure: 36-year-old patient with 
acinar-ductal type and high tissue density and 34-year-old patient with amorphous 
structure and low tissue density (Figure 2). In order to form a survey group, it is 
necessary to determine not only the breast structure but also the correspondence 
between the structure type and age-related electrical conductivity of the breast.
Electrical impedance evaluation of age-related electrical conductivity of the 
breast. The application of percentile method for the electrical impedance mam-
mograms of healthy women in the following age ranges, <20, 20–29, 30–39, 40–49, 
50–59, 60–69 and >70 years old, allowed to evaluate age-related electrical conduc-
tivity of the breast from the point of view of electrical impedance mammography. 
For each age group, the 5th, 50th and 95th percentile limits of electrical conductiv-
ity were calculated. The data can be represented in the form of percentile curves of 
Table 4. 
The structure of the breast according to electrical impedance mammography and types of density according to 





Amorphous structure More than 0.66 >90‰
Mixed type with amorphous component prevailing 0.57–0.65 75–90‰
Mixed type 0.30–0.56 25–75‰
Mixed type with acinar-ductal component prevailing 0.22–0.29 10–25‰
Acinar-ductal type prevailing Less than 0.22 <10‰
Table 3. 
Percentile limits for different types of breast structure in electrical impedance mammography.
Figure 1. 
Type IV (ACR IV). Acinar-ductal type. Extreme tissue density.
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age-related electrical conductivity and in the form of a diagnostic table (Table 5). In 
accordance with the suggested estimations, the values in the 1st percentile corridor 
[below the 5th percentile] should be treated as significantly lowered, in the 2nd 
percentile corridor [5–25 percentile] as lowered, in the 3rd and 4th [25–75 percen-
tile] as medium, in the 5th [75–95 percentile] as increased and in the 6th [above 
the 95th percentile] as significantly increased. In order to form survey groups, it 
is necessary to use percentile limits of age-related electrical conductivity. The risk 
group should include the patients who have abnormally low values of age-related 
electrical conductivity of the breast, i.e. below the fifth percentile, which is the sig-
nal of high density of the acinar-ductal component of the breast for this age range. 
High density of acinar-ductal component is potentially dangerous since it may be 
combined with insufficient trophic function of connective tissue. It is a known fact 
that the ground substance of connective tissue plays the main role in the fulfillment 
of this function. Homeostasis disruption may lead to dystrophic processes including 
those in the basement membrane. Therefore, this method allows to detect the risk 
of tumorigenesis in women before the disease manifests itself, and it allows us to 
form risk groups for monitoring and correction of breast condition.
3. Early diagnostics of breast cancer
The electrical properties of cancer tumor differ greatly from the electrical prop-
erties of the surrounding tissues. It was established during several researches that 
malignant tumors have lower electrical impedance than normal tissues. The results 
of these studies are given in Table 6 [29].
S. Haltiwanger published the results of several studies about the specific features 
of tumor cells that influence their electrical activity:
Figure 2. 
Type I (ACR I). Amorphous type. Low tissue density.
Table 5. 
Diagnostic table of age-related electrical conductivity of breast.
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age-related electrical conductivity and in the form of a diagnostic table (Table 5). In 
accordance with the suggested estimations, the values in the 1st percentile corridor 
[below the 5th percentile] should be treated as significantly lowered, in the 2nd 
percentile corridor [5–25 percentile] as lowered, in the 3rd and 4th [25–75 percen-
tile] as medium, in the 5th [75–95 percentile] as increased and in the 6th [above 
the 95th percentile] as significantly increased. In order to form survey groups, it 
is necessary to use percentile limits of age-related electrical conductivity. The risk 
group should include the patients who have abnormally low values of age-related 
electrical conductivity of the breast, i.e. below the fifth percentile, which is the sig-
nal of high density of the acinar-ductal component of the breast for this age range. 
High density of acinar-ductal component is potentially dangerous since it may be 
combined with insufficient trophic function of connective tissue. It is a known fact 
that the ground substance of connective tissue plays the main role in the fulfillment 
of this function. Homeostasis disruption may lead to dystrophic processes including 
those in the basement membrane. Therefore, this method allows to detect the risk 
of tumorigenesis in women before the disease manifests itself, and it allows us to 
form risk groups for monitoring and correction of breast condition.
3. Early diagnostics of breast cancer
The electrical properties of cancer tumor differ greatly from the electrical prop-
erties of the surrounding tissues. It was established during several researches that 
malignant tumors have lower electrical impedance than normal tissues. The results 
of these studies are given in Table 6 [29].
S. Haltiwanger published the results of several studies about the specific features 
of tumor cells that influence their electrical activity:
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Type I (ACR I). Amorphous type. Low tissue density.
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Diagnostic table of age-related electrical conductivity of breast.






Nature of study and results
Fricke et al. 
[29], 1926
20 kHz They measured the parallel capacitance and resistance of the 
following excised samples from the breast—fat, gland, mastitis, 
fibroadenoma and carcinoma They found significantly higher 




100 Hz–100 kHz They performed in vivo impedance measurements on female breasts 
with and without tumors. Their results showed that malignant 
tumors have higher relative permittivity and lower resistance than 




3 MHz–3 GHz They examined excised normal and malignant breast tissues and 
found that the conductivity and permittivity of malignant tissues 





20 kHz–100 MHz They conducted in vitro dielectric studies in three different samples 
of breast tissues—the main tumor tissue, the tissue immediately 
surrounding the tumor and the peripheral normal tissue. They found 
that the tumor tissues have a low-frequency (100 kHz) conductivity 
around 2–4 mS/cm which is higher than the conductivity of normal 
tissue (below 1 mS/cm) and lower than that of the tissue surrounding 
the tumor (8 mS/cm).
Morimoto 
et al. [33, 34], 
1990
0–200 kHz They measured the extracellular and intracellular resistances and 
membrane capacitance of breast tumors in vivo. They concluded 
that there are statistically significant differences between normal 
and cancerous tissues. However, it has been reported that malignant 
tumors have lowered capacitance compared to benign tumors. This 
is different from the results of the study conducted by Jossinet [36] 




488 Hz–1 MHz The study examined six groups of normal and pathological breast 
tissues in vitro. The variability of impedivity within each group was 
assessed by statistical methods. It was found that the variability was 
smaller in adipose tissue, carcinoma and fibroadenoma above 10 kHz.
Jossinet [36], 
1998
488 Hz–1 MHz Using the same data from [35], it was found that the cancerous 
tissue differed significantly from fibroadenoma and mammary 
gland tissues by the modulus of impedivity up to 31.25 kHz and 
from the remaining tissue groups (connective tissue, adipose 
tissue and mastopathy) by the low-frequency-limit resistivity and 
the phase angle from 125 kHz to 1 MHz. It was also observed that 
neither the impedivity nor the low-frequency-limit resistivity nor 
the fractional power value was different between the groups of 
normal and benign tissues.
Jossinet et al. 
[37], 1999
488 Hz–1 MHz Again using the same excised data collected for previous studies, 
they defined a set of eight parameters that could differentiate 
cancerous breast tissues from noncancerous ones. They concluded 
that a combination of the parameters over various frequencies is 




10 kHz–10 MHz They conducted an in vitro study of normal and pathological 
breast tissues and observed significant differences in their 
dielectric properties. They have determined three indices based 
on extracellular resistance, intracellular resistance and membrane 
capacitance to differentiate between various tissue pathologies—
normal, invasive ductal carcinoma (IDC), IDC with stromal 
reaction and fibrocystic changes.
Table 6. 
The results of several researches of the electrical properties of cancer tumor.
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1. Cancer cells have cell membranes that exhibit different electrochemical proper-
ties and a different distribution of electrical charges than normal tissues [30].
2. Cancer cells also have different lipid and sterol content than normal cells [31].
3. Cancer cells have altered membrane composition and membrane permeability, 
which results in the movement of potassium, magnesium and calcium out of 
the cell and the accumulation of sodium and water into the cell [32].
4. Cancer cells have lower potassium concentrations and higher sodium and 
water content than normal cells [33, 34].
5. The result of these mineral movements, membrane composition changes, 
energy abnormalities and membrane charge distribution abnormalities is a 
drop in the normal membrane potential and membrane capacitance.
6. An increase in the intracellular concentration of positively charged sodium 
ions and an increase in negative charges on the cell coat (glycocalyx) are two 
of the major factors causing cancerous cells to have lower membrane potential 
than healthy cells [31].
7. Two of the most outstanding electrical features of cancer cells are that they 
constantly maintain their membrane potential at a low value and their intracel-
lular concentration of sodium at a high concentration [34, 35].
8. A sustained elevation of intracellular sodium may act as a mitotic trigger caus-
ing cells to go into cell division [35].
The results of the researches confirm that electrical conductivity is an appropri-
ate parameter for the differentiation between healthy tissue and tumor tissue. The 
fundamental difference of electrical impedance scanning from other tomographic 
methods is that besides visual evaluation of the image, the electrical impedance 
mammography offers quantitative information [28]. If the diagnostic method under 
discussion yields a quantitative result, a value is defined, the overpassing of which is 
deemed to be a sufficient cause for qualitative evaluation, i.e. the so-called dif-
ferentiation point. It is essential to define a precise differentiation point. The point 
with electrical conductivity exceeding 3 standard deviations [std] is considered to 
be the point of differentiation between breast cancer patients and healthy people. 
The detection of areas with high electrical conductivity exceeding 3 std. outside the 
lactiferous sinus in electrical impedance mammograms, which differs greatly from 
the electrical conductivity of normal breast tissue, is used as a diagnostic criteria 
for the detection of breast cancer [28]. Moreover, sizes of tumors as a rule do not 
exceed 10 mm.
Figure 3 shows the electrical impedance mammogram of a breast cancer patient 
with the following parameters: IC = 0.56, std. = 0.12. In the mammogram, at the 3 
o’clock position near the areola, a focus without a sharp contour is visualized, its IC 
being equal to 0.94. Therefore, the IC in the area of interest exceeds the mammo-
gram IC by more than 3 std.
Below X-ray images [fibroadipose involution, the upper external quadrant shows 
a mass less than 1 cm in size with uneven contour] and ultrasound mammograms 
[the external quadrant contains a lesion of irregular shape with uneven structure, 
7 × 8 mm in size, with vascularization] of the same patient are presented.
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being equal to 0.94. Therefore, the IC in the area of interest exceeds the mammo-
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For the last few years, clinical studies have been held in different countries 
determining the potential of electrical impedance mammography in breast cancer 
diagnostics. All these studies used electrical impedance computer mammograph 
MEIK v.5.6, abnormal electrical conductivity being the diagnostic criterion [28].
Sachin Prasad and colleagues performed a study to determine the diagnostic 
efficiency of 3D electrical impedance tomography [EIT] compared to mam-
mography (mg) and ultrasonography (USG) in breast imaging [36]. A group of 
88 patients with various breast complaints was examined using combined mam-
mography and ultrasonography [MG & USG] or either of these modalities alone. 
The same patients were then examined using the 3D EIT imaging system MEIK. The 
study revealed that there was no overall significant difference in sensitivity between 
MG-USG [p = 0.219] and MG-EIT [p = 0.779] and USG-EIT [p = 0.169].
O. Raneta and colleagues [37] performed a study to analyze the possibilities of 
electrical impedance tomography [EIT] application in the differential diagnosis 
of pathologic lesions of the breast either solely or in combination with MMG/USG 
[37]. A group of 870 eligible women with suspected pathological breast lesion dis-
covered by mammography [MMG] or ultrasound examination [USG] were recom-
mended to pass histological examination to verify the diagnosis. The sensitivity of 
MMG increased from 87.8% when using it as an independent method to 94.5% with 
EIT added. The sensitivity of USG increased from 86.7% when used as an indepen-
dent method to 93.3% with EIT added. The results of the study showed that the use 
of EIT in addition to MMG/USG can improve the sensitivity of these methods and 
Figure 3. 
Upper row: Electrical impedance mammogram of a breast cancer patient. At the 3 o’clock position near the 
areola a focus without a sharp contour, with abnormal electrical conductivity, is visualized. It is colored red 
(7 × 10 mm). The lower row shows X-ray and ultrasound images for the same patient.
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increase the rate of early detection of breast cancer with minimal economic costs 
and time input of highly qualified staff.
Daglar and colleagues [38] performed a study to compare the usefulness of the 
breast electrical conductivity measures performed in a surgical examination room 
against conventional breast screening modalities for identifying the symptomatic 
lesions of the breast tissue [38]. A group of 181 patients were examined with 
ultrasonography [USG], mammography [MG] and electrical impedance scanning 
[EIS] modalities, which were followed up for 24 months to clarify the lesion tumor 
progression relationship. EIS exhibited compatible sensitivity [81.2%], accuracy 
[84.6%] and PPV [81.8%] rates with USG in BI-RADS 4 subgroup, combination of 
these modalities raised sensitivity rates to 92.31%, accuracy and PPV to 100%. EIS 
results in BI-RADS 3 subgroup were pointed out 77.8% specificity and 87.5% NPV 
rates. Breast electrical impedance measures should be useful to reduce the number 
of the unnecessary follow-up and biopsy rates in the clinical setting.
Xu Feng and colleagues [39] performed a study to investigate the diagnostic 
accuracy of electrical impedance tomography [EIT] for benign and malignant 
breast diseases in comparison to conventional ultrasonography and mammography 
[39]. A total of 121 patients with 126 breast lesions who underwent ultrasonogra-
phy mammography and EIT were enrolled in the study. All of these lesions were 
confirmed by pathological biopsy. The accuracy, sensitivity, specificity, positive 
predictive value and negative predictive value of EIT, ultrasonography and mam-
mography were calculated with histology used as the ‘gold’ standard. The accuracy 
of EIT, ultrasonography and mammography were 75.4, 81.7 and 76.1%, respectively. 
The sensitivity was 76.8, 94.6 and 74.4%, respectively. The specificity was 74.3, 71.4 
and 77.6%, respectively. The accuracy, sensitivity and specificity of EIT combined 
with ultrasound in the diagnosis of breast lesions were 91.3, 98.2 and 85.7%, respec-
tively. The accuracy [χ2 = 4.896, P = 0.027] and specificity [χ2 = 4.242, P = 0.039] 
were significantly higher on EIT than ultrasound. The accuracy, sensitivity and 
specificity of EIT combined with mammography were 95.5, 97.4 and 93.9%, respec-
tively, which were significantly higher than those of mammography [χ2 = 13.474, 
P < 0.001; χ2 = 8.573, P = 0.003; χ2 = 5.333, P = 0.021]. Used together with ultra-
sound or mammography, the electrical impedance tomography could be a valuable 
complementary examination in the diagnosis of breast diseases. Furthermore, EIT 
could provide very useful additional information for metabolic assessment of mam-
mary glands, which may be used for early screening of breast diseases.
Blanca Murillo-Ortiz and colleagues [40] performed a study to know the effec-
tiveness of the electrical impedance mammography for the detection of mammary 
carcinoma in 615 women from 25 to 70 years of age [40]. The sensitivity and 
specificity of the electrical impedance mammography (MEIK) was 85 and 97%, 
respectively.
Therefore, the studies showed high level of sensitivity and specificity, which 
allows to use abnormal electrical conductivity as the diagnostic criterion in screen-
ings for early detection of breast cancer.
4. Distorted mammographic scheme in cases of breast cancer
Distortion of normal mammographic scheme appears in case of structural 
changes, such as pathological shadows and microcalcifications. These focal changes 
can be easily detected with the help of medical equipment checking the density of 
tissue. But along with focal changes, breast cancer can reveal itself through diffuse 
changes of breast structure, which also leads to the disruption of normal mammo-
graphic scheme, and this can be detected with electrical impedance mammography. 
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For X-ray diagnostics, diffuse changes are a difficult matter since they do not 
change the density of breast tissue.
As the disease develops, which leads to the destruction of the basement mem-
brane of the epithelium, the lesion and surrounding tissues may undergo various 
phenomena followed by changes of electrical properties of the tumor mass:
• Edema and softening of fibrous connective tissue
• Slimming, hyalinosis, calcification
• Appearance of purulent areas
• Lymphocytic infiltration of tissue
Therefore, tumor growth is naturally accompanied by the changes of electrical 
properties of tumor and surrounding tissues. The criteria of distortion of normal 
mammographic scheme in cases of breast cancer are changes of contour, anatomical 
changes, local changes of electrical conductivity and change of comparative electrical 
conductivity. As previously stated, the electrical impedance method gives a possibility 
of quantitative imaging [28]. Quantitative analysis of an electrical impedance image 
allows to receive a histogram of electrical conductivity distribution and compares it 
with reference values. As a rule, distorted mammographic scheme in case of breast 
cancer is accompanied by changes of electrical conductivity of breast tissues. This phe-
nomenon facilitates visual and quantitative interpretation of the lesion and can be used 
for diagnostic purposes. Figure 4 shows several variants of distorted mammographic 
scheme in cases of breast cancer and their visual evaluation [1, contour deformation; 
2,4, thickening of contour; 3, anatomic distortion; 5,6, local changes].
For the classification of a patient (healthy or affected), test of differences in the 
form of distributions [λ criterion], i.e. Kolmogorov-Smirnov test in Dx modifica-
tion, is used [41]. This criterion, which is a nonparametric test, allows to determine 
the statistical value of differences in the distribution of any normal or abnormal 
features, including the distribution of electrical conductivity in electrical imped-
ance tomograms. For the assessment of informativeness of distribution divergence, 
Kulback informativeness measure is applied [41]. High informativeness of the 
detected differences allows to refer the patient with high degree of probability to 
one class or the other (e.g. norm or cancer). In case of breast cancer, histogram of 
affected breast gets displaced, and Dx criterion exceeds 40% (Figure 5).
Table 7 shows the comparative electrical conductivity data for patients with 
breast cancer, benign changes, for healthy patients and for those with different 
types of breast structure; the data was received during clinical studies in the hospi-
tals of Russia. It is evident that divergence of histograms of electrical conductivity 
distribution by more than 40% is observed only in cases of breast cancer, and actu-
ally divergence of histograms of electrical conductivity distribution by more than 
30% in the majority of cases is observed during oncological processes in the breast.
Figure 4. 
Several variants of distorted mammographic scheme in cases of breast cancer.
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Figure 5. 
Upper row, EIM. Seven scan planes. Breast cancer. Bottom row, EIM. Seven scan planes. Healthy breast. The 
second row shows the divergence between the histograms of electrical conductivity distribution of the affected 
and healthy breast.
Table 7. 
Percentage distribution of healthy patients, patients with benign changes and breast cancer depending on the 
percentage of comparative electrical conductivity of the breasts.
EIM ACR
Common scale BI-RADS categories
No score BI-RADS 0 poor image
0–1 BI-RADS 1 lesion is not defined
2–3 BI-RADS 2 benign tumors—routine mammography
4 BI-RADS 3 probably benign findings
5–7 BI-RADS 4 suspicious abnormality—biopsy
>8 BI-RADS 5 highly suggestive of malignancy—treatment/biopsy
Table 8. 
EIM scale and ACR BI-RADS.
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During the oncological process, natural changes of general and local electrical 
conductivity occur. And distortion of normal mammographic scheme may occur at 
an early stage of the disease. This is the reason why this criterion is included in the 
EIM scale of breast cancer diagnostics [41].
A scoring scale used for the evaluation of mass lesions in the breast by means 
of electrical impedance mammography allowed to relate the information received 
with BI-RADS ACR categorization (Table 8). The EIM scoring scale allowed to 
standardize the description of mass lesions examined by means of electrical imped-
ance mammography and to use the patient follow-up algorithm developed by the 
American College of Radiology.
Therefore, the distortion of normal mammographic scheme along with abnormal 
electrical conductivity is one of the most frequent diagnostic indicators of breast cancer.
5. Discussion
Sensitivity and specificity are operational characteristics that allow to evaluate 
the effectiveness of a diagnostic method. Operational characteristics are influenced 
by several factors: size and area of pathology, age of patients in the groups under 
study and prevalence in the group under study. In the process of sensitivity and 
specificity calculation, the disease prevalence in the group is not taken into account. 
It is a significant benefit since it gives a possibility to spread the data received in a 
group of people onto other groups, with different prevalence. However, it is also a 
drawback of evaluation. The diagnostic test data should be spread cautiously onto 
groups of people that differ significantly from the group under study.
The calculation method used for operational characteristics such as sensitivity 
and specificity has its own peculiarities in cases of low and high prevalence.
Low-prevalence studies. As a rule, studies with low prevalence are preventive 
checkups. Screenings are low-prevalence studies as well.
Characteristics of screenings:




• Significant prevailing of healthy patients over patients with pathologies
• Impossibility to use reference method and histological verification of the 
diagnosis due to a large number of healthy patients
• Significant prevailing of patients with early stages of disease from among the 
number of those with revealed pathologies
• Impossibility to apply operational characteristics: specificity and sensitivity
High-prevalence studies. Studies performed in a diagnostic department of a 
specialized clinic are high-prevalence studies.
Characteristics of a diagnostic study:
• Restricted sampling population, several dozens of respondents
17




• Significant prevailing of patients with pathologies over healthy ones
• Significant prevailing of patients with progressing disease over those with 
early stages
• Use of referential method and histological verification of diagnosis
• Application of operational characteristics: sensitivity and specificity
Medium prevalence, which can be called an intermediate link, is a study held in 
a diagnostics department of a general practice clinic.
Characteristics of a diagnostic study:
• Unrestricted sampling population and timing
• Medium prevalence
• Standardized methodology
• Prevailing of healthy patients over patients with pathologies
• Full range of disease manifestation: from early-stage patients to patients with 
progressing disease
• Use of referential method and histological verification of diagnosis
• Application of operational characteristics: specificity and sensitivity
Is it correct to spread operational characteristics received from the second and 
third examples onto the screening?
1. Spreading the estimations received in high-prevalence conditions onto low-preva-
lence conditions should be done with caution. High-prevalence spectrum of disease 
manifestations differs from low-prevalence spectrum. Since diagnostic centers 
accumulate patients with a certain disease, in the structure of high-prevalence cases 
of progressing disease dominate significantly over early stages of disease.
2. Since every stage of disease has its own symptoms or specific criteria, for every 
stage the diagnostic criteria should have their own operational characteristics.
3. Operational characteristics are determined on the basis of restricted sample 
group of patients with verified diagnoses. Since reference tests, as a rule, are 
indifferent for the respondents, in such studies the number of persons not 
affected by the disease under study is minimal. In case of data spreading, it can 
influence the expected number of false-positive and false-negative results.
4. The optimal study for receiving operational characteristics of the method used 
from the point of view of patient selection, prevalence level, from the point of 
view of commonality of the methodology used and the usage of the reference 
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method and histological verification is not a low-prevalence study, such as 
screening, and is not a high-prevalence study as inpatient examination but a 
study held in an imaging room for the prevalence typical for the settlement. 
Shifting of operational characteristics in the situation of medium prevalence is 
preferable since it has a well-balanced data set.
Electrical impedance mammography is a tool for primary breast cancer screen-
ing. It is confirmed by its high informativeness, safety for the staff and patient, 
portability and mobility. Operational characteristics (sensitivity and specificity) are 
determined on a restricted sample group, the so-called high- and medium-preva-
lence group, with the use of reference method (X-ray mammography) and verified 
diagnosis. The studies were held in oncological centers and clinics. The study on a 
group of patients with high and medium prevalence demonstrated high sensitivity 
and specificity of the electrical impedance mammography. The received operational 
characteristics can be spread onto groups of patients with low prevalence and be 
used during planning of screening studies. It allows to use the electrical impedance 
mammography for primary breast cancer screening of big groups of population 
with low prevalence. The electrical impedance mammography fulfills its functional 
screening tasks without ionizing radiation and other potentially hazardous means. 
It can be used to perform examinations for women of all age groups in outpatient 
departments, schools, clinics for women, maternity hospitals and sanatoriums, i.e. 
in the gathering places for women. In such a way, the problem of organization of 
mass screening for women can easily be solved.
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method and histological verification is not a low-prevalence study, such as 
screening, and is not a high-prevalence study as inpatient examination but a 
study held in an imaging room for the prevalence typical for the settlement. 
Shifting of operational characteristics in the situation of medium prevalence is 
preferable since it has a well-balanced data set.
Electrical impedance mammography is a tool for primary breast cancer screen-
ing. It is confirmed by its high informativeness, safety for the staff and patient, 
portability and mobility. Operational characteristics (sensitivity and specificity) are 
determined on a restricted sample group, the so-called high- and medium-preva-
lence group, with the use of reference method (X-ray mammography) and verified 
diagnosis. The studies were held in oncological centers and clinics. The study on a 
group of patients with high and medium prevalence demonstrated high sensitivity 
and specificity of the electrical impedance mammography. The received operational 
characteristics can be spread onto groups of patients with low prevalence and be 
used during planning of screening studies. It allows to use the electrical impedance 
mammography for primary breast cancer screening of big groups of population 
with low prevalence. The electrical impedance mammography fulfills its functional 
screening tasks without ionizing radiation and other potentially hazardous means. 
It can be used to perform examinations for women of all age groups in outpatient 
departments, schools, clinics for women, maternity hospitals and sanatoriums, i.e. 
in the gathering places for women. In such a way, the problem of organization of 
mass screening for women can easily be solved.
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Chapter 2
Detection of Breast Cancer in




This research proposes a new framework for detection of breast cancer in
mammograms. It extracts certain dynamic features to distinguish between benign
and malignant mammograms. To this aim, this framework uses set of various
techniques. First step we have achieved improvement on breast mammogram to
improve the image accuracy based on this framework, after new method has been
used for features extraction. New methods named Sparse Principal Component
Analysis and Weighted Sparse Principal Component Analysis are used to select the
distinctive features of the mammograms. The analyzed mammograms are then
identified as benign or malignant through codebook technique is more efficient
than other on the MIAS data set. The proposed framework tested on MIAS data set
achieved an overall classification accuracy of 98% with codebook classifier for
sequential selection of benign and malignant mammograms. Suggested method
achieves good results when we have verified on various mammograms.
Keywords: chest cancer, mammograms feature extraction, weighted features,
codebook design technique
1. Introduction
There are a number of renowned and probable causes for chest cancer. These
can be split into seven broad classes: hormonal factors, age, proliferate chest dis-
ease, family history of chest cancer, lifestyle factors and [1–5]. Estimates show with
the development of technology, radiation scientists have the opportunity to
advance their interpretation of image using computer technology capabilities that
can develop image resolution from mammography [6–11]. A variety of computer
assisted diagnostic systems were proposed such as [12, 13]. In this paper, enhanced
Principle Component Analysis (PCA) was used to extract features. Although PCA
has been widely applied in the area, but the features considered in this study have
not been extracted before [14]. Further, these extracted features are reduced to the
best features only. This process is accomplished by two variations of PCA as Sparse
Principle Component Analysis (SPCA) [15, 16] and Weighted Sparse Principle
Component Analysis (WSPCA). The choice of the (ideally “small”) number of
principal components (PCs)to include into the description of the data without
losing too much information was somewhat arbitrary [14]. Codebooks represents is
final optimized codebook for samples will be generated. It can represent the attri-
butes of the mammograms images more adequately. Proposed technique realized
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quite perfect. Project is ordered displayed in stage first. Stage second presents
related work. Stage third defines the suggested method. Stage forth contains
experimental outcomes and conclusion is presented in stage fifth.
2. Proposed technique
The projected method is split into four major phases as presented in Figure 1.
The first phase is representing enhancement by applying histogram equalization,
the second phase is representing feature selection, the third phase is representing
codebook and the final phase is representing Design Classifier. Every part of these
four phases is defined below one after another.
2.1 Enhancement for image
In this phase, the improvement is focused in flat regions avoid over development
decreased influence of edge shadowing.
2.2 Features extraction




Breast Cancer and Breast Reconstruction
2.2.1 Discrete cosine transform (DCT)
Features Discrete cosine transform (DCT) is applied for converting the
signal into its frequency parts. DCT has the property of separability
and symmetry. 2-Dimensional DCT of the input is presented by the following
equation:



























In the past, researchers used to reduce the dimensions apply PCA here. Each
PC is basically a linear combination of all the original features. This makes the
results difficult to interpret [14, 16]. Various approaches have been attempted to
overcome this problem. We present a novel technique called WSPCA applying
LASSO (elastic net) to generate modified PCs with sparse loadings. Important
features are selected based on their weights. The aim behind is to use WSPCA to
construct a regression framework in which PCA is reconstructed exactly, and use
LASSO to construct modified PCs with sparse loadings. Then important features
are selected with adaptive feature’s weights to find the best loading vector
corresponding the features to achieve high accuracy. The uncorrelated linear
combinations are called principal components, which express maximal variations
in the data. This provided the researchers with a method of transforming the
original high-dimensional dataset into one of the much lower dimension. This
method was devised inevitably at the cost of some information loss (variance) and
limited ability to interpret new variables and analysis. SPCA can successfully
derive sparse loadings.
Despite of its positive aspects, SPCA is not efficient in identifying important
features with high accuracy. It also lacks a better step to choose its regulation
parameter [14, 16]. WSPCA uses strict criterion and flexible control for selected the
important features. To fit our WSPCA models for both features weights expression
arrays and regular multivariate features, an efficient algorithm is proposed. In
addition, we propose a novel form to calculate the total difference of the modified
PCs. In this study, the algorithm for WSPACA in parallel to PCA and SPCA is
presented in detail with example: let DCT features (variables) F = (F1, F2... Fp)’
represent a p-dimensional random vector with a multivariate normal distribution.
It is possible that some features correlate with one another. For instance, if the
variables F1 and F2 are highly correlated, such that the correlation index between F1
and F2 approaches 0.9, then either F1 or F2 could be eliminated from the analysis as
its role is duplicated by the other. By doing this, the basis of the original features is
altered to a more efficient set by using linear combinations. In the general
p-dimensional case, this leads to a candidate set of new features. The explained
steps are presented in Algorithm 1.
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Algorithm 1
Step 1: Suppose A beginning at V [1: k], the loadings of the headmost k (PCs).




W jX j , j = 1,… .,n (2)




þ Sign αTj XWTXW
� �
, j = 1,..,k (3)
Step 4: For a fixed β j = [βSPCA1,...,βSPCkf], PCA can be found via compute the SVD of the features
matrix, calculate the SVD of XWTXW = UDVT, (4)
then update A = UVT. (5)
Step 5: reiterate Steps 4–5, until concourse.




In step 1, the presented PCs are the linear combinations of all original features, V is
the response vector (nonzero components) and it is less than or equal to k, given an
integer kwith 1≤ k≤ p. In Step 2, A is a vectormatrix. In Step 3, assumed variables of X
are presented in (n�p)matrix, where n rows represent an independent feature from
features (number of observations) and p is the number of variables (dimensions),
where is spare coefficients, j be the predictors for nonzero entries, is feature vector,
XTX is represent (covariance matrix) transpose for vector matrix by row vector of
features, where represents the norm in the constraint. In the present research, in order
to find the optimal number of features, λ is penalty by directly imposing a constraint on
PCA and λ1, j = 0 call SPCA criterion r. B = (β0, β1, β2,., βk)T, where its regression
coefficients represent the optimal minimizing. In Step 4, SVD is a singular value
decomposition, UD are PCs, the columns of VT are the consistent loading of the PCs
eigenvectors, V diagonalizes the covariance matrix XTX, U are called Eigen values of
the covariance matrix, D is the diagonal matrix, which has the eigenvalues of covari-
ance matrix. XTX and V are the Eigen—genes, which represent the sparse loading of
featurematrix. In Step 6,Wj is weighted features, and, βj = [βSPCA1,..., βSPCAf]. Then
(XW)was calculated, which represents weighted feature matrix.Where X is a new
feature matrix of SPCA and represents eight types of features.
Coefficients for WSPCA technique were obtained by minimizing both SPCA and
weighted feature matrix [17, 18]. In Step 7, represents highly correlated by weighted
features among all features, is penalty by directly imposing an constraint on PCA
and (λ1, j = 0), represents to exclude redundant features with very little variation
from other features that sufficiently represents it. This is where adaptive weights
were used for penalizing different coefficients in the 1 penalty, Here, we can ignore
the penalty part in calculating Step 8.
Then, AW = UVT was updated where PCs were selected for displaying the
selected features. Thus, a large dimensionality decrease was realized. Then after
(Vj), normalization was calculated for approximated weighted sparse principal
components. Step 9 was where βWSPCA was the WSPCA coefficient.
2.4 Codebook design
After representing each set of features, hierarchical clustering groups the fea-
tures selection based on similarity to build a hierarchy of clusters. This clustering
approach starts with each object as a single class and merges objects into the classes
until all objects are in one cluster [18, 19]. The proposed technique needs to define a
dimension measure allowing comparison of two classes. The operation of a hierar-
chical clustering is illustrated in Figure 2.
As an example, seven labeled patterns are shown in Figure 2a, in this research
these seven labeled pattern can be consider as seven fragmented windows, which is
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then group together in a single cluster. Figure 2b represents the binary tree
corresponding to the patterns in Figure 2a. In the binary tree, each patterns are the
leaves, each branching points are the similarity between sub-trees. Horizontal cuts
using different line patterns in the tree represents classes.
The distance between the two classes can be calculated as the minimum, maxi-
mum or the average of the dimensions between attributes of patterns in different
clusters. This research employed the average-link method for clustering. In this
method, the distance between two categories is defined as the average of the
dimensions between all the objects in the two categories. This method is expressed
by the next equation.
ð7Þ
where, ci and cj be two categories. Dist defines the dimension between ci and cj.
In addition, since the number of classes for each mammogram is not known, this
study uses the distance criterion to represent the number of cluster. For each mam-
mogram the proposed technique generates the clusters from the important features.
In this research, the important features clusters are also termed as codebooks.
3. Outcomes and discussion
We have applied widely presented datasets MIAS [20]. The database image of 69
mammograms were being benign, 54 malignant also 207 normal Improvement has
been done by histogram equalization. Outcomes have been display in Figure 3.
Once the codebook for important features are generated, the proposed technique
Figure 2.
Points falling in hierarchical cluster in (a) and binary tree of hierarchical clustering in (b).
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Algorithm 1
Step 1: Suppose A beginning at V [1: k], the loadings of the headmost k (PCs).
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sorts the classes according to the cardinality and keeps only those classes which
have sufficient number of features. As a codebook produced from feature selection
are illustrated in Figure 3, respectively.
Figure 3.
Results by histogram equalization (a, a1); original images (b, b1); and histogram equalized images.
Figure 4.
Mammograms: codebook obtained from the important features on a mammograms sample.
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In codebook there are different number classes. Each class contains relatively
homogeneous groups of similar forms, which are dissimilar to elements in the other
classes. These classes are separated by the black window in the codebook as
illustrated in Figure 4.
Once the codebook is generated for each mammograms sample, the next step is
to determine how to use this information to represent mammograms sample
recognition as discussed in the following section.
4. Verification
These codebooks contain different information about a mammograms image
and complement each other. It would therefore be a good idea the codebooks to
compare two mammogram images. When two mammogram images are compared,
the proposed technique computes the distance between them using their code-
books. The final dimension between the two mammogram samples is calculated as a
weighted combination of the two distances (Table 1).
5. Conclusion
Suggested method is improved for test the breast cancer from mammograms.
This technique achieves this testing in multiple stages. The preprocessing stage on
improve image accuracy. Features selection by SPCA and WSPCA has been
achieved. Codebook generated for each mammograms sample represent classify as
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Breast cancer remains the most common female cancer worldwide. The major-
ity will arise spontaneously, with almost a third having a heritable component. 
Approximately 5–10% of all breast cancers will have a strong inherited element 
with pathogenic variants in the BRCA1 and BRCA2 amongst the most studied 
breast cancer genes. An overview of breast cancer is provided with references to the 
clinical and pathological features in BRCA1 and BRCA2 related cancers. The roles 
of PARP inhibitors and immunotherapy are discussed. The management of healthy 
individuals harbouring a pathogenic variant in the two genes is reviewed and future 
directions considered.
Keywords: BRCA1, BRCA2, breast cancer, risk reduction, mastectomy,  
pathogenic variant
1. Introduction
Breast cancer remains the most common cancer amongst women in the world 
[1]. In the UK, 25% of all female cancers originate from the breast with estimates 
that 1 in 7–10 will develop this disease during their lifetime [2]. In 2018, there were 
over 2 million new cases of breast cancer worldwide, accounting for almost 12% of 
all cancer [3]. In developed countries, almost 80% of breast cancers occur in post-
menopausal women, predominantly in the Caucasian population.
Breast cancer represents a heterogenous disease process and an understanding 
of the clinical aspects is required prior to appreciating the aspects of breast cancer 
amongst BRCA1/2 pathogenic variant (PV) carriers.
2. Invasive or in-situ (non-invasive cancer)
The vast majority of breast cancers are invasive (up to 90%) presenting via 
a symptomatic pathway. In contrast, in-situ disease tends to be more commonly 
identified via breast screening programmes (e.g., NHSBSP) with advances in 
digital mammography or incidentally. In the USA, in situ disease comprises 
almost 25% of all breast cancers, 80% of which are identified by breast  
screening [4].
In histopathological terms, invasive cancers will have breached the basement 
membrane with metastatic potential compared with the more innocuous in-situ 
disease where the disease process is contained within the basement membrane, with 
theoretically limited or no metastatic potential.
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3. Ductal or lobular origin
The microanatomy of the breast can be considered to comprise of terminal 
ductal lobular unit [5, 6]. Each breast lobule is by a collecting duct terminating in 
the lobule. This serves as the basic functional unit of the breast. Invasive ductal car-
cinoma (also termed no special type carcinoma) represents the most common type 
of breast cancer accounting for almost 80% of cancer. Invasive lobular carcinoma is 
less common accounting for almost 10% of cases.
These two types of breast cancer are biologically different. Invasive lobular cancers 
tend to have a more spreading growth pattern, meaning that they can be more difficult 
to diagnose or size on routine mammograms or clinical examination. In addition, they 
may be resistant to neo-adjuvant chemotherapy. Invasive lobular cancers tend to be 
more hormone-sensitive, HER2 negative and lower grade breast cancer (see below).
4. Grade of breast cancer
This refers to the microscope assessment of the breast cancer and determining 
how the cells look compared with normal breast tissue [6]. This in turn will predict 
the biological activity of the breast cancer, with high-grade tumours considered to 
be faster growing with a more aggressive behaviour.
4.1 Grades in in-situ disease
Low grade—slow growing and more closely resemble normal breast tissue.
Moderate/intermediate grade—more abnormal looking compared with low 
grade, with a more rapid growth pattern.
High grade—cells look quite different to normal breast tissue, grow quicker with 
an increased chance of progressing to an invasive cancer.
4.2 Grades in invasive cancer
There are three different grades of invasive breast cancer based on an assessment 
of tubule formation, nuclear pleomorphism and mitotic count:
Grade 1 (well differentiated).
Grade 2 (moderately differentiated).
Grade 3 (poorly differentiated).
5. Hormone receptor status
Oestrogen receptors (ER) were first identified in 1958 (Elwood, Chicago) but an 
appreciation of the hormonal component of breast cancer predates this to the 1890s 
when George Beatson performed oophorectomy as a treatment for breast cancer in 
women [7]. It still remains a critical biological factor in the modern day manage-
ment of breast cancer.
The oestrogen (ER) and progesterone receptors (PR) relevant to breast cancer 
are intracellular receptors that are activated by the hormone oestrogen (17 beta 
oestrodiol) acting as a DNA-binding transcription factor, in particular stimulation 
of mammary cells.
Approximately 70–80% of breast cancers overexpress ER [8]. These hormone 
sensitive breast cancers may be treated with anti-hormone therapy by either selec-
tive oestrogen receptor modulators (e.g., Tamoxifen) or aromatase inhibitors.
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6. HER2 receptor status
The HER2 receptor (human epidermal growth factor receptor) is a trans-
membrane tyrosine kinase that is overexpressed in 15–20% of breast cancers [9]. 
Amplification of this oncogene is considered a marker of aggressiveness and is an 
important biomarker for targeted therapy. Drugs targeting the HER2 receptor (e.g., 
Trastuzumab, Pertuzumab) have significantly altered the clinical outcomes of 
otherwise poor prognosis HER2 positive breast cancers.
7. Molecular subtypes of breast cancer
Gene expression profiling has enabled molecular classification of breast cancer 
into intrinsic subtypes [10] that include:
1. Luminal A: hormone receptor positive (ER/PR +ve) and HER2 negative. They 
express low levels of the protein Ki-67, a cellular marker for proliferation. 
These cancers tend to be low grade, slow growing, good prognosis cancers.
2. Luminal B: hormone receptor positive (ER/PR +ve) and either HER2 positive 
or negative with a high level of Ki-67 expression. Faster growing and worse 
prognosis than luminal A cancers.
3. Triple negative breast cancer (TNBC)/basal-like: these are hormone receptor 
negative and HER2 negative (ER/PR/HER2 −ve). This accounts for 10–20% of 
all breast cancers, more commonly found in women with a BRCA1 PV, young 
women and African-American women. It is a rapidly growing, poor prognosis 
cancer.
4. HER2-enriched: these are HER2 positive and ER/PR negative cancer (HER2 
+ve, ER/PR −ve). They tend to grow faster than luminal cancers but can be 
treated with targeted therapies.
8. Treatments for breast cancer
The management of breast cancer is a multi-modal delivered in a multi- 
disciplinary setting. In brief, treatments include:
8.1 Surgery
Excision of the breast lesion and assessment of the axillary lymph node for 
regional metastasis. Historically this involved mastectomy with axillary clearance, 
which has now been refined following some seminal trial in breast cancer surgery 
to offering appropriate women breast conserving surgery (“lumpectomy”) and 
sentinel node biopsy. There are still important indications for mastectomy that 
would include genetic mutation status, family history, previously treated breast 
cancer, inflammatory breast cancer and patient choice.
8.2 Anti endocrine therapy
Hormone sensitive breast cancers are treated with anti hormonal therapy for 
a minimum period of 5 years that can be extended to 10–15 years based on recent 
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sensitive breast cancers may be treated with anti-hormone therapy by either selec-
tive oestrogen receptor modulators (e.g., Tamoxifen) or aromatase inhibitors.
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6. HER2 receptor status
The HER2 receptor (human epidermal growth factor receptor) is a trans-
membrane tyrosine kinase that is overexpressed in 15–20% of breast cancers [9]. 
Amplification of this oncogene is considered a marker of aggressiveness and is an 
important biomarker for targeted therapy. Drugs targeting the HER2 receptor (e.g., 
Trastuzumab, Pertuzumab) have significantly altered the clinical outcomes of 
otherwise poor prognosis HER2 positive breast cancers.
7. Molecular subtypes of breast cancer
Gene expression profiling has enabled molecular classification of breast cancer 
into intrinsic subtypes [10] that include:
1. Luminal A: hormone receptor positive (ER/PR +ve) and HER2 negative. They 
express low levels of the protein Ki-67, a cellular marker for proliferation. 
These cancers tend to be low grade, slow growing, good prognosis cancers.
2. Luminal B: hormone receptor positive (ER/PR +ve) and either HER2 positive 
or negative with a high level of Ki-67 expression. Faster growing and worse 
prognosis than luminal A cancers.
3. Triple negative breast cancer (TNBC)/basal-like: these are hormone receptor 
negative and HER2 negative (ER/PR/HER2 −ve). This accounts for 10–20% of 
all breast cancers, more commonly found in women with a BRCA1 PV, young 
women and African-American women. It is a rapidly growing, poor prognosis 
cancer.
4. HER2-enriched: these are HER2 positive and ER/PR negative cancer (HER2 
+ve, ER/PR −ve). They tend to grow faster than luminal cancers but can be 
treated with targeted therapies.
8. Treatments for breast cancer
The management of breast cancer is a multi-modal delivered in a multi- 
disciplinary setting. In brief, treatments include:
8.1 Surgery
Excision of the breast lesion and assessment of the axillary lymph node for 
regional metastasis. Historically this involved mastectomy with axillary clearance, 
which has now been refined following some seminal trial in breast cancer surgery 
to offering appropriate women breast conserving surgery (“lumpectomy”) and 
sentinel node biopsy. There are still important indications for mastectomy that 
would include genetic mutation status, family history, previously treated breast 
cancer, inflammatory breast cancer and patient choice.
8.2 Anti endocrine therapy
Hormone sensitive breast cancers are treated with anti hormonal therapy for 
a minimum period of 5 years that can be extended to 10–15 years based on recent 
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emerging data. There is an improved overall survival, reduced recurrence rate and 
reduction in the incidence of a contralateral breast cancer.
8.3 Radiotherapy
This is a localised, targeted therapy of high-energy X-rays that complements 
breast conservation surgery in almost all cases of invasive cancer, reducing local 
recurrence rates by almost 20–30% [11]. It may be offered following mastectomy if 
there is a high burden of disease.
8.4 Chemotherapy
This systemic treatment may be offered pre surgery (neo adjuvant) or post 
surgery (adjuvant). The choice of chemotherapy regimen is determined by number 
factors and may include anthracycline-taxane combinations. Perceived benefits 
include an improvement in survival, reduction in local recurrence and downstaging 
of tumour burden.
8.5 Anti HER2 treatment
HER2 targeted immunotherapy consists of monoclonal antibodies (e.g., 
Trastuzumab)—previously discussed.
8.6 Other treatments
PARP inhibitors: poly ADP Ribose Polymerase inhibitors are targeted therapies 
with increasing use in patients with a PV in the BRCA1/2 gene. This is discussed in 
more detail later.
Immunotherapy: this involves stimulating the host immune system actively 
immunisation (use of cancer vaccine) or passive immunisation (use of tumour 
specific antibodies or immune modulators). Of particular growing importance is 
the identification of patients with TNBC overexpressing immune evasion molecules 
(e.g., PDL: programmed death ligand) that may offer an additional treatment 
modality in this poor prognosis group [12].
9. Breast cancer genetics
The majority of breast cancers arise spontaneously—with known risk factors that 
include oestrogen exposure, reproductive history (late first or no pregnancy) and 
lifestyle practices. However, a significant proportion (20–30%) of cancers will have 
an inherited component, with family history remaining the strongest risk factor [13]. 
These tend to be classed as germline PVs in contrast to somatic  mutations—arising 
from the interactions between environment and genetics.
Approximately 5–10% of breast cancer will have a strong inherited component 
that can be further sub-divided [13] according to strength of penetrance:
















9.3 Low penetrance genes
The advent of Genome wide association studies has rapidly enabled the identi-
fication of over 100 breast cancer single nucleotide polymorphisms [14] that confer 
a small individual increase or decrease in breast cancer risk, but appear to work in a 
polygenic, multiplicative pattern contributing to a more significant risk.
10. Breast cancer and the BRCA1 gene
This tumour suppressor gene was first identified in 1990 and cloned 4 years later in 
the US [15]. During the next two decades a bitter commercial battle ensued regarding 
patenting of the genomic DNA sequence to both BRCA1 and BRCA2. Ultimately, the 
2013 US Supreme Court (Association of Molecular Pathology vs. Myriad Genetics) 
ruled that “isolation of genes found in nature do not render them patentable” [16].
The human BRCA1 gene (Chromosome 17—codes for the breast cancer type 1 
susceptibility protein) is involved in non error prone homologous DNA repair. The 
majority of PVs are frameshift resulting in a truncated protein with founder PVs in 
the Ashkenazi Jewish populations and Eastern European population [13].
10.1 Penetrance and lifetime risk
The inheritance pattern is autosomal dominant with birth incidence of a BRCA1 
PV estimated at 1 in 500–900, accounting for 7–10% of familial breast cancer [13].
Harbouring a BRCA1 PV confers a lifetime risk of breast cancer of approxi-
mately 60–85% [17, 18] and up to 60% for developing ovarian cancer (usually 
high-grade serous carcinomas). Risk of breast cancer is inversely proportional to 
age—a trend not so clearly seen in ovarian cancer (i.e., not age dependant). A recent 
prospective cohort study of 6036 BRCA1 PV carriers [19] identified that the breast 
cancer incidences per decade of age increased from 21–30 years to 31–40 years 
but then remained at 23.5–28.3 per 1000 person years from age 31 to 70 years. 
Therefore, there is a rapid increase in breast cancer incidence in early childhood 
that plateaus and remains constant throughout the remaining adult life.
Family history of breast cancers amongst first and second-degree relatives 
increased the relative risk breast cancer, a trend not seen in ovarian cancer risk in 
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families with ovarian cancer. BRCA1 PVs located outside the region bounded by 
c.2282 to c.4071 were associated with the highest risk of developing breast cancer [19].
There is a significant risk of developing a contralateral breast cancer once 
diagnosed with breast cancer. Our own studies have confirmed that this risk is 
approximately 2–3% per year, persists for at least 30 years.
Other cancers associated with this PV include pancreatic cancer (RR 2.26), uter-
ine body and cervical cancer (RR 2.65, RR 3.72, respectively) and prostate cancer in 
the under 65s (1.82) [13].
10.2 Pathology of BRCA1 cancers
BRCA1 related breast cancers are heterogenous but have some important clinical 
features. They are most often triple negative approximately 70–80% (ER, PR, Her2 
−ve) with expression of basal markers (CK5/6, CK14, SMA, P Cadherin, EGFR0). 
Histologically, they are similar to high-grade medullary carcinomas with pushing 
margins, high mitotic counts and lymphocytic infiltrate [20].
The international collaborative study (CIMBA) assessed pathological characteristics 
amongst 3797 BRCA1 carriers [21] and identified that the mean age of breast cancer 
was 40 years. The majority of breast cancers were of the ductal, no-special type variety 
with the majority of cancers demonstrating a basal-triple negative phenotype (78% 
of tumours were ER-negative, 79% were PR-negative, 90% HER2-negative and 68% 
TNBC). High-grade tumours were most common, with a clear relationship between age 
at diagnosis and grade of breast cancer—grade decreased with increasing age.
11. Breast cancer and the BRCA2 gene
This DNA repair gene was localised in the UK in 1994 and identified (cloned) 
in 1995 [22]. It is situated on Chromosome 13 at position 12.3 (13q12.3). Although 
the structures of the BRCA1 and BRCA2 gene vary from each other, there is some 
functional overlap. BRCA1 associates with BRCA2 through PALB2, a major binding 
partner of BRCA2. There is some data to suggest that BRCA1 acts as an upstream 
regulator of BRCA2 as BRCA1 promotes the concentration of PALB2 and BRCA2 at 
DNA damage sites [23].
11.1 Penetrance and lifetime risk
PVs in BRCA2 are nearly all inherited suggesting a large founder effect. This is 
important for practical purposes as certain populations can be tested for known PVs 
(e.g., single PV 999del5 accounts for almost all inherited breast and ovarian cancer 
in Iceland) [13].
Lifetime breast cancer risk has a wider range (40–85%) compared with 
BRCA1, and a slightly lower risk of developing ovarian cancer (20–30%) [13]. 
Approximately 1 in 400–800 women carry a PV (outbred population) that accounts 
for 10% of familial breast/ovarian cancer [14].
Several other cancers are more commonly associated with these PV: cholangio-
carcinoma, melanoma, pancreatic cancer (overall RR 4.1), gastric cancer (RR 2.7) 
and prostate cancer (10–20% life time risk) [13]. Approximately 10% of male breast 
cancer is associated with BRCA2, a trend not seen in BRCA1 PVs.
11.2 Pathology of BRCA2 cancers
Breast cancer in BRCA2 PVs carriers is a more heterogeneous group compared 
with BRCA1 carriers, with more semblance to sporadic breast cancers. Pathology 
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shows that these breast cancers are more often ER+ve compared with controls, with 
some studies showing increased DCIS and lobular cancer [20].
A study of breast cancer amongst 6893 BRCA1 and BRCA2 PV carriers found 
similar proportion of ductal, no-special type cancers (approximately 80%) with a 
four-fold increase in lobular cancers amongst BRCA2 carriers (8% compared with 
2% in BRCA1 patients) [21]. Overall, there were double the number of Grade 1 and 
2 cancers in the BRCA2 compared with BRCA1, with more Grade 3 cancers in the 
BRCA1 group (77% compared with 50% in BRCA2 carriers).
There is paucity of data regarding the pre-invasive progression pathway amongst 
BRCA1/2 carriers. Whereas a DCIS associated pre-malignant pathway has been 
postulated in sporadic cancers, this has not been shown in BRCA1/2 PV carriers. 
There is conflicting data regarding incidence of DCIS in this patient group. Some 
reports suggest an increased incidence of DCIS identified in risk-reducing mastec-
tomy specimens as opposed to other studies identifying DCIS less frequently near 
the invasive cancer compared with sporadic tumours [24].
12. Prognosis for BRCA mutated breast cancer
The POSH study (Prospective Outcomes in Sporadic versus Hereditary breast 
cancer), designed as a prospective cohort study, assessed the outcomes of women 
aged 40 years or below diagnosed with an invasive breast cancer in the UK [25]. 
With a follow up of nearly 10 years, 12% of all patients were identified with a PV 
in either the BRCA1/2 gene. Multivariate analysis identified no overall difference in 
survival between BRCA positive or BRCA negative patients. Amongst patients with 
TNBC, there was a short-term survival benefit at 2 years amongst BRCA carriers. 
The authors hypothesised that this short-lived benefit may reflect greater sensitivity 
of BRCA mutant cancer to chemotherapy and/or greater visibility of BRCA related 
cancers to the immune system [25].
Studies prior to the POSH studied inconsistent effects of BRCA1/2 PV status on 
breast cancer outcomes. A meta-analysis of 66 relevant studies [26] did not identify 
inferior breast cancer outcomes amongst BRCA1/2 PV carriers despite the biological 
differences in breast cancer type already discussed.
In addition these women have similar survival whether they are treated with breast 
conservation surgery or a mastectomy, despite having significant higher rates of local 
failure with breast conservation [27]. An international longitudinal study of 655 
patients with BRCA1/2 PVs showed no differences in overall survival, distant or regional 
recurrence at 20 years whether women underwent a mastectomy or breast conservation 
therapy with radiotherapy. Interestingly, most local recurrences are second primary 
breast cancers rather than failure to control the primary breast cancer [27].
12.1 Radiotherapy
The effect of radiotherapy on BRCA1/2 associated breast cancer merits consid-
eration. These cancers are characterised by defects in homologous recombination, 
resulting in inadequate repair of double stranded DNA breaks—a hallmark of PVs 
in the BRCA1/2 genes. In particular, younger patients with a higher rate of cell 
proliferation may be more susceptible to the carcinogenic effects of radiotherapy. 
Studies have confirmed an increased risk of contralateral breast cancer amongst 
young patients with a sporadic breast cancer treated with radiotherapy suggesting 
an effect of low-dose scatter radiation to surround healthy tissue [28].
In patients with a BRCA1/2 PV associated breast cancer treated with unilateral 
radiotherapy, hypothetically there should be an increased risk of contralateral 
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proliferation may be more susceptible to the carcinogenic effects of radiotherapy. 
Studies have confirmed an increased risk of contralateral breast cancer amongst 
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In patients with a BRCA1/2 PV associated breast cancer treated with unilateral 
radiotherapy, hypothetically there should be an increased risk of contralateral 
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breast cancers particularly in the younger patient group, as the contralateral healthy 
breast will receive some scatter radiation. In addition, adjuvant radiotherapy to the 
index breast of BRCA1/2 PV carriers should be more efficacious compared with 
sporadic cancer by virtue of the aberration in DNA repair. A recent Dutch study 
was not able to demonstrate any association between radiotherapy and contralateral 
breast cancer risk [29]. They observed a growing trend in their population group 
of BRCA1/2 PV carriers away from breast conservation with radiotherapy towards 
mastectomy and contralateral mastectomy.
12.2 Chemotherapy
Healthy, normal breast tissue exposed to toxic, chemotherapeutic agents will 
result in DNA damage that is then partly repaired by the BRCA1/2 DNA damage 
response. Different chemotherapy agents used to treat breast cancers exhibit differ-
ences in mechanism of action. Taxane-based agents work by disrupting the micro-
tubule function whereas anthracyclines induce topoisomerase II mediated toxicity, 
DNA intercalation and generation of reactive oxidative species. In vitro studies have 
shown that platinum based chemotoxic agents have a greater sensitivity for BRCA1 
mutated cell lines which may in part be due to the disruption of DNA [30].
12.3 PARP inhibitors
This class of targeted therapy work on the principle of “synthetic lethality” [31], 
whereby a defect in one gene/protein results in cell survival however when synthe-
sised with another gene/protein results in cell death.
Poly ADP Ribose Polymerase (PARP1) is an important protein that repairs single 
strand DNA breaks. Drugs that inhibit this protein (PARP inhibitors) result in 
multiple breaks in double stranded DNA that cannot be repaired, resulting in cell 
death. A proof of concept international study [32] showed a favourable therapeutic 
index for Olaparib (an orally active PARP inhibitor) amongst patients with advanced 
or recurrent breast cancer who harboured a BRCA1/2 PV. The OlympiAD study, an 
international, randomised, Phase III trial recently reported an improved progression 
free survival amongst patients with metastatic breast cancer who were HER2 negative 
with a germline PV in either BRCA1/2 [33]. Future directions of research will include 
combining PARP inhibitors with radiotherapy and platinum based agents [34].
12.4 Risk-reducing surgery
Bilateral risk-reducing mastectomy (BRRM) offers the greatest magnitude of 
overall risk reduction in health patients harboring a BRCA1/2 PV by removing in 
excess of 90% of the breast tissue. A recent Cochrane review showed that BRRM 
reduces the risk of developing breast cancer by 85–100 [35] in high-risk patients. It 
also showed that BRRM reduced the risk of dying from breast cancer by 81–100% in 
high-risk patients and 100% in the moderate risk group.
Uptake of BRRM varies amongst women in this high-risk group. From a patient’s 
perspective, young age and motherhood seem to be positive predictors for choosing 
surgery [36–38]. Several studies have shown international variations in uptake of 
BRRM with the highest rates in the UK and the Netherlands (33–50%) and the US 
(36%) compared with Poland (3%) and Israel (4%) [39, 40]. Differences in culture, 
healthcare systems and access to genetic testing are likely to contribute to these 
differences. However, wide variations are found within countries—for example in 
three different Canadian regions, the range of uptake was from 8 to 46% [41]— 
suggesting that other factors are important.
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Media coverage and public interest in BRRM has been heightened since 2013 
when Angelina Jolie’s revealed her personal experience of bilateral mastectomies 
based on her inheriting a pathogenic BRCA1 PV from her late mother. The so-called 
“Angelina Jolie Effect” ensued with increased uptake of genetic testing and BRRM 
in the US and UK [42–44].
12.5 Bilateral risk-reducing salpingo oophorectomy (BRRSO)
Women choosing this procedure will reduce their risk of developing ovarian by 
almost 90%. In addition, there appears to be a reduction in their subsequent risk of 
developing breast cancer (premenopausal women) [45, 46], with several previous 
studies showing a risk-reduction of almost 50%. Unlike breast cancer, surveillance 
for ovarian cancer is limited to measurements of tumour markers (CA125) and 
transvaginal ultra-sound—both of which may lack sensitivity. As such, uptake of 
BRRSO is high (up to 75%).
BRRSO renders women post menopausal (surgical menopause) with additional 
risks to the cardiovascular and skeletal system. In addition, most women are recom-
mended to have completed their family prior to considering this surgery. The cli-
macteric symptoms following this procedure can be debilitating and many women 
will consider use of HRT to combat these symptoms. Use of HRT itself may increase 
the risk of developing breast cancer in these women already deemed at high-risk.
The risk reduction for breast cancer has recently been reassessed for potential 
selection bias [47]. This study used the same methodology previously described 
[45] to study a cohort of Dutch BRCA1/2 healthy carriers and found that following 
BRRSO, the incidence of breast cancer was almost halved (Hazard Ratio 0.36–0.62). 
A revised analysis taking into account the various biases described above showed no 
real protective effect of BRRSO on breast cancer development (Hazard Ratio 1.09). 
This has important clinical implications when considering the variations of uptake 
of BRRM compared with BRRSO—women only choosing BRRSO over BRRM may 
have had their breast cancer risk reduction overestimated if they only chose BRRSO.
12.6 Chemoprevention
In the UK, healthy women with a BRCA1/2 PV may consider three medications 
to reduce their risk:
Tamoxifen: this selective oestrogen receptor modulator (first generation) has 
been shown to reduce the risk in asymptomatic women by approximately 40–50% 
[48]. In women with breast cancer, tamoxifen has a similar risk reduction in devel-
oping CBC. The side-effect profile (hot flushes, increased incidence of endometrial 
cancer, thromboembolic phenomenon) is an important consideration as less than 
15% of women will choose this and remain compliant [49]. Tamoxifen may be 
considered in pre and post menopausal women.
Raloxifene (second generation SERM), used in the prevention and treatment of 
osteoporosis has a much better side effect profile with no increase in endometrial 
cancers but increases thromboembolic risk similar to tamoxifen. Risk reduction was 
inferior to tamoxifen over an extended follow [50]. Raloxifene is considered in the 
post-menopausal setting only.
Aromatase inhibitor: Exemestane has been shown to offer 65% relative risk 
reduction in post-menopausal women at increased risk with a minimal side-effect 
profile [51]. The IBIS II trial (International Breast Cancer Intervention Studies) 
randomised post-menopausal women with an increased risk of breast cancer to 
anastrozole or placebo. At 5 years follow-up, 2% of women taking Anastrozole had 
developed breast cancer compared with 4% in the placebo group [52].
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result in DNA damage that is then partly repaired by the BRCA1/2 DNA damage 
response. Different chemotherapy agents used to treat breast cancers exhibit differ-
ences in mechanism of action. Taxane-based agents work by disrupting the micro-
tubule function whereas anthracyclines induce topoisomerase II mediated toxicity, 
DNA intercalation and generation of reactive oxidative species. In vitro studies have 
shown that platinum based chemotoxic agents have a greater sensitivity for BRCA1 
mutated cell lines which may in part be due to the disruption of DNA [30].
12.3 PARP inhibitors
This class of targeted therapy work on the principle of “synthetic lethality” [31], 
whereby a defect in one gene/protein results in cell survival however when synthe-
sised with another gene/protein results in cell death.
Poly ADP Ribose Polymerase (PARP1) is an important protein that repairs single 
strand DNA breaks. Drugs that inhibit this protein (PARP inhibitors) result in 
multiple breaks in double stranded DNA that cannot be repaired, resulting in cell 
death. A proof of concept international study [32] showed a favourable therapeutic 
index for Olaparib (an orally active PARP inhibitor) amongst patients with advanced 
or recurrent breast cancer who harboured a BRCA1/2 PV. The OlympiAD study, an 
international, randomised, Phase III trial recently reported an improved progression 
free survival amongst patients with metastatic breast cancer who were HER2 negative 
with a germline PV in either BRCA1/2 [33]. Future directions of research will include 
combining PARP inhibitors with radiotherapy and platinum based agents [34].
12.4 Risk-reducing surgery
Bilateral risk-reducing mastectomy (BRRM) offers the greatest magnitude of 
overall risk reduction in health patients harboring a BRCA1/2 PV by removing in 
excess of 90% of the breast tissue. A recent Cochrane review showed that BRRM 
reduces the risk of developing breast cancer by 85–100 [35] in high-risk patients. It 
also showed that BRRM reduced the risk of dying from breast cancer by 81–100% in 
high-risk patients and 100% in the moderate risk group.
Uptake of BRRM varies amongst women in this high-risk group. From a patient’s 
perspective, young age and motherhood seem to be positive predictors for choosing 
surgery [36–38]. Several studies have shown international variations in uptake of 
BRRM with the highest rates in the UK and the Netherlands (33–50%) and the US 
(36%) compared with Poland (3%) and Israel (4%) [39, 40]. Differences in culture, 
healthcare systems and access to genetic testing are likely to contribute to these 
differences. However, wide variations are found within countries—for example in 
three different Canadian regions, the range of uptake was from 8 to 46% [41]— 
suggesting that other factors are important.
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Media coverage and public interest in BRRM has been heightened since 2013 
when Angelina Jolie’s revealed her personal experience of bilateral mastectomies 
based on her inheriting a pathogenic BRCA1 PV from her late mother. The so-called 
“Angelina Jolie Effect” ensued with increased uptake of genetic testing and BRRM 
in the US and UK [42–44].
12.5 Bilateral risk-reducing salpingo oophorectomy (BRRSO)
Women choosing this procedure will reduce their risk of developing ovarian by 
almost 90%. In addition, there appears to be a reduction in their subsequent risk of 
developing breast cancer (premenopausal women) [45, 46], with several previous 
studies showing a risk-reduction of almost 50%. Unlike breast cancer, surveillance 
for ovarian cancer is limited to measurements of tumour markers (CA125) and 
transvaginal ultra-sound—both of which may lack sensitivity. As such, uptake of 
BRRSO is high (up to 75%).
BRRSO renders women post menopausal (surgical menopause) with additional 
risks to the cardiovascular and skeletal system. In addition, most women are recom-
mended to have completed their family prior to considering this surgery. The cli-
macteric symptoms following this procedure can be debilitating and many women 
will consider use of HRT to combat these symptoms. Use of HRT itself may increase 
the risk of developing breast cancer in these women already deemed at high-risk.
The risk reduction for breast cancer has recently been reassessed for potential 
selection bias [47]. This study used the same methodology previously described 
[45] to study a cohort of Dutch BRCA1/2 healthy carriers and found that following 
BRRSO, the incidence of breast cancer was almost halved (Hazard Ratio 0.36–0.62). 
A revised analysis taking into account the various biases described above showed no 
real protective effect of BRRSO on breast cancer development (Hazard Ratio 1.09). 
This has important clinical implications when considering the variations of uptake 
of BRRM compared with BRRSO—women only choosing BRRSO over BRRM may 
have had their breast cancer risk reduction overestimated if they only chose BRRSO.
12.6 Chemoprevention
In the UK, healthy women with a BRCA1/2 PV may consider three medications 
to reduce their risk:
Tamoxifen: this selective oestrogen receptor modulator (first generation) has 
been shown to reduce the risk in asymptomatic women by approximately 40–50% 
[48]. In women with breast cancer, tamoxifen has a similar risk reduction in devel-
oping CBC. The side-effect profile (hot flushes, increased incidence of endometrial 
cancer, thromboembolic phenomenon) is an important consideration as less than 
15% of women will choose this and remain compliant [49]. Tamoxifen may be 
considered in pre and post menopausal women.
Raloxifene (second generation SERM), used in the prevention and treatment of 
osteoporosis has a much better side effect profile with no increase in endometrial 
cancers but increases thromboembolic risk similar to tamoxifen. Risk reduction was 
inferior to tamoxifen over an extended follow [50]. Raloxifene is considered in the 
post-menopausal setting only.
Aromatase inhibitor: Exemestane has been shown to offer 65% relative risk 
reduction in post-menopausal women at increased risk with a minimal side-effect 
profile [51]. The IBIS II trial (International Breast Cancer Intervention Studies) 
randomised post-menopausal women with an increased risk of breast cancer to 
anastrozole or placebo. At 5 years follow-up, 2% of women taking Anastrozole had 
developed breast cancer compared with 4% in the placebo group [52].
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Although there is not good quality evidence to show that endocrine therapy is 
not effective in BRCA1 as 70–80% of breast cancers are triple negative and these 
medications only reduce ER positive cancers they may have less efficacy in BRCA1 
PV carriers.
12.7 Lifestyle
Worldwide, the number of oestrogen receptor positive breast cancers is increas-
ing with a reverse pattern seen with oestrogen negative cancer. In developed 
countries, hormone sensitive breast cancer is particularly amenable to lifestyle 
prevention—with recent studies suggesting that modification of lifestyle measure 
may prevent up to 30% of breast cancers [53].
Amongst BRCA carriers, smoking, increased weight and reduced physical 
activity further increases the risk of breast cancer. These lifestyle measures need to 
commence in adolescence and adherence to this (150 min weekly activity, BMI < 25, 
<1 alcoholic drink daily) has been shown to reduce mortality in BRCA carriers by 
almost 60% [54].
The LIBRE study (Lifestyle Intervention in BRCA1/2 PV carriers) aims to ran-
domise healthy BRCA1/2 PV carriers to a number of lifestyles interventions versus a 
control group and assess changes in physical and psychological well being [55].
13. Discussion
The worldwide burden of breast cancer poses significant challenges to health 
care providers. There is an increasing awareness that this heterogenous disease 
requires a multi-modality approach with consideration to both prevention and 
treatment.
Diet and lifestyle are important modifiers in the prevention of breast cancer. 
Adherence to physical activity and alcohol guidelines may reduce the risk of devel-
oping breast cancer (pre and post menopausal), with weight control being more 
important in prevention in the post menopausal cohort [56]. Energy restriction, in 
particular intermittently is association with changes in breast gene expression and 
systemic metabolism [57]. Future studies will need to assess the mechanism and 
clinical significance in breast cancer pathogenesis.
Breast cancer metabolomics is an area of growing interest. A recent study was 
able to determine a differential metabolic signature based on BRCA1 functionality 
[58] and may provide future biomarkers.
An area of interest is establishing whether breast cancer may be considered a 
communicable disease. There is established causality of infection with the Human 
Papilloma Virus and a number of cancers namely cervical cancer and associations 
with penile, anal and vulvar cancer. A similar aetiology has been postulated with 
breast cancer with entry of the virus via the nipple areolar complex resulting in 
biological activity within the mammary duct epithelium resulting in breast cancer. 
Data from Norway [59] have identified a possible association of pre-malignant 
changes in the cervix and an increased risk of subsequent breast cancer. A subse-
quent UK study [60] has identified the presence of high-risk HPV DNA in 42% of 
breast cancers with viral activity confirmed in less than 20% of invasive cancers 
suggesting that this may be an area of on going interest in the future.
Gene therapy in cancer aims at correcting specific genetic anomalies contribut-
ing to the development of certain cancers. This can be subdivided into germline and 
somatic cell gene therapy and is an important treatment modality in disease pro-
cesses like cystic fibrosis and blood disorders. Several BRCA1 retroviral vectors were 
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assessed in Phase 2 clinical trials in ovarian cancer almost two decades ago [61] with 
some initial potential as a therapeutic modality. The lack of progress in viral vectors 
suggests that newer techniques such as gene editing may find a place.
The UK 100,000 Genome project completed recruitment in 2018. Breast cancer 
patients represent a significant proportion of the 85,000 patients either with a can-
cer or rare disease diagnosis. Whole genome sequencing has allowed rapid analysis 
of the entire genome in this patient subgroup and is already aiding clinicians in 
making therapeutic decision in breast cancer, although no new hereditary genes 
have yet been identified from this initiative.
14. Conclusion
Pathogenic variants in the BRCA1 and BRCA2 gene confer a substantial lifetime 
risk of developing breast cancer. These breast cancers display characteristic clini-
cal and pathological features that are important in the clinical management of the 
disease.
Multiple strategies exist for healthy individuals harbouring PVs in these genes. 
This comprises surveillance using modern day radiology (mammography and 
MRI scans) and risk reducing strategies. The latter include bilateral risk-reducing 
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Abstract
The objective of this population-based study is to describe epidemiological and 
genetic features of breast and ovarian cancer in North Sardinia, Italy. Patients who 
carry a high-risk mutation in one or both of the BRCA genes (BRCA1 or BRCA2) 
have a significantly increased risk of developing breast/ovarian cancer (BOC) and 
other cancers (e.g., prostate cancer in male). Epidemiological data on incidence dis-
tribution of breast/ovarian cancer from 2016 to 2019 in North Sardinia are obtained 
from the local tumor registry and from the cumulative results of 209 genetic testing 
for BRCA gene mutations performed in all young breast cancer patients and all 
women (over 50 years) with family history of BOC (total of 164 cases); further, 45 
genetic testing is performed, on ovarian cancer patients, at any age. The results pro-
vide a different distribution of fraction mutations carried by women and a higher 
prevalence of the BRCA2 mutation in the north of Sardinia than the entire popula-
tion and highlight the presence of specific germline mutation associated with the 
“founder effect” in distinct genetic subgroups reflecting genetic drift. Advances 
in next-generation sequencing technology, data analysis, and clinical investigation 
have revolutionized efforts to identify potential targets for BRCA molecular-based 
therapeutic agents.
Keywords: BRCA1, BRCA2, genetic epidemiology, genetic testing, founder 
mutations, breast cancer (BC), ovarian cancer (OC), breast and ovarian cancer 
syndrome (BOC)
1. Introduction
Breast cancer (BC) is the second most common cancer in the female world 
population, with more than 1.3 million new cases every year [1]. Systemic treat-
ment of breast cancer is based on accurate knowledge of the clinical and molecular 
characteristics of the tumor and includes cytotoxic, hormonal, or biological agents. 
Therapies are used in the adjuvant, neo-adjuvant, and metastatic settings of BC 
patients. In general, systemic agents are active at the beginning of therapy in 90% 
of primary breast cancers and 50% of metastases. However, disease progression and 
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1. Introduction
Breast cancer (BC) is the second most common cancer in the female world 
population, with more than 1.3 million new cases every year [1]. Systemic treat-
ment of breast cancer is based on accurate knowledge of the clinical and molecular 
characteristics of the tumor and includes cytotoxic, hormonal, or biological agents. 
Therapies are used in the adjuvant, neo-adjuvant, and metastatic settings of BC 
patients. In general, systemic agents are active at the beginning of therapy in 90% 
of primary breast cancers and 50% of metastases. However, disease progression and 
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resistance to therapy are expected to occur in a variable period of time, though they 
are becoming a less common event.
Ovarian cancer (OC) is the seventh most common cancer in women from 
Western countries (about 5% of all cancers) [2]; its frequency however var-
ies widely among different geographic regions and ethnic groups, with a high 
incidence in Northern Europe and the United States and low rates in Africa and 
Asia. In Europe, about 61,000 new cases are estimated to be diagnosed per year. 
The age-adjusted world incidence is around 11 new cases per 100,000 inhabitants 
per year.
The majority of OC cases are sporadic, and only 5–10% of them are familial. 
Ovarian cancer is usually diagnosed at an advanced stage and etiology remains 
poorly understood. Nevertheless, about 30% of patients present with early-
stage disease (FIGO stage I–IIA). Surgery plays a main role in the treatment of 
epithelial ovarian cancer, and an extensive surgical staging is crucial in selecting 
the most appropriate systemic therapy. Several factors are associated with the 
onset of the epithelial ovarian cancer, including age (it is a disease of older age), 
genetic features (approximately, 5–10% of them result from a hereditary pre-
disposition), site-specific ovarian cancer syndrome (10–15% of all cases), and a 
positive family history with an affected first-degree relative (mother, daughter, 
or sister).
In the presence of the breast-ovarian cancer syndrome (BOC), families present 
with multiple cases (two or more) affected by ovarian and breast cancer in succes-
sive generations, tumors with earlier age of onset (usually in the premenopausal 
age), and evidence of both maternal and paternal transmission [3]. This hereditary 
syndrome has been linked to the BRCA1 gene at chromosome 17q12–21 (81% of 
cases) and, less frequently, to the BRCA2 gene at chromosome 13q.
Cumulative breast cancer risks by age 70 are estimated to be 65% for BRCA1 and 
45% for BRCA2 mutation carriers. In addition, women with BRCA mutations are at 
significant risk of developing ovarian cancer and other malignancies [4].
Both BRCA1 and BRCA2 encode proteins that are involved in maintenance 
of genome stability and in the repair of double-stranded DNA breaks (DSBs) by 
homologous recombination (HR).
HR is a potentially error-free mechanism of DNA damage repair that requires 
RAD51 localization to DSBs. BRCA2 interacts directly with RAD51 and is required 
for the formation of RAD51 complex, as is a BRCA2-associated protein called DSS1. 
The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, 
and these motifs mediate binding to the RAD51 recombinase, which functions in 
DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 
mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. 
BRCA1 is also required for the formation of RAD51 foci, perhaps through direct 
or indirect interaction with RAD51 or BRCA2 [5]. BRCA2 has also been identified 
as the FANCD1 gene, a member of the Fanconi anemia complex of proteins, and 
cells deficient in this protein have a similar phenotype to those deficient in BRCA 
[6]. Chromosomal instability as a result of BRCA1 or BRCA2 deficiency may be the 
pathogenic basis for breast tumor formation. In women who inherit an inactivating 
mutation, BRCA deficiency is critical to the development of disease and is the result 
of both the inherited inactivating allele and somatic genomic loss of the wild-type 
allele in breast or ovarian epithelial cells. The risk of developing BRCA-associated 
ovarian cancer is modified by several factors such as the reproductive history and 
hormonal exposure of an affected individual, and the coinheritance of modifying 
genes [6].
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2. Breast ovarian cancer family selection
The overall criteria to reconstruct the possible family history of patients with 
breast cancer can be established by identifying three risk levels: profile 1, level of 
cancer risk equivalent to general population; profile 2, level of cancer risk two-fold 
higher than that of general population; and profile 3, level of cancer risk three or 
more times higher than that of general population.
Six main criteria are taken into consideration to address women diagnosed with 
breast cancer into the general population to BRCA mutation testing: (a) younger 
women with breast cancer diagnosed at age less than 36 years; (b) affected male indi-
viduals (at any age of onset); (c) women with occurrence of both breast and ovarian 
cancer (at any age); (d) women with bilateral carcinoma diagnosed before 50 years; 
(e) women with triple-negative breast cancer who are younger than 50 years; and 
(f) all women with ovarian (and fallopian tube) carcinoma before 50 years or with 
high-grade serous ovarian cancer at any age.
Current guidelines recommend genetic testing for women diagnosed with breast 
cancer and at least one affected family member; a personal history of breast cancer 
and one or more relatives with breast cancer diagnosed before age 50; two or more 
relatives diagnosed with breast cancer at any age; one or more relatives with ovarian 
cancer; one or more relatives with male breast cancer, or two or more relatives with 
prostate cancer or pancreatic cancer.
In this sense, the American Society of Clinical Oncology, the American College 
of Obstetrics and Gynecology, and the National Comprehensive Cancer Network 
do not recommend BRCA mutation testing for women younger than 50 years 
with breast cancer unless there is a family history of breast/ovarian cancer [7, 8]. 
Therefore, many young women with breast cancer and lack of a family history 
of disease will not have the opportunity to undergo BRCA mutation testing. As a 
result of this, a significant proportion of newly diagnosed women with breast can-
cer who are younger than 50 years may not be identified as BRCA mutation carri-
ers, and they remain at high risk for subsequent breast and ovarian cancer. Positive 
BRCA mutation testing in women with ovarian carcinoma allows relatives access 
to oncological genetic counseling and preventive testing, aimed at verifying the 
presence or absence in family members, of pathogenic sequence variants. Genetic 
results are essential to carry out specific recommendations for clinical management 
of at-risk relatives. In the case of a positive result, the programs are aimed at pro-
moting screening strategies for early diagnosis as well as favoring primary preven-
tion interventions for the reduction in the risk of breast/ovarian cancer. The BRCA 
test is recommended for all patients with nonmucinous and nonborderline ovarian 
cancer, carcinoma of the fallopian tubes, or peritoneal primitive carcinoma. It is 
important to offer the BRCA test since cancer diagnosis. The identification of a 
pathogenic variant in BRCA genes also allows patients to plan an adequate thera-
peutic pathway. The identification of pathogenic variant in BRCA genes at germinal 
level in a patient with ovarian cancer allows to undertake a path of oncogenetic 
counseling in family members in order to identify high-risk carriers and to propose 
targeted programs for early diagnosis of syndrome-associated tumors with BRCA-
related and to carry out strategies aimed at reducing the risk.
In BRCA-mutated women, with ascertained diagnosis of ovarian cancer, a 
psychosocial approach must be envisaged, which takes into account the impact of 
the diagnosis and treatment on the physical and psycho-emotional sphere, as well 
as the psychological implications of the hereditary problem and the involvement of 
healthy family members at risk in the decision-making process [9].
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genes [6].
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2. Breast ovarian cancer family selection
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important to offer the BRCA test since cancer diagnosis. The identification of a 
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peutic pathway. The identification of pathogenic variant in BRCA genes at germinal 
level in a patient with ovarian cancer allows to undertake a path of oncogenetic 
counseling in family members in order to identify high-risk carriers and to propose 
targeted programs for early diagnosis of syndrome-associated tumors with BRCA-
related and to carry out strategies aimed at reducing the risk.
In BRCA-mutated women, with ascertained diagnosis of ovarian cancer, a 
psychosocial approach must be envisaged, which takes into account the impact of 
the diagnosis and treatment on the physical and psycho-emotional sphere, as well 
as the psychological implications of the hereditary problem and the involvement of 
healthy family members at risk in the decision-making process [9].
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2.1 BRCA molecular profiling and epidemiology in Sardinia population
In Sardinia, breast cancer represents the principal death-causing malignancy, 
with an incidence similar to that observed in western countries [10]. Familial 
aggregation is thought to account for 5–10% of all breast cancer cases, and germline 
mutations in different genes involved in pathways critical to maintain the genomic 
integrity have accounted for less than 25% of the inherited breast cancer. Prevalence 
of mutation carriers with breast or ovarian cancer depends on the population 
studied and displays considerable variation based on ethnic and geographical 
diversity [11]. In Italy, 4–27% of the identified mutations recurred among appar-
ently unrelated families, while a regional founder effect has been demonstrated for 
few mutations; contribution of BRCA1–2 mutations to breast cancer predisposition 
has been reported for populations from the Northern part of Sardinia as well as 
strong founder effects for several genetic diseases were founded with some geo-
graphical differences within the island [12]. BRCA2 mutations are notably more 
recurrent than BRCA1 mutations in breast cancer families from North Sardinia [13]. 
Moreover, allelic transmission is identical in males and females as the entire popula-
tion should comply with the Hardy–Weinberg law [14].
In southern Italy, including Sardinia, standardized mortality rate in ovarian 
cancer patients is 8.5/100,000 lower than in Italy; also, the cumulative risk of death 
from the disease is extremely low (0.4%) [4, 15].
Germline mutations in either BRCA1 or BRCA2 genes occur in approximately 
10% of unselected women with ovarian cancer, and women with inherited BRCA1/2 
mutations are at significant risk of developing ovarian cancer [16].
The lifetime risk of developing ovarian cancer in women who carry a germline 
BRCA mutation has been estimated to be of 40–60% for BRCA1 and 11–27% for 
BRCA2 [17]. A meta-analysis of 22 studies with over 8000 disease probands has 
defined the incidence for ovarian cancer to be approximately 39% for BRCA1 and 
11% for BRCA2 [18]. In North Sardinia, less than 10% of breast cancer families 
presented an association with ovarian cancer (at least one affected family member) 
[12]. Nevertheless, the presence of ovarian cancer was demonstrated to significantly 
increase the occurrence of BRCA1/2 germline mutations in Sardinian breast cancer 
families [12, 19].
2.2  Next-generation sequencing approaches for mutation analyses  
in Sardinian population
In recent past years, epidemiological data have become available from the 
Cancer Registry of the Province of Sassari. This registry was created in 1992 by the 
Local Health Agency (Azienda Sanitaria Locale, ASL) of Sassari for the epidemio-
logical surveillance of tumors in the province. In 1999, it became part of wider web 
tumor registries, coordinated today by the Italian Association for Tumor Registries 
(Associazione Italiana Registri Tumori) [20]. Crude incidence and mortality rates 
for 100,000 inhabitants per year were calculated and standardized rates adjusted 
for European age population standards. The age-class distribution of cases was 
analyzed; relative incidence and mortality date was compared between Sardinia and 
the rest of Italy (Table 1).
Numerous studies by our group have assessed the BRCA1/2 mutation prevalence in 
various cohorts, although few have evaluated the predictors for the occurrence of both 
BRCA1 and BRCA2 mutations among younger patients in a hospital-based population.
Breast/ovarian cancer patients, originating from North Sardinia, were recruited 
from clinics at the University of Sassari and Local Health Agencies accounting for 
cancer patients from the Central and Northern part of the island (Sassari, Olbia, 
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Nuoro). Sardinian origin was ascertained in all cases through genealogical studies. 
Patients with a histologically-proven diagnosis of breast/ovarian cancer diagnosed 
before 50 years were consecutively-collected during a period of 4 years; no addi-
tional selection criteria were used for their inclusion into the study.
In such a population-based series of early-onset breast/ovarian cancer, family 
history of breast and ovarian cancers were assessed according to the above-described 
standardized criteria. Patients were informed of the aims of the study and blood 
samples were obtained with their written consent. Genomic DNA was isolated and 
next-generation sequencing (NGS) investigations were performed using a specific 
BRCA1/2 gene. Research assay panel allows to detect simultaneously point mutations 
and CNVs. Samples were sequenced on the Ion Torrent S5 System (Life Technologies, 
Waltham, MA, USA), and data were processed with the Ion Torrent platform.
Between 2016 and 2019, 209 patients originating from North Sardinia under-
went the NGS-based mutation analyzed in BRCA1/2 genes; among them, 164 were 
diagnosed with primary breast cancer and 45 with primary ovarian cancer, with 
median age at onset of 51 years (range 27 ± 84), any age for ovarian cancer.
Patients with first diagnosis of breast cancer were evaluated for familial occur-
rence of malignancy using a questionnaire to interview probands about their first- 
and second-degree relatives. In our series of Sardinian cases, we analyzed sporadic 
young patients with a breast cancer diagnosis before 50 years (59/164; 36%) and 
any familiar history; a number of probands with a positive family history for breast 
cancer (33/164; 20%) and age of onset before 50 years; and patients (72/164; 44%) 
with breast/ovarian cancer familiar history at any age. Moreover, the analysis was 
performed on 45 (45/209; 21.5%) ovarian cases at any age.
2.3 Deleterious variants in BRCA1 and BRCA2 genes
Overall, prevalence of deleterious BRCA1/2 variants was 10 times higher in 
patients with a positive family history (19/105; 18.09%) as compared with those 
with sporadic tumors (2/104; 1.92%). Interestingly, all uncertain variants-that is, 
those with unknown functional significance-were nearly completely prevalent in 
Age class No. of 
cases
% of cases













*Asterisk indicates familial breast cancer patients.
Table 1. 
Epidemiological data in North Sardinia.
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familiar tumor cases. Deleterious variants were found in 68% (15/22) of breast 
cancer cases and 31.8% (7/22) of ovarian cancer cases; variants with unknown 
significance (VUS) were observed in 81.2% of breast cancer patients and in 18.7% 
of ovarian cancer patients. Deleterious germline variants in BRCA2 5.74% (12/209) 
were featured, followed by BRCA1 4.78%(10/209) patients according to our previ-
ous study that explained a different geographical distribution of BRCA1–2 muta-
tions with a higher prevalence of the BRCA2 mutation in the north of Sardinia than 
the entire population [19].
Among families with high recurrence of breast cancer (≥ 3 cases in first-degree 
relatives), almost all ones from northern Sardinia were previously demonstrated by 
our group to share the same haplotype and carry a single mutation in BRCA2 gene 
(BRCA2-8765delAG), which thus acts as a pathogenic variant with founder effect in 
the population of this part of the island (due to the occurrence and propagation of 
a common ancestral deleterious alteration) [21]. The BRCA2-8765delAG mutation 
was firstly described in breast cancer families from French-Canadian and Jewish-
Yemenite populations; however, the families from French Canadian and Jewish-
Yemenite populations were demonstrated to present with distinct genetic assets at 
the BRCA2 locus, arguing thus against a common origin of this mutation among 
such different populations (it seems to be conducted to the high propensity to dele-
tion error in this part of the BRCA2 gene, within a so-called hot-spot mutational 
region) [22] (Table 2).
Few BRCA functional mutations account for BRCA-associated cancers among 
homogenous populations such as Sardinia (a single BRCA2 founder mutation), 
French-Canadian population (French colonization of the province of Quebec, 
five recurrent mutations of which one is common with Sardinia BOC family), and 
Jewish-Yemenite Ashkenazi Jewish families of eastern European ancestry (specific 
subpopulations; three recurrent founder mutations are known), while more hetero-
geneous populations tend to display a broad mutation spectrum; founder mutations 
are specific mutations that appear repeatedly in ethnically defined groups because 
of a shared common ancestry [23].
The presence of a singleBRCA2 mutation that is extremely rare (in less than 
1% of breast cancer cases) is characterized in another isolated population such as 
Iceland, which explains a substantial proportion of the familial risk of breast cancer 
in Iceland and accounts for most of the prostate and ovarian cancer observed in 
families of breast cancer patients [24].
The epidemiological and clinical impact of the BRCA2 founder mutation on 
cancer in isolated population has been extensively studied, particularly with regard 
to significantly higher risk of BOC. The mutations fall into cluster region of BRCA-
gene and can be associated with significantly higher risk of breast and ovarian 
cancer in female population and prostate cancer in males.
Women carrying ascertained pathogenic mutations have a higher lifetime risk 
of the disease. It’s estimated that 55–65% of women with a germinal mutation 
in BRCA1 will develop breast cancer before age 70. In our series, median age of 
first diagnosis of breast cancer was 42.5 years (range 27 ± 50); the median value 
increases significantly up to 57 years (range 39 ± 83) in ovarian cancer cases. 
Approximately 45% of women with a BRCA2 mutation will develop breast cancer 
by age 70.
BRCA2 mutation carrier patients with a family history of breast cancer have 
early median onset of 44 years (range 27 ± 54). The increase of median value is 
even more significant in ovarian cancer patients selected at any age: 59 years (range 
48 ± 77).
Cancers related to a BRCA1 mutation are also more likely to be triple-negative 
breast cancer, which can be more aggressive and difficult to treat. Triple-negative 
55



























































































































































































































































































































































































































































































































































































































































Breast Cancer and Breast Reconstruction
54
familiar tumor cases. Deleterious variants were found in 68% (15/22) of breast 
cancer cases and 31.8% (7/22) of ovarian cancer cases; variants with unknown 
significance (VUS) were observed in 81.2% of breast cancer patients and in 18.7% 
of ovarian cancer patients. Deleterious germline variants in BRCA2 5.74% (12/209) 
were featured, followed by BRCA1 4.78%(10/209) patients according to our previ-
ous study that explained a different geographical distribution of BRCA1–2 muta-
tions with a higher prevalence of the BRCA2 mutation in the north of Sardinia than 
the entire population [19].
Among families with high recurrence of breast cancer (≥ 3 cases in first-degree 
relatives), almost all ones from northern Sardinia were previously demonstrated by 
our group to share the same haplotype and carry a single mutation in BRCA2 gene 
(BRCA2-8765delAG), which thus acts as a pathogenic variant with founder effect in 
the population of this part of the island (due to the occurrence and propagation of 
a common ancestral deleterious alteration) [21]. The BRCA2-8765delAG mutation 
was firstly described in breast cancer families from French-Canadian and Jewish-
Yemenite populations; however, the families from French Canadian and Jewish-
Yemenite populations were demonstrated to present with distinct genetic assets at 
the BRCA2 locus, arguing thus against a common origin of this mutation among 
such different populations (it seems to be conducted to the high propensity to dele-
tion error in this part of the BRCA2 gene, within a so-called hot-spot mutational 
region) [22] (Table 2).
Few BRCA functional mutations account for BRCA-associated cancers among 
homogenous populations such as Sardinia (a single BRCA2 founder mutation), 
French-Canadian population (French colonization of the province of Quebec, 
five recurrent mutations of which one is common with Sardinia BOC family), and 
Jewish-Yemenite Ashkenazi Jewish families of eastern European ancestry (specific 
subpopulations; three recurrent founder mutations are known), while more hetero-
geneous populations tend to display a broad mutation spectrum; founder mutations 
are specific mutations that appear repeatedly in ethnically defined groups because 
of a shared common ancestry [23].
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breast cancer has been classified as a breast cancer subgroup with lack of ER, PR, 
and HER2 expression and accounts for 15 to 20% of breast cancer cases. Despite a 
notably favorable rate of response to chemotherapy, triple-negative patients present 
with a higher risk of relapse and a relatively poor outcome [25].
3. BRCA-related treatments
For breast cancer, treatment options depend on the stage of disease and other 
factors such as tumor size, results of specific pathology tests (hormone receptors, 
HER2 receptors, grade of the cells, and proliferation rate of the cells), family his-
tory or other risk factors associated with a predisposition for developing breast or 
ovarian cancer, and age.
Most women with ductal carcinoma in situ (DCIS), a noninvasive breast cancer, 
have breast-conserving surgery, also known as lumpectomy followed by radiation 
therapy [26]. Chemotherapy before surgery in women with large stage II or IIIA 
breast tumors is neo-adjuvant therapy to make possible that breast-conserving 
surgery. Moreover, after surgery, adjuvant therapy and radiation treatment lower 
the chance of breast cancer returning [27].
The presence of positive hormone receptor tumor cells is called estrogen recep-
tor-positive (ER-positive) breast cancer; standard hormone therapy (tamoxifen) is 
based on drug administration that blocks the action of estrogen or prevents it from 
binding to the estrogen receptor [28]. Among women whose tumors do not express 
the estrogen receptor (ER-negative breast cancer) and are positive for progesterone 
receptor (PR), tamoxifen has no effect on recurrence [29].
Herceptin (trastuzumab) can be used to treat HER2-positive breast cancer that 
is either early-stage or advanced stage/metastatic [30]; it is a humanized mono-
clonal antibody, specifically used in breast carcinomas in which the HER2/neu 
transmembrane protein is overexpressed [31]. Herceptin is currently approved to 
treat metastatic HER2-positive breast cancer to stop the cancer from growing; to 
treat earlier stages of HER2-positive breast cancer, either as part of a regimen with 
chemotherapy or alone after a chemotherapy regimen that includes an anthracy-
cline; and to reduce the risk of the breast cancer coming back (recurrence) [32], 
in combination with pertuzumab and docetaxel before surgery to treat HER2-
positive, early-stage (the cancer must be larger than 2 cm or cancer must be in the 
lymph nodes), inflammatory, or locally advanced-stage breast cancer with a high 
risk of metastasizing or becoming fatal [33]. Moreover, adjuvant treatment (after 
surgery) with the combination of pertuzumab, trastuzumab, and chemotherapy 
significantly reduces the risk of recurrence of breast cancer or death in women with 
early-stage cancer HER2-positive compared to the therapeutic standard consisting 
of trastuzumab and chemotherapy [34].
Patients with advanced diagnosis of ovarian cancer are expected to relapse 
within 3 years, after standard treatment with surgery and chemotherapy (carbopla-
tin-Taxol) [35]. Platinum-based therapy continues to be the principal regimen used 
to treat ovarian tumors that recur at least 6 months after prior therapy [36].
Carboplatin monotherapy is very convenient to administer, is well tolerated, and 
produces relatively high response rates (RRs). However, the response usually lasts for 
only a few months, and with each subsequent course of therapy, the treatment-free 
interval usually becomes shorter until the tumor is declared ‘platinum resistant.’ 
Several studies have combined platinum-based drugs with other agents. Combinations 
increase the tumor RR and extend the progression-free survival (PFS) [37, 38].
Targeted therapy of ‘platinum-sensitive’ recurrent OC is conducted in patients 
at different stages of the treatment pathway. Two classes of drug are being 
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extensively explored in the ‘platinum-sensitive’ group. These are inhibitors of 
angiogenesis, an important driver of tumor growth, with a humanized monoclonal 
antibody, bevacizumab, directed against circulating vascular endothelial growth 
factor (VEGF) A, an important ligand that binds to the VEGF receptor (VEGFR), 
stimulating angiogenesis and poly-ADP ribose polymerase (PARP) inhibitors that 
are active in patients with BRCA gene mutations, and those deficient in the repair of 
DNA damage through homologous recombination [39, 40].
A germline mutation in one BRCA1 or BRCA2 (gBRCAm) allele is associated 
with a high risk of the development of a number of cancers, including breast, ovar-
ian, and prostate cancer [41, 42]. Heterozygous BRCA mutations determine loss 
of function of the remaining wild-type allele, resulting in deficient homologous-
recombination DNA repair, which causes genetic aberrations that drive carcinogen-
esis; the inactivation of the wild-type allele in the tumor is thought to be an obligate 
step in this process [43, 44].
This tumor-specific defect can be exploited by using PARP inhibitors (e.g., 
olaparib) to induce selective tumor cytotoxicity, sparing normal cells. Poly(ADP-
ribose) polymerase (PARP) is an enzyme involved in base excision repair mecha-
nisms, enabling the adjustment of DNA single-strand breaks repair [45]. Different 
Parp inhibitors were approved by US FDA: olaparib was approved for use in women 
with deleterious germline BRCA mutated advanced ovarian cancer and deleterious 
gBRCAm HER2-negative metastatic breast cancer, while rucaparib was approved 
for use in women with germline and/or somatic BRCA mutation in advanced ovar-
ian cancer. Several additional Parp inhibitors are in late-phase clinical trials [46].
PARP inhibition in mutated tumor cells with deficient homologous-recombina-
tion repair generates unrepaired DNA single-strand breaks that are likely to cause the 
accumulation of DNA double-strand breaks and collapsed replication forks [47, 48]. 
Contrariwise, the normal tissue cells that are heterozygous for BRCA mutations and 
that therefore retain homologous-recombination function have a sensitivity to PARP 
inhibitors similar to that of wild-type cells, predicting a high therapeutic effect for 
PARP inhibition in BRCA carriers [49, 50].
The benefits of olaparib (as inhibitor of poly-adenosine diphosphate ribose 
polymerase) are already widely known in disease relapses. The SOLO-1 study, a 
double-blind, randomized, prospective phase 3 trial, went to explore for the first 
time the effects of olaparib as a maintenance therapy, immediately after surgery 
and chemotherapy, in the newly diagnosed tumor forms, advanced (phase III-IV), 
BRCA mutated, with a partial or complete clinical response after chemotherapy. 
Results of the study are encouraging: after a median follow-up of 41 months, the 
risk of disease progression and/or mortality was 70% lower in patients treated with 
olaparib than in the control group [51].
4. Conclusions
Genetic testing for breast and ovarian cancer has clinical importance for identi-
fication of potentially affected families and for cancer prevention. Approximately, 
only 5–10% of breast and ovarian cancer are familiar.
Sardinia population shows genetic peculiarity due to geographical isolation and 
strong genetic drift. The geographical distribution of BRCA1–2 mutations is related 
to three specific large areas of Sardinia, reflecting its ancient history: the Northern 
area, linguistically different from the rest of the island where a BRCA2-8765delAG 
mutation with founder effect, already displayed in our previously study, is pre-
dominant [19]. Considering the incidence of the BRCA2-8765delAG variant among 
the unselected patients from the Sardinian population, our extensive past screening 
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breast cancer has been classified as a breast cancer subgroup with lack of ER, PR, 
and HER2 expression and accounts for 15 to 20% of breast cancer cases. Despite a 
notably favorable rate of response to chemotherapy, triple-negative patients present 
with a higher risk of relapse and a relatively poor outcome [25].
3. BRCA-related treatments
For breast cancer, treatment options depend on the stage of disease and other 
factors such as tumor size, results of specific pathology tests (hormone receptors, 
HER2 receptors, grade of the cells, and proliferation rate of the cells), family his-
tory or other risk factors associated with a predisposition for developing breast or 
ovarian cancer, and age.
Most women with ductal carcinoma in situ (DCIS), a noninvasive breast cancer, 
have breast-conserving surgery, also known as lumpectomy followed by radiation 
therapy [26]. Chemotherapy before surgery in women with large stage II or IIIA 
breast tumors is neo-adjuvant therapy to make possible that breast-conserving 
surgery. Moreover, after surgery, adjuvant therapy and radiation treatment lower 
the chance of breast cancer returning [27].
The presence of positive hormone receptor tumor cells is called estrogen recep-
tor-positive (ER-positive) breast cancer; standard hormone therapy (tamoxifen) is 
based on drug administration that blocks the action of estrogen or prevents it from 
binding to the estrogen receptor [28]. Among women whose tumors do not express 
the estrogen receptor (ER-negative breast cancer) and are positive for progesterone 
receptor (PR), tamoxifen has no effect on recurrence [29].
Herceptin (trastuzumab) can be used to treat HER2-positive breast cancer that 
is either early-stage or advanced stage/metastatic [30]; it is a humanized mono-
clonal antibody, specifically used in breast carcinomas in which the HER2/neu 
transmembrane protein is overexpressed [31]. Herceptin is currently approved to 
treat metastatic HER2-positive breast cancer to stop the cancer from growing; to 
treat earlier stages of HER2-positive breast cancer, either as part of a regimen with 
chemotherapy or alone after a chemotherapy regimen that includes an anthracy-
cline; and to reduce the risk of the breast cancer coming back (recurrence) [32], 
in combination with pertuzumab and docetaxel before surgery to treat HER2-
positive, early-stage (the cancer must be larger than 2 cm or cancer must be in the 
lymph nodes), inflammatory, or locally advanced-stage breast cancer with a high 
risk of metastasizing or becoming fatal [33]. Moreover, adjuvant treatment (after 
surgery) with the combination of pertuzumab, trastuzumab, and chemotherapy 
significantly reduces the risk of recurrence of breast cancer or death in women with 
early-stage cancer HER2-positive compared to the therapeutic standard consisting 
of trastuzumab and chemotherapy [34].
Patients with advanced diagnosis of ovarian cancer are expected to relapse 
within 3 years, after standard treatment with surgery and chemotherapy (carbopla-
tin-Taxol) [35]. Platinum-based therapy continues to be the principal regimen used 
to treat ovarian tumors that recur at least 6 months after prior therapy [36].
Carboplatin monotherapy is very convenient to administer, is well tolerated, and 
produces relatively high response rates (RRs). However, the response usually lasts for 
only a few months, and with each subsequent course of therapy, the treatment-free 
interval usually becomes shorter until the tumor is declared ‘platinum resistant.’ 
Several studies have combined platinum-based drugs with other agents. Combinations 
increase the tumor RR and extend the progression-free survival (PFS) [37, 38].
Targeted therapy of ‘platinum-sensitive’ recurrent OC is conducted in patients 
at different stages of the treatment pathway. Two classes of drug are being 
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ian, and prostate cancer [41, 42]. Heterozygous BRCA mutations determine loss 
of function of the remaining wild-type allele, resulting in deficient homologous-
recombination DNA repair, which causes genetic aberrations that drive carcinogen-
esis; the inactivation of the wild-type allele in the tumor is thought to be an obligate 
step in this process [43, 44].
This tumor-specific defect can be exploited by using PARP inhibitors (e.g., 
olaparib) to induce selective tumor cytotoxicity, sparing normal cells. Poly(ADP-
ribose) polymerase (PARP) is an enzyme involved in base excision repair mecha-
nisms, enabling the adjustment of DNA single-strand breaks repair [45]. Different 
Parp inhibitors were approved by US FDA: olaparib was approved for use in women 
with deleterious germline BRCA mutated advanced ovarian cancer and deleterious 
gBRCAm HER2-negative metastatic breast cancer, while rucaparib was approved 
for use in women with germline and/or somatic BRCA mutation in advanced ovar-
ian cancer. Several additional Parp inhibitors are in late-phase clinical trials [46].
PARP inhibition in mutated tumor cells with deficient homologous-recombina-
tion repair generates unrepaired DNA single-strand breaks that are likely to cause the 
accumulation of DNA double-strand breaks and collapsed replication forks [47, 48]. 
Contrariwise, the normal tissue cells that are heterozygous for BRCA mutations and 
that therefore retain homologous-recombination function have a sensitivity to PARP 
inhibitors similar to that of wild-type cells, predicting a high therapeutic effect for 
PARP inhibition in BRCA carriers [49, 50].
The benefits of olaparib (as inhibitor of poly-adenosine diphosphate ribose 
polymerase) are already widely known in disease relapses. The SOLO-1 study, a 
double-blind, randomized, prospective phase 3 trial, went to explore for the first 
time the effects of olaparib as a maintenance therapy, immediately after surgery 
and chemotherapy, in the newly diagnosed tumor forms, advanced (phase III-IV), 
BRCA mutated, with a partial or complete clinical response after chemotherapy. 
Results of the study are encouraging: after a median follow-up of 41 months, the 
risk of disease progression and/or mortality was 70% lower in patients treated with 
olaparib than in the control group [51].
4. Conclusions
Genetic testing for breast and ovarian cancer has clinical importance for identi-
fication of potentially affected families and for cancer prevention. Approximately, 
only 5–10% of breast and ovarian cancer are familiar.
Sardinia population shows genetic peculiarity due to geographical isolation and 
strong genetic drift. The geographical distribution of BRCA1–2 mutations is related 
to three specific large areas of Sardinia, reflecting its ancient history: the Northern 
area, linguistically different from the rest of the island where a BRCA2-8765delAG 
mutation with founder effect, already displayed in our previously study, is pre-
dominant [19]. Considering the incidence of the BRCA2-8765delAG variant among 
the unselected patients from the Sardinian population, our extensive past screening 
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clearly indicated that such a mutation is recurrent in North Sardinia, confirming its 
role as founder mutation in this part of the island but absent in South Sardinia [52].
Breast cancer families originating from South Sardinia, where BRCA1 mutations 
are demonstrated to be much more prevalent, present markedly higher rates of 
association with ovarian cancer [12].
BRCA2 mutations were notably more recurrent than BRCA1 mutations in breast 
cancer families from North Sardinia and less than 10% of breast cancer families 
presented an association with ovarian cancer (at least one affected family member) 
[17]. Nevertheless, the presence of ovarian cancer was demonstrated to significantly 
increase the occurrence of BRCA1/2 germline mutations in Sardinian breast cancer 
families [12, 19].
The incidence and mortality trends of ovarian cancer in North Sardinia 
remained relatively stable in the last decade with cumulative risk of death from 
the disease being low. Furthermore, survival of patients with ovarian cancer was 
relatively good in the area, sanctioning the adequacy of the preventive and clinical 
measures employed in the management of the disease. As for other malignancies, 
concurrence of different environmental factors and genetic backgrounds may 
determine the incidence of ovarian cancer.
4.1 Future perspectives
The identification of pathogenic mutations makes it possible to identify, within 
familial cases, a subpopulation of individuals who present mutations in BRCA-
genes. In this classification, however, individuals in whom deleterious mutations 
could not be identified are excluded, despite having an important family history. 
Furthermore, the uncertain variants of two major genes do not explain the cancer 
susceptibility to germ cells.
The future venue of this study is to extend the analysis to possible minor 
breast cancer susceptibility genes involved in homologous recombination 
pathways and in repair mechanisms, thanks to the use of increasingly advanced 
sequencing technologies that involve the use of multigene cancer panels. 
Functional study and bioinformatics prediction tools provide a putative clinical 
significance for the identification of somatic variants of interaction between 
BRCA1 and DNA repair genes and may contribute to identify a role many genes in 
cancer development.
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Genetic Mutation Carriers: 
Special Considerations for Their 
Influence on a Modern Breast 
Reconstruction Practice
Ashley A. Woodfin and Anuja K. Antony
Abstract
With medical advancement, increasing numbers of genetic variations and 
mutations are being uncovered that offer greater insight into which patients have 
a predisposition for the development of breast cancer. Reasonable management 
for these patients includes high-risk surveillance, medical prophylaxis, or bilateral 
prophylactic mastectomy with immediate reconstruction which is becoming 
increasingly popular. However, this cohort of patients differs from the average 
breast cancer patient in that they are typically younger and may have distinct 
reconstructive objectives for their outcomes. This chapter considers this unique 
and expanding population, as well as their expectations for surgical outcomes both 
aesthetically and oncologically. We will discuss the evolving role of social media in 
this population, with patient to patient virtual information sharing and how this 
may impact patient referrals in a manner diverging from traditional hospital-based 
patterns. Furthermore, we discuss how practices in which cutting-edge and novel 
surgical treatments are available, such as pre-pectoral and single stage reconstruc-
tion, and that incorporate team collaboration with the surgical oncologist to deliver 
aesthetically pleasing results with nipple sparing mastectomy and concealed scars 
may ultimately be attractive to genetic mutation carriers concerned not only with 
risk reduction but also post-operative aesthetics.
Keywords: bilateral prophylactic mastectomy, genetic mutation carriers, breast 
reconstruction, referrals, direct to implant reconstruction
1. Introduction
Primed with internet and social media, high risk breast cancer patients today 
are increasingly aware of potential outcomes, both oncologic and aesthetic. Modern 
surgeons today are adapting to an era of technology where patients are empow-
ered like never before. Patients are connected through online groups where they 
can support each other, share information regarding their treatment and discuss 
management well ahead of their surgical consultation. The era of the “simply 
grateful” patients has been replaced with an increasingly sophisticated generation 
of patients who can access information rapidly and network with other individuals 
facing similar decisions. Patients have the power to investigate, rate and review 
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their physicians and surgeons through online platforms, the results of which can 
have significant implications for a practitioner.
Considering the relative ease of obtaining information about surgical options 
coupled with patients’ growing self-awareness regarding their own health, the 
high-risk breast cancer patient population now confronts a myriad of surgical 
options. Decisions regarding bilateral prophylactic mastectomy (BPM) are being 
contemplated by high risk mutation carriers who wish to not only elude breast 
cancer’s grasp, but also remain physically attractive, feminine and desirable. In 
addition, awareness from prominent public figures and known mutation carriers, 
such as Angelina Jolie, has drawn admirers and critics alike for their decision to 
undergo BPM and reconstruction in the absence of cancer; surgeons must now 
adapt to a younger generation of patients with an elevated consciousness. A surgeon 
today must not only be constantly on top of the literature associated with breast 
cancer care, they must also evolve their practice to be cognizant that patients now 
may seek out their surgeons via less traditional methods. Online reviews, Facebook 
groups and virtual patient to patient interactions, which were once reserved for 
identifying high quality eating establishments, are now being used to distinguish 
high quality surgeons from a menu of practitioners. Physicians practicing in today’s 
medical environment can no longer rely solely on traditional methods of establish-
ing credibility such as pedigree, years of practice, and direct physician to physician 
recommendations. Google searches, medical review sites, online communities and 
social media can significantly impact a patient’s impression of MD integrity and 
excellence.
The genetic mutation carrier (GMC) female patient seeking risk reduction 
surgery with reconstruction is unique and we hope to elucidate how a surgeon 
can navigate their associated unique considerations and enhanced expectations, 
both aesthetic and oncologic. We will discuss the role of social media for patient-
to-patient virtual experience sharing, as well online physician review websites in 
regard to referral practices [1]. Furthermore, we will clarify what referral practices 
contributed to our institution’s recent surge in the GMC patient population. In 
addition, we will discuss optimal collaboration between the surgical oncologist and 
plastic surgeon needed to provide cutting-edge surgical treatment and novel surgi-
cal techniques such as prepectoral (above the muscle) and direct to implant (single 
stage) reconstruction, as well as how these practices may attract future patients.
2. Decisions facing a younger population of breast surgery patients
GMCs are an emerging population of patients with unique characteristics, per-
spective, and expectations of surgery. Only 1 out of every 400 people in the general 
population is estimated to be a BRCA1/2 mutation holder, with ~5–10% of breast 
cancers at all ages being associated with an inherited gene mutation [2]. Currently 
the BRCA1/2, ATM, CHEK2, PALB2, TP53, PTEN, CH1, STK11, NBN, NF1 muta-
tions all confer increased risk for breast cancer development, warranting the 
consideration of BPM for risk reduction [3]. Overall, we expect a 12% lifetime risk 
of breast cancer development in the general population without any risk factors [4]. 
This risk increases to 45–65% by age 70 in the population of known mutation carri-
ers of BRCA1/2 [2]. BPM has been shown to reduce the risk by roughly 90% in high 
risk populations [3], with prophylactic mastectomy and immediate reconstruction 
becoming increasingly more popular [5, 6]. However, not all GMCs choose BPM, 
some may prefer to elect chemoprophylaxis or high-risk surveillance instead. This 
decision is often determined by patient factors, with a recent study showing that 
GMCs choosing BPM over surveillance tend to have a college education, income 
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>$50,000, a first-degree relative with breast cancer, higher total number of relatives 
with breast cancer, and a prior pregnancy [7].
Frequently, woman does not receive a GMC status until after they are diagnosed 
with a cancer, generally at a younger age. Additionally, many are also being found 
prior to a cancer diagnosis because of a previously diagnosed family member that 
underwent that genetic work-up. With these avenues to diagnosis as a GMC, these 
patients are younger than the average breast cancer patient when they first see a 
surgeon. This younger age often plays a major role in the decisions these patients 
make regarding risk reduction surgery and reconstruction.
GMCs that elect for BPM and reconstruction tend to have higher aesthetic 
expectations than those who require the procedure for treatment of active cancer. 
There are multiple reasons for this, chief among them being that prophylactic sur-
gery is not considered ‘life-saving’ and that the patients are at a point in life where 
cosmesis may play a larger factor. The heightened concern for looking ‘natural’ and 
‘unoperated’ is an ongoing driver for novel surgical treatments when caring for a 
patient in this cohort.
In addition, unlike a breast cancer patient, GMC patients have the option of 
choosing when they want to undergo BPM. Certain life factors can greatly influ-
ence when a patient decides to ultimately undergo this prophylactic surgery in 
her lifetime. Large life events such as marriage and having children can be a major 
concern in this younger population. Additionally, bilateral mastectomies eliminate 
the possibility of a woman breastfeeding her children, which many women value 
as an important bonding experience between mother and child. Aspiring mothers 
considering BPM may not want to sacrifice this opportunity and timing will be an 
important factor. A GMC patient’s decision regarding surgical timing for BPM is 
completely personal, and ultimately weighs quality of life with the risk of breast 
cancer development during the delay. Thus, in a patient strongly desiring to breast-
feed her children, family planning plays a very important role in timing for BPM.
3. Long term considerations: implant longevity, surveillance
Yet another facet of caring for the younger age breast surgery patient popu-
lation is regarding the long-term durability of their reconstruction following 
BPM. Historically, it has been recommended that patients who underwent cosmetic 
breast augmentation have their implants exchanged approximately every 10 years. 
This was after a study published in 1995 found that 81% of implants studied at 
10 years were found to have been ruptured [8, 9]. However, due to advancements 
in implant technology resulting in increased stability of silicone implants using 
cohesive gel cross-linking technology and thicker implant shells, it is suggested that 
silicone implants today have greater longevity, but still are not considered ‘lifetime 
devices’. A patient can expect her implants to last at least a decade, with a 1% risk of 
rupture per year [10]. Another source estimates the new cohesive silicone implants 
to have a lifetime of 25–35 years [11]. Considering that women may be undergoing 
BPM with immediate reconstruction as early as their second and third decades 
of life, they would be expected to live another 50 or greater years following this 
surgery. Over this long of a timespan, a patient’s implants may experience signifi-
cant degradation, even considering new implant technology, with future surgery for 
replacement being considered by many an eventuality [10, 11].
It is important to remember that implant-based breast reconstruction comes 
with risk of prosthesis rupture, albeit minimal. Commonly, silicone implant rup-
ture is related to the normal aging of the prosthesis, but can also rarely be caused 
by forceful blunt trauma [11]. Implant rupture can occur both silently (without 
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>$50,000, a first-degree relative with breast cancer, higher total number of relatives 
with breast cancer, and a prior pregnancy [7].
Frequently, woman does not receive a GMC status until after they are diagnosed 
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cohesive gel cross-linking technology and thicker implant shells, it is suggested that 
silicone implants today have greater longevity, but still are not considered ‘lifetime 
devices’. A patient can expect her implants to last at least a decade, with a 1% risk of 
rupture per year [10]. Another source estimates the new cohesive silicone implants 
to have a lifetime of 25–35 years [11]. Considering that women may be undergoing 
BPM with immediate reconstruction as early as their second and third decades 
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by forceful blunt trauma [11]. Implant rupture can occur both silently (without 
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symptom development) or symptomatically, and is also classified as being intracap-
sular or extracapsular in nature. Intracapsular rupture is defined as being contained 
within the fibrous breast capsule, whereas extracapsular rupture is more concern-
ing and consists of extravasated silicone gel outside of the fibrous capsule into the 
surrounding tissues and can lead to inflammation and granuloma formation [11]. 
Extracapsular rupture is a rare occurrence with silicone implants [29], especially 
considering the high cohesive types used today. At this time, formal recommenda-
tions from the FDA include screening for silent rupture in patients with silicone 
implants using MRI at 3 years following prosthesis placement, and then every 
2 years thereafter [12]. However, a recent meeting of the advisory panel to the FDA 
released recommendations for revision in implant rupture screening guidelines 
in late March 2019. These updated recommendations consist of MRI screening at 
5–6 years post-operatively, and then every 2–3 years thereafter, with ultrasound 
being an acceptable alternative to MRI for screening in asymptomatic patients [13]. 
Unfortunately, these amendments are considered just panel recommendations 
to the FDA at this time, with the notion that they will be formally adopted by the 
agency in the upcoming months.
Another critical consideration in this patient population is that of continued 
surveillance following BPM and reconstruction. As discussed earlier, GMC patients 
need to be educated about the persistent need for surveillance despite prior mas-
tectomy. Patients should understand that although the majority of breast tissue is 
removed, the small amount left behind can still ultimately allow for cancer develop-
ment. Traditional surveillance with mammography is not an option following BPM 
with reconstruction, requiring this responsibility be placed on the patient and her 
physicians. Bearing this in mind, it is important for these patients to continue to 
follow with medical practitioners regularly. Furthermore, self-breast examination 
and awareness is encouraged to monitor for the formation of any new bumps or 
irregularities, as these could be cancer development from remnant breast tissue.
Considering all the long-term matters discussed above, it is essential for both the 
surgical oncologist and plastic surgeon to fully discuss these factors with prospec-
tive BPM and reconstruction patients. These factors may play important roles in the 
choice of those extremely adverse to further procedures, and may ultimately influ-
ence their decision regarding whether or not prophylactic surgery is the optimal 
way to manage their GMC status.
4. Prophylactic surgery and high expectations
Reconstructive expectations of breast cancer patients have evolved greatly over 
the past few decades with quality of life and survivorship becoming a central focus. 
This is especially true when treating GMCs, putting a greater demand on the surgi-
cal collaboration required for successful execution. Today, it is not uncommon for 
patients to expect their post-surgical breasts to improve their appearance and more 
closely match their desired size and shape than their pre-surgery breast aesthetic. 
Ultimately, the GMC patient has a choices regarding surgical timing, type and the 
decision to pursue surgery or not, so expectations are inherently high.
One reason for this rise may be the downstream effect of popular culture 
with increasing acceptance for a GMC’s surgical choices, normalizing the idea of 
having a bilateral mastectomy with reconstruction for risk reduction, while also 
demonstrating the fact that a woman can still be considered desirable and attrac-
tive after this surgery. Angelina Jolie, through a series of op-ed pieces written for 
the New York Times and other media outlets, recounted her personal journey with 
having the BRCA mutation, the passing of her mother from ovarian cancer, and 
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her surgical choices for BPM and reconstruction. She single-handedly has perhaps 
most profoundly affected public opinion regarding BPM and amplified awareness 
for a GMC’s breast cancer risk. Today, the modern GMC female interested in BPM 
expects she will retain her femininity and ability to identify as a beautiful woman 
post-operatively.
For the modern surgeon, it is important to convey a confident, but realistic 
depiction of the likely outcomes during the pre-operative consultation. This 
includes discussion of individual patient factors that can influence the final aes-
thetic outcome such as BMI, current breast size and ptosis, as well as the possibility 
of requiring revisional procedures in the future (e.g., fat grafting). Patients with 
realistic expectations of their reconstructive journey and cosmetic outcomes have 
been shown more likely to be satisfied with their BPM results. Additionally, it 
appears that patients who discuss BPM with their partners prior are more likely to 
be satisfied with intimacy post-operatively [14].
5. Online era: social media and patient influence
Social media plays an ever-expanding role in our lives. There are many online 
support groups for mutation carriers that easily and immediately connect patients 
around the world [15]. Within these online groups, and social media in general, 
now exists a special category of users referred to as ‘influencers’. These are users 
who cultivate a particularly large community of ‘followers’ with which they 
share experiences, ideas, products, and influence the general attitudes of those 
that follow them. It is not uncommon to see an individual sharing their entire 
experience as a ‘mutation carrier,’ ‘cancer thriver,’ or ‘cancer survivor’ on some 
form of social media (e.g., Instagram, Facebook, or a blog) [15]. This influence 
is not confined to the normal events of everyday life, but also extends to health 
decisions. Since the experiences of one person can be so easily disseminated, the 
clinical course and opinions of a single patient can disproportionally reverberate 
throughout the entire community. This process can act as an endorsement for, 
or dissuasion against, a certain treatment, surgery, or surgeon depending on the 
level of satisfaction of a single patient. This is particularly important to a surgeon’s 
referral-based practice as the large social media following of certain patients 
can have greater consequences, both good and bad, to their “business” than seen 
historically.
Moreover, online review sites for patients to publicly rate their physicians are 
becoming more and more prevalent. Patients are taking control over who they 
choose for their care, and this does not exclude surgeons. Many visit these web-
sites prior to committing their care to a certain surgeon, and use the information 
presented there to help guide their decision. Yet, an important question needs to 
be addressed: do the ratings on these websites actually correlate with the clinical 
outcomes achieved by the physicians? Recently this has become an area of intrigue 
in the surgical community, and over the past few years, a handful of small studies 
were published exploring the possible correlation between online health ratings 
of surgeons and their surgeon-specific measurable outcomes. Some of these 
investigated outcomes include infection rate, re-admission rate, revisional surgery 
rate, and risk-adjusted mortality rate, in surgeries such as total knee replacements, 
hernia repairs, and coronary artery bypass grafting. All of these studies failed 
to find any correlation between a surgeon’s online ratings and their measurable 
outcomes, including those listed above [16–18]. These results seriously undermine 
the utility of such websites, however are unlikely to be realized by the average 
health care consumer.
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post-operatively.
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of requiring revisional procedures in the future (e.g., fat grafting). Patients with 
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been shown more likely to be satisfied with their BPM results. Additionally, it 
appears that patients who discuss BPM with their partners prior are more likely to 
be satisfied with intimacy post-operatively [14].
5. Online era: social media and patient influence
Social media plays an ever-expanding role in our lives. There are many online 
support groups for mutation carriers that easily and immediately connect patients 
around the world [15]. Within these online groups, and social media in general, 
now exists a special category of users referred to as ‘influencers’. These are users 
who cultivate a particularly large community of ‘followers’ with which they 
share experiences, ideas, products, and influence the general attitudes of those 
that follow them. It is not uncommon to see an individual sharing their entire 
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is not confined to the normal events of everyday life, but also extends to health 
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clinical course and opinions of a single patient can disproportionally reverberate 
throughout the entire community. This process can act as an endorsement for, 
or dissuasion against, a certain treatment, surgery, or surgeon depending on the 
level of satisfaction of a single patient. This is particularly important to a surgeon’s 
referral-based practice as the large social media following of certain patients 
can have greater consequences, both good and bad, to their “business” than seen 
historically.
Moreover, online review sites for patients to publicly rate their physicians are 
becoming more and more prevalent. Patients are taking control over who they 
choose for their care, and this does not exclude surgeons. Many visit these web-
sites prior to committing their care to a certain surgeon, and use the information 
presented there to help guide their decision. Yet, an important question needs to 
be addressed: do the ratings on these websites actually correlate with the clinical 
outcomes achieved by the physicians? Recently this has become an area of intrigue 
in the surgical community, and over the past few years, a handful of small studies 
were published exploring the possible correlation between online health ratings 
of surgeons and their surgeon-specific measurable outcomes. Some of these 
investigated outcomes include infection rate, re-admission rate, revisional surgery 
rate, and risk-adjusted mortality rate, in surgeries such as total knee replacements, 
hernia repairs, and coronary artery bypass grafting. All of these studies failed 
to find any correlation between a surgeon’s online ratings and their measurable 
outcomes, including those listed above [16–18]. These results seriously undermine 
the utility of such websites, however are unlikely to be realized by the average 
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Furthermore, a similar study went one step further to try and identify what 
positively versus negatively influences a physician’s rating by reading and analyz-
ing the written reviews/comments on these websites. In order to accomplish this, 
the reviews were read by study staff and comments were classified as being either 
surgeon-dependent factors (competence or likeability) or surgeon-independent 
factors (office environment, staff, billing, etc.). Interestingly, this study found that 
comments on surgeon-dependent factors were associated with higher ratings, and 
furthermore that comments on surgeon-independent factors were associated with 
lower ratings [19]. This ultimately reinforces the results of the previously discussed 
studies, that physician ratings are not associated with outcomes, but rather highly 
influenced by office interactions. However, it does emphasize the importance of 
a good bedside manner for the surgeon, as well as his office staff, in addition to 
bringing awareness to the significance of the overall perceived patient experience 
when rating their physician on these websites—not unlike how a patron would 
consider their entire culinary dining experience and not just their food to formulate 
a restaurant review.
6. Our experience: what guides patient referrals
To better understand how the internet and social media affects patient referrals, 
we reviewed our patient database and identified recent GMCs in the absence of can-
cer (n = 10) that underwent BPM with immediate reconstruction at our institution. 
GMCs without a current diagnosis of cancer were of interest as they are inherently 
less pressured to make surgical decisions. Given these patients did not have active 
cancer, they had the advantage of taking as much time as they needed to research 
online, look for personal referrals, and read online health grade reviews before 
making their decision. Theoretically, they also had less tying them to a specific 
institution given no cancer diagnostic information had to be transferred from one 
institution to another. Patients’ referral patterns were reviewed and, if interested, 
were asked to complete a telephone survey (70% response rate) regarding their 
decision to pursue surgery at our institution.
Many stated that they first chose to undergo consultation at our institution 
because of internal referrals from physicians they already trusted. Most notably the 
patients stated their referrals tended to come from OB/GYNs when looking a surgi-
cal oncologist, and from the surgical oncologist when looking for a plastic surgeon. 
This emphasizes the importance of a strong collaborative relationship between the 
two surgeons.
The majority stated that the aspect of utmost importance in confirming their 
decision was feeling confident and comfortable with their surgeons after meeting 
them for initial consultations. Many women stated that their interactions with both 
the surgical oncologist and plastic surgeon were very open and honest, especially 
in taking the time to answer all the patients’ questions. They felt a strong personal 
connection with their surgeons and the warmth they experienced helped build 
trust, which comforted them and positively influenced their decision to receive care 
at our institution.
For many, the internet and social media served as a resource affirming their 
decision to receive care at our institution. One patient detailed that her surgical 
oncologist was mentioned favorably in Facebook groups, and plastic surgeon 
was known to have a great reputation online as well, but noted that this did not 
primarily drive her decision. Approximately one third of the patients looked at 
online health reviews and ratings for their surgeons prior to committing care to our 
institution, and stated again that these served to positively reinforce their decision.
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When asked about the most important factor regarding these surgeries, the 
majority of former patients stated that risk reduction was most important to them, 
however cosmetic outcomes were found to be almost equally as important. Younger 
patients appeared more concerned with cosmetic outcomes. In regard to novel 
surgical techniques attracting patients and influencing their decisions, most stated 
that the possibility of having single stage, also known as direct to implant (DTI), 
reconstruction was very appealing to them, and was sought out. Knowing that their 
plastic surgeon was a specialist in prepectoral DTI reconstruction was important 
to these women as well. However, not all were candidates for this option at initial 
consultation, but this fact did not dissuade their ultimate decision.
7. Novel reconstructive techniques: a patient attractor
We believe that in ultimately selecting a plastic surgeon for their breast recon-
structive needs, the modern GMC patient not only evaluates outcomes, but also 
considers surgeons performing state-of-the-art procedures, using the newest 
technologies and novel techniques, especially when they offer obvious advantages 
to the patient. This includes pre-pectoral implant placement, as well as single stage 
(also referred to as direct to implant (DTI)) reconstruction. Though not necessar-
ily actively sought out by all, the possibility of being able to have immediate single 
stage reconstruction could solidify a patient’s decision to receive care with a certain 
plastic surgeon by offering them the option of a shortened reconstructive course. 
More recently popularized mastectomy techniques such as the nipple sparring mas-
tectomy (NSM), when oncologically appropriate, are being more actively sought 
out from oncologic surgeons as well, as they also contribute to more aesthetically 
pleasing results.
The nipple is generally considered a distinguishing feature of a natural breast. 
Considering this fact, NSM continues to be increasingly popular with GMCs. In 
2018, a review of the American Society of Breast Surgeons (ASBrS) NSM database 
showed the majority of NSMs as being performed for prophylactic reasons [20]. 
Furthermore, NSM patients tend to be younger, Caucasian, and have smaller BMIs 
[21]. Another study showed higher body image scale scores in NSM compared to 
skin sparring mastectomy (SSM), but the difference was not statistically significant 
[22]. Other studies have also noted higher psychosocial [23] and sexual wellbeing 
scores in NSM patients [21].
However, NSM is not without risk; their documented complication rate is low 
but not insignificant, and includes possible complications to the nipple areolar 
complex (NAC) such as nipple necrosis and epidermolysis, in addition to infection 
and mastectomy flap necrosis risk seen in all mastectomies. A recent review of the 
ASBrS NSM database documented a NAC complication rate of 4.4% [20]. Moreover, 
there is a statistically significant decrease in the measured sensation of the NAC 
after NSM when compared to control groups [22]. Unfortunately, this reality of a 
nipple sparing mastectomy is not always completely understood by patients prior to 
consultation. Explaining these risks and realities can be more difficult in a patient 
population that has less tolerance for imperfection because of how it may affect 
their quality of life. Transparency and informed consent remain critical compo-
nents to counseling the GMC patient considering BPM.
New techniques in reconstructive surgery are also likely to influence a patient’s 
decision on their surgeon preference. Novel techniques available include the option 
for prepectoral implant placement, as well as single stage (direct to implant) 
reconstruction. The availability of these techniques to patients depends on several 
factors, the first of which being plastic surgeon’s experience with the procedures, 
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the patient’s current and desired final appearance, as well as mastectomy flap thick-
ness, perfusion and viability.
Two-stage breast reconstruction using tissue expanders placed subpectorally has 
been the traditional method for immediate breast reconstruction since the 1970s. 
This technique was developed during a time when mastectomies were more radical, 
excising more skin in the surgical process. Over time, the progression of mastecto-
mies from modified-radical to skin-sparring, and now nipple-sparing, has increased 
preservation of the breast envelope and allowed for reconstructive advancements 
as well. These larger breast envelopes create the option for placing implants at 
the initial surgery without placing excess tension on the mastectomy flaps. In 
properly chosen patients, this technique can be employed without an increased 
risk for complications [24]. Reconstructive surgery performed in two stages has 
drawbacks that DTI circumvents including the avoidance of multiple episodes of 
anesthesia [25–28]. Recent studies have also elucidated other possible advantages 
with DTI, including increased patient satisfaction, reduction in pain, and possible 
reduction in cost when comparing DTI with two stage reconstruction [25–27]. DTI 
reconstruction when first introduced capitalized on the safety and advantages of 
an expanded dual plane pocket using acellular dermal matrix (ADM) as an inferior 
sling to support implant placement under the pectoralis muscle in a single stage 
surgery [29, 30]. Despite the perceived benefits, DP DTI reconstructions still retain 
the same issues created by placing a prosthesis in the subpectoral or dual plane (DP) 
position, namely animation deformity and pectoralis major origin disruption caus-
ing weakened adduction [31].
Prepectoral (PP) implant placement resolved the issue of animation deformity 
caused by subpectoral placement [31, 32]. However, without routine use of ADM, 
the subcutaneous or prepectoral techniques were historically fraught with high 
rates of early capsular contracture [33], flap necrosis, implant loss [34], and 
concern for worsened aesthetics (e.g., implant visibility, rippling) often requiring 
additional procedures for revision such as fat grafting. One study compared PP 
placement with and without the use of ADM, demonstrating significantly lower 
rates of capsular contracture in the ADM cohort [35]. From our experience, the 
crucial components necessary for successful PP DTI include initial intraoperative 
assessment of flap perfusion with sizer in place, followed by the creation of a tight 
anterior ADM pocket for implant insertion [24]. Use of anterior ADM coverage 
for implant support and off-loading pressure on the mastectomy flaps prevents 
the complications traditionally associated with PP [24], while avoiding the disad-
vantages of DP placement. Despite this, the PP DTI technique has yet to be widely 
adopted secondary to the lingering concerns over historical complications and the 
steep learning curve.
Our group performed one of the largest DTI-only comparative study (n = 134) 
between outcomes of dual plane (DP) DTI and prepectoral (PP) DTI, and showed 
an overall low complication incidence, with PP DTI complications being slightly 
less frequent (PP 2% vs. DP 12%, p = 0.07). No implant losses were documented in 
this study. Furthermore, regarding the concern over increased need for aesthetic 
revisional procedures in PP patients, no difference was shown in the likelihood 
of either DP or PP DTI patients to undergo these additional procedures. Last, this 
study reinforced the positive aesthetic outcomes of PP DTI with a blinded panel 
scoring PP DTI reconstructions higher than DP DTI in terms of aesthetic outcome 
[32]. This study effectively corroborated the non-inferiority of PP DTI to DP DTI 
reconstructive techniques, as well as demonstrated its advantage in better cosmetic 
outcomes. Because of this, the ability to perform PP DTI could be potentially attrac-
tive to patients concerned with aesthetic outcomes when looking for a reconstruc-
tive surgeon.
73
Genetic Mutation Carriers: Special Considerations for Their Influence on a Modern Breast…
DOI: http://dx.doi.org/10.5772/intechopen.86795
Finally, it should be noted that appropriate patient selection is of utmost impor-
tance for successful PP DTI. As explained earlier in this chapter, adequate mastec-
tomy flap perfusion is crucial for employment of this reconstructive technique, and 
we advocate intra-operative use of fluorescence imaging technology to ensure this. 
Our group considers active smoking and uncontrolled medical co-morbidities to be 
absolute contraindications to PP DTI. Whereas, obesity is only considered a relative 
contraindication and our group has found that the use of oncoplastic reconstructive 
techniques in conjunction with implant placement has yielded great results. More 
ideal patients for PP DTI include those desiring results similar to their native breast 
size [24], though we have found upsizing of the breast to be possible in the compli-
ant envelope.
8. Surgeon collaboration: oncologic and reconstructive considerations
The goal of BPM in GMCs is risk reduction, and in order to achieve this goal, 
removal of as much breast tissue as possible provides the best oncologic benefit. 
A mastectomy, while drastically reducing cancer occurrence, does not completely 
eliminate the possibility of breast cancer development in the future. As tissue 
removal and oncologic benefit increases, risk benefit must be considered as 
excessively thin mastectomy flaps incur higher risk for ischemia, complicating 
reconstructive efforts. Adequate flap vascularity is a critical component to success-
ful breast reconstruction, especially single stage, with thicker flaps conferring less 
risk of ischemia and flap necrosis [31, 36]. This relationship between removing the 
maximum amount of breast tissue while retaining flap perfusion are the competing 
priorities that surgical oncologists and plastic surgeons must navigate effectively 
together.
Approaching a combined mastectomy/reconstruction patient most importantly 
requires effective communication between the two surgeons. Additionally, in 
our institution we employ fluorescence imaging technology in immediate breast 
reconstruction cases to help quantify perfusion to the flaps [37]. This practice 
identifies the flaps at risk for ischemia so that the appropriate reconstructive path 
for each patient can be followed, guiding the decision-making process surround-
ing whether a patient is more appropriate for one or two stage reconstruction, or 
delayed reconstruction.
9. Conclusion
Overall, the improved understanding of genetic mutation and risk for breast 
cancer development has created a special population of breast surgery patients. 
They have specific priorities that must be considered when it comes to surgical 
planning, risk tolerance, long term considerations, and both oncologic and aesthetic 
outcomes. This population’s younger age may play a large role in expectations with 
higher value placed on cosmesis. In response, techniques such as NSM and single 
stage prepectoral reconstruction are being more commonly used to meet this popu-
lation’s particular demands for excellent outcomes, both oncologic and cosmetic.
Considering our modern online era, we believe that the internet and social 
media will continue to increasingly affect patient referral patterns. Although online 
rating and review websites so far have shown no correlation with a surgeon’s actual 
measurable outcomes, it appears as though they continue to be popular informa-
tion sources for prospective patients and help confirm their decisions on where to 
receive care. Being mindful of this online presence will be crucial for the successful 
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Two-stage breast reconstruction using tissue expanders placed subpectorally has 
been the traditional method for immediate breast reconstruction since the 1970s. 
This technique was developed during a time when mastectomies were more radical, 
excising more skin in the surgical process. Over time, the progression of mastecto-
mies from modified-radical to skin-sparring, and now nipple-sparing, has increased 
preservation of the breast envelope and allowed for reconstructive advancements 
as well. These larger breast envelopes create the option for placing implants at 
the initial surgery without placing excess tension on the mastectomy flaps. In 
properly chosen patients, this technique can be employed without an increased 
risk for complications [24]. Reconstructive surgery performed in two stages has 
drawbacks that DTI circumvents including the avoidance of multiple episodes of 
anesthesia [25–28]. Recent studies have also elucidated other possible advantages 
with DTI, including increased patient satisfaction, reduction in pain, and possible 
reduction in cost when comparing DTI with two stage reconstruction [25–27]. DTI 
reconstruction when first introduced capitalized on the safety and advantages of 
an expanded dual plane pocket using acellular dermal matrix (ADM) as an inferior 
sling to support implant placement under the pectoralis muscle in a single stage 
surgery [29, 30]. Despite the perceived benefits, DP DTI reconstructions still retain 
the same issues created by placing a prosthesis in the subpectoral or dual plane (DP) 
position, namely animation deformity and pectoralis major origin disruption caus-
ing weakened adduction [31].
Prepectoral (PP) implant placement resolved the issue of animation deformity 
caused by subpectoral placement [31, 32]. However, without routine use of ADM, 
the subcutaneous or prepectoral techniques were historically fraught with high 
rates of early capsular contracture [33], flap necrosis, implant loss [34], and 
concern for worsened aesthetics (e.g., implant visibility, rippling) often requiring 
additional procedures for revision such as fat grafting. One study compared PP 
placement with and without the use of ADM, demonstrating significantly lower 
rates of capsular contracture in the ADM cohort [35]. From our experience, the 
crucial components necessary for successful PP DTI include initial intraoperative 
assessment of flap perfusion with sizer in place, followed by the creation of a tight 
anterior ADM pocket for implant insertion [24]. Use of anterior ADM coverage 
for implant support and off-loading pressure on the mastectomy flaps prevents 
the complications traditionally associated with PP [24], while avoiding the disad-
vantages of DP placement. Despite this, the PP DTI technique has yet to be widely 
adopted secondary to the lingering concerns over historical complications and the 
steep learning curve.
Our group performed one of the largest DTI-only comparative study (n = 134) 
between outcomes of dual plane (DP) DTI and prepectoral (PP) DTI, and showed 
an overall low complication incidence, with PP DTI complications being slightly 
less frequent (PP 2% vs. DP 12%, p = 0.07). No implant losses were documented in 
this study. Furthermore, regarding the concern over increased need for aesthetic 
revisional procedures in PP patients, no difference was shown in the likelihood 
of either DP or PP DTI patients to undergo these additional procedures. Last, this 
study reinforced the positive aesthetic outcomes of PP DTI with a blinded panel 
scoring PP DTI reconstructions higher than DP DTI in terms of aesthetic outcome 
[32]. This study effectively corroborated the non-inferiority of PP DTI to DP DTI 
reconstructive techniques, as well as demonstrated its advantage in better cosmetic 
outcomes. Because of this, the ability to perform PP DTI could be potentially attrac-
tive to patients concerned with aesthetic outcomes when looking for a reconstruc-
tive surgeon.
73
Genetic Mutation Carriers: Special Considerations for Their Influence on a Modern Breast…
DOI: http://dx.doi.org/10.5772/intechopen.86795
Finally, it should be noted that appropriate patient selection is of utmost impor-
tance for successful PP DTI. As explained earlier in this chapter, adequate mastec-
tomy flap perfusion is crucial for employment of this reconstructive technique, and 
we advocate intra-operative use of fluorescence imaging technology to ensure this. 
Our group considers active smoking and uncontrolled medical co-morbidities to be 
absolute contraindications to PP DTI. Whereas, obesity is only considered a relative 
contraindication and our group has found that the use of oncoplastic reconstructive 
techniques in conjunction with implant placement has yielded great results. More 
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The goal of BPM in GMCs is risk reduction, and in order to achieve this goal, 
removal of as much breast tissue as possible provides the best oncologic benefit. 
A mastectomy, while drastically reducing cancer occurrence, does not completely 
eliminate the possibility of breast cancer development in the future. As tissue 
removal and oncologic benefit increases, risk benefit must be considered as 
excessively thin mastectomy flaps incur higher risk for ischemia, complicating 
reconstructive efforts. Adequate flap vascularity is a critical component to success-
ful breast reconstruction, especially single stage, with thicker flaps conferring less 
risk of ischemia and flap necrosis [31, 36]. This relationship between removing the 
maximum amount of breast tissue while retaining flap perfusion are the competing 
priorities that surgical oncologists and plastic surgeons must navigate effectively 
together.
Approaching a combined mastectomy/reconstruction patient most importantly 
requires effective communication between the two surgeons. Additionally, in 
our institution we employ fluorescence imaging technology in immediate breast 
reconstruction cases to help quantify perfusion to the flaps [37]. This practice 
identifies the flaps at risk for ischemia so that the appropriate reconstructive path 
for each patient can be followed, guiding the decision-making process surround-
ing whether a patient is more appropriate for one or two stage reconstruction, or 
delayed reconstruction.
9. Conclusion
Overall, the improved understanding of genetic mutation and risk for breast 
cancer development has created a special population of breast surgery patients. 
They have specific priorities that must be considered when it comes to surgical 
planning, risk tolerance, long term considerations, and both oncologic and aesthetic 
outcomes. This population’s younger age may play a large role in expectations with 
higher value placed on cosmesis. In response, techniques such as NSM and single 
stage prepectoral reconstruction are being more commonly used to meet this popu-
lation’s particular demands for excellent outcomes, both oncologic and cosmetic.
Considering our modern online era, we believe that the internet and social 
media will continue to increasingly affect patient referral patterns. Although online 
rating and review websites so far have shown no correlation with a surgeon’s actual 
measurable outcomes, it appears as though they continue to be popular informa-
tion sources for prospective patients and help confirm their decisions on where to 
receive care. Being mindful of this online presence will be crucial for the successful 
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modern plastic surgery practice, in addition to offering novel surgical techniques 
to satisfy the expectations of today’s patients. However, the traditional practice of 
upholding a good bedside manner, developing excellent surgeon-patient rapport, 
and patient trust in their referring physician will continue to be important factors.
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Oncoplastic Surgery in Breast 
Cancer
Atallah David, Moubarak Malak and Abdallah Abdallah
Abstract
Oncoplastic surgery is an emerging approach which combines breast-conserving 
surgery and plastic surgery techniques. It aims to provide wider volume resec-
tion with oncologically clear margins and at the same time to maintain the breast 
shape and optimize cosmetic outcomes. Inspired from esthetic breast surgery 
techniques, oncoplasty consists of breast volume displacement to fill the defect 
of large resections and optimize the cosmetic outcomes without interfering with 
the oncoplastic safety. In this chapter, the concept, indications, and principles of 
oncoplastic techniques used in conservative breast surgeries will be exposed. A 
photo-based atlas for oncoplastic incisions will concern seven cases starting with 
the preoperative planning and marking and ending up with the long-term postop-
erative outcomes.
Keywords: breast cancer, oncoplasty, oncological safety, cosmetic outcome
1. Introduction
During the last century, breast surgery has witnessed a tremendous evolution 
leading to radical changes in surgical concepts and standards. In 1894, William 
S. Halsted published the first results of the known “Halsted radical mastectomy” 
which consisted of en bloc resection of all suspected tissues including all breast 
tissue, axillary lymph nodes, and both pectoral muscles [1]. This technique lasted 
for more than 50 years until Patey and Dyson have introduced the modified 
radical mastectomy with sparing of the pectoralis muscles [2]. Later in the 1970s 
with the introduction of the radiotherapy in the management of breast cancer, 
we started to abandon the “fits all” mastectomy approach as we demonstrated 
the equivalency of breast-conserving surgery when combined to radiotherapy 
in comparison to mastectomy. With the comparable survival and recurrence 
rates between the two approaches published by the Milan trials and the National 
Surgical Adjuvant Breast and Bowel Project (NSABP) B-04 trial, we entered a new 
era in the breast cancer management and shifted the paradigm away from the psy-
chological burden that was associated with the mastectomy [3, 4]. Gradually the 
breast-conserving surgery combined with radiotherapy has become the preferred 
approach in the case of early breast cancer cases however with high rates of poor 
cosmetic outcomes (30–40%) and residual deformities, especially when larger 
volume excision is needed. The failure of classical breast-conserving surgery 
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techniques has anticipated the development of new approaches to improve 
cosmetic outcomes as well as patient satisfaction. From this ideal, the oncoplastic 
surgery was born in the last two decades [5].
2. Definition and concept
Oncoplastic surgery is a new approach that combines surgical oncological 
principles with plastic surgical techniques. It aims to provide wide tumor excision 
with an immediate reshaping of the remaining breast tissue using many forms of 
remodeling techniques. The goal of oncoplastic surgery is to completely remove 
the lesion with clear margins and with good to excellent cosmetic result in one 
definitive procedure [6]. This novel technique does not compromise the oncological 
safety. At the contrary, it proves good oncological efficacy in terms of margin status 
and recurrence in comparison to traditional breast-conserving surgery techniques. 
This could be related to the large breast volume excision and consequently safe 
margins that this technique provides [7–10]. It is worthy to note that the surgeon 
can perform this approach with sentinel lymph node biopsy or axillary lymph node 
dissection.
3. Principle
Before deciding if a patient is eligible to undergo an oncoplastic surgery, we 
need to consider three factors: excision volume, tumor location, and glandular 
density [11].
First of all, excision volume is the most predictive factor for poor outcomes. 
It was suggested that excision of >20% of breast tissue could impair the breast 
shape and lead to a poor cosmetic outcome [12, 13]. With oncoplastic tech-
niques, the surgeon can remove an average of 200 g up to 1000 g and without 
interfering with the natural breast shape [14]. A remodeling of the adjacent 
remaining breast tissue enables the surgeon to fill the defect created by the 
tumor resection. A preoperative assessment of the breast volume and tumor size 
as well as a proper evaluation of the imaging findings guides the surgeon in his 
operative decision.
Second, the tumor location plays an essential role in guiding the incision type 
and the size of volume excision. For example, correcting a defect after removing 
a tumor from the upper outer quadrant is easier in comparison to a defect in the 
upper inner quadrant where less breast tissue is available to be mobilized [11].
Third, the breast density guides the extent of breast undermining and reshaping. 
A breast with high fat composition limits the tissue manipulation and mobilization 
and may expose to higher rates of complications especially fat necrosis. A preopera-
tive mammographic evaluation aids in the breast density assessment and helps the 
surgeon in his operative choice [11].
Additional factors to be considered are:
• The fat content in the axillary area in the case of resection in the outer quadrants
• The size of the breast and its implication on the extent of volume excision
• The grade of ptosis
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• The associated clinical conditions, especially smoking, uncontrolled diabetes, 
or older age that may interfere with the healing process and lead to higher 
 complications rates [15]
4. Preoperative planning
The success of an oncoplastic procedure starts with a good and reasonable 
preoperative planning. The first issue to be considered is the estimated volume of 
the tumor relative to the overall breast [15]. Imaging modalities play an impor-
tant role in the evaluation of the local extent of disease in patients with breast 
cancer.
Performing a magnetic resonance imaging (MRI) preoperatively helps 
the surgeon in assessing the extent of disease especially in the case of dense 
breast tissue. The sensitivity and specificity of MRI are 93–100% and 26–91%, 
respectively [16–18]. MRI also helps to identify lesions on the contralateral side. 
Besides, it is useful for the detection of multifocal or multicentric lesions and 
consequently may alter the surgical management [19]. In a meta-analysis, the 
authors found that 8.1% of patients were converted from breast-conserving 
therapy to mastectomy and 11.3% of patients were converted from breast-
conserving therapy to more extensive surgery after performing an MRI [20]. 
Another benefit is that MRI enables the surgeon to assess the amount of fat and 
dense breast tissue. The surgeon must reconsider both the incision type and the 
need for mobilization when planning the operation in the case of mostly fatty 
breasts due to the increased rate of fat necrosis in this type of breasts when 
manipulated too much.
MRI alone is not sufficient for decision-making and should be combined 
with mammography. MRI in addition to mammography is an accurate tool 
to determine the suitability for a breast-conserving surgery. Although MRI 
predicts the possibility of conservative treatment, this can be improved with 
the addition of mammography which may increase the extent of the disease 
compared to that seen on MRI due to the visualization of microcalcifications 
[21]. Moreover, digital breast tomosynthesis (DBT) has emerged recently as a 
novel approach permitting to reduce the obscuring effect of overlying breast 
tissue and to overcome the limitations of the regular mammogram [22–24]. Also 
integrating the tomosynthesis in the preoperative work-up may increase the 
diagnostic accuracy of mammographic lesion evaluation and improve the breast 
cancer staging significantly in patients with dense breasts compared to conven-
tional mammography alone [25, 26].
A mammogram is always complemented with ultrasound examination to 
localize the mammographic and tomographic lesions. Ultrasound-guided biopsies 
are needed to confirm the diagnosis as well as to evaluate the axillary lymph node 
status. Suspicious lymph nodes are evaluated with needle biopsy [6]. Also, wire 
localization of the tumors is mostly done under ultrasound guidance preoperatively. 
Sometimes, multiple wires are needed to guide the surgeon in the extent of the 
resection [27].
Preoperative planning also requires the case presentation in the tumor board 
where a multidisciplinary team is involved in the decision-making. Oncologic 
surgeon, radiologist, pathologist, oncologist, radiation oncologist, and others may 
be included [6]. For a better outcome, the patient can also be implicated in the 
operative decision.
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5. Techniques
Many techniques of oncoplastic incisions were described in the literature. It is 
not a one technique fits all. In every case, the surgeon needs to take into consid-
eration the tumor size, the volume of the breast, the grade of ptosis, the age of 
the patients, and other factors without compromising the oncologic safety. Many 
techniques may be applicable for every tumor location. An experienced surgeon 
in oncoplastic surgery will be able to decide which technique will provide better 
oncological as well as cosmetic outcomes. We will cite the most commonly used 
techniques, and then we will expose photos of the markings as well as postoperative 
outcomes of seven cases.
We need to distinguish between two types of oncoplastic techniques:
1. Reconstruction of the breast from local breast tissue which may include:
a. The rotation techniques (rotational/advancement flap) (case 1, 2 and 4)
b. B-plasty
c. Tumor-adapted reduction mammoplasty: for lower quadrant lesions, also 
in the case of severe ptosis (case 3)
d. Central quadrantectomy
e. Round block or volume displacement technique in the case of periareolar 
lesions
2. Reconstruction of the breast using adjacent fat tissue, for example:
a. Quadrantectomy or hemimastectomy with a latissimus dorsi flap (case 5)
b. Quadrantectomy or lumpectomy with thoraco-epigastric flap (rarely 
used), (case 6)
5.1 Case 1
5.1.1 Description of case 1
The tumor is located in the upper inner quadrant (Figure 1a). First, the 
tumor is resected with the skin over the tumor bed (Figure 1b). The status after 
resection of the full thickness arriving at the major pectoralis muscle is shown in 
Figure 1c. After that, the skin in the axillary area is removed (Figure 1d). This 
step can also be done at the beginning when the sentinel lymph node should be 
removed. Then, the tissue is mobilized medially, and the flap is remodeled in 
the defect area (Figure 1e and f ). As a last step, the skin incision is extended to 
perform the mastopexy in order to recentralize the nipple-areolar complex (NAC) 
(Figure 1g). Finally, the wound is sutured with 3.0 Monocryl running sub- and 
intracutaneously (Figure 1h).
Figure 2a shows how the skin and flap tissue are medially mobilized after 
resection of the tumor and removing of the sentinel lymph node. For a better 
symmetry, the incision is extended to realize a mastopexy (Figure 2b).  
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Figure 2c presents the status after the adaptation of the wound and perfor-
mance of a mastopexy for better optimization. The postoperative result is 
shown in Figure 2d.
Figure 1. 
Step-by-step illustration of tumor resection in the upper inner quadrant followed by reconstruction with a 
rotational flap.
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5.2 Case 2
5.2.1 Description of case 2
In this case, the tumor is located in the right inner quadrant around 4 o’clock  
(Figures 3a and 4a). In order to gain additional tissue from the caudal area and to increase 
the volume of the flap, the incision line is performed 1.5 cm under the inframammary fold 
(Figures 3b and 4a). After the incision along the marking, the tumor is resected together 
with the skin leaving a huge defect in the medial area (Figures 3c and 4b). Following 
tumor resection, the gland tissue is mobilized from the pectoral fascia cranially until 
the level of the NAC (Figure 3d). The extent of mobilization is well shown in Figure 3e. 
Then, the skin over the inframammary fold is removed permitting to rotate the caudal 
part of the flap inwardly and consequently to gain more volume (Figure 3e and f  ). The 
flap is rotated in the medial area to fill the defect (Figure 3g). Finally, the NAC is recen-
tralized after adaptation of the wound (Figure 3h). The postoperative outcome is shown 
in Figure 4c and d [28].
5.3 Case 3
5.3.1 Description of case 3
Figure 5a shows the preoperative drawing that is usually used in the case of a 
tumor-adapted reduction mammoplasty. The operation starts with the resection of the 
NAC and the whole tissue thickness underneath it to the muscle (Figures 5b and 6a). 
An important issue to be considered at this time of the operation is to leave all around a 
minimum of 0.5 cm chorion when removing the NAC bloc so that the future areola sits 
Figure 2. 
Intraoperative photos and the postoperative result after resection of the tumor in the upper inner quadrant.
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on it (tip) (Figures 5c and 6b). Then, the preparation of the flap will be started. The 
surgeon needs to perform a deepithelization of the skin leaving a skin island, which 
will be the newly formed areola (Figure 6c). After that, the flap is mobilized medially, 
laterally, and caudally (Figure 5d and e). At this level, the flap is only basally stalked 
(Figure 5f  ). Finally, both sides of the wound are adapted (Figure 6d), and the final 
result will be as shown in Figure 6e and f. The areola position is supported through the 
left chorion. Otherwise, the NAC can sink into the defect area.
Figure 3. 
Step-by-step illustration of tumor resection in the inner quadrant followed by reconstruction with a rotational flap.
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5.2 Case 2
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Figure 5. 
Intraoperative photos illustrating the steps of tumor-adapted reduction mammoplasty (a–f).
Figure 4. 
Intraoperative photos and the postoperative result after resection of the tumor in the inner quadrant.
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5.4 Case 4
5.4.1 Description of case 4
The tumor location and the preoperative incision marking are shown in  
Figure 7a and b (front and side). The previously marked area is resected leaving a 
defect in the breast segment where the tumor was located (Figure 7c and d). After 
removing the tumor, the breast tissue is mobilized from the caudal as well as the 
axillary area to fill the defect. Both sides of the wound are adapted together.  
The reshaping of the breast is completed by performing a mastopexy to recentral-
ize the nipple-areolar complex.
5.5 Case 5
5.5.1 Description of case 5
In this case, the patient first received a breast-conserving surgery for breast 
cancer on the right side. The initial tumor was resected in free margins. On the 
Figure 6. 
Illustration of central resection and remodeling of the breast using a flap from the caudal area. Postoperative 
outcome is shown in (f).
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final pathology, ductal carcinoma in situ (DCIS) components were incidentally 
found on the lateral margins making the first surgery a R1-resection. A hemimas-
tectomy was indicated to ensure a R0-resection. The extension of the resection is 
shown in Figure 8a and b. The incision marking on the back is shown in Figure 8c 
and d. After the hemimastectomy, the fat tissue is mobilized and separated from 
the lateral thoracic wall arriving at the latissimus muscle edge (Figure 8e and f). 
Then, the latissimus skin and fat island with the underlying muscle is mobilized 
and transposed in the breast defect area (Figure 8g). After fixation of the mobi-
lized caudal tissue on the major pectoral muscle, the flap is adapted to the wound 
edges (Figure 8h). The postoperative result was as shown in Figure 9a and b [28].
5.6 Case 6
5.6.1 Description of case 6
In this case, the patient has previously received breast-conserving surgery followed 
with radiotherapy for breast cancer. She presented at our clinic for a defect in the 
Figure 7. 
Drawings of tumor resection in the left upper outer quadrant with the postoperative outcome.
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Figure 8. 
Step-by-step illustration of a right hemimastectomy followed by reconstruction with a latissimus dorsi flap.
Figure 9. 
Postoperative outcome after reconstruction of the hemimastectomy defect with a latissimus dorsi muscle flap.
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Figure 10. 
Preoperative incision drawing in a patient presenting a defect in the inferior quadrant after receiving a breast-
conserving surgery and radiotherapy for breast cancer.
Figure 11. 
Step-by-step illustration of reconstruction of lower breast defect with a thoraco-epigastric flap.
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operation area accompanied with pain. She was planned for removal of the scarred 
tissue and defect coverage with a thoraco-epigastric flap. The drawings in Figure 10a 
and b show the breast area to be removed and also the flap that needs to be mobilized. 
The lower marked scar is an old open cholecystectomy scar (Figure 11a). First, the 
scarred area is removed as shown in Figure 11b. Second, the incision is extended later-
ally and then inferiorly as preoperatively marked permitting to harvest the intended 
flap (Figure 11c). Then, the upper abdominal flap is mobilized and separated from 
the abdominal wall. The scar of the cholecystectomy is as well dissected. The red dots 
show the extension of the mobilization (Figure 11d). The black dots show the skin area 
which is deepithelialized and inserted in the wound area (Figure 11c and e). The flap is 
transposed, and the deepithelialized area is inserted in the defective areal and fixed on 
Figure 12. 
Tumor located at the union of outer quadrants and using the lateral fat to fill the defect. An intraoperative 
photo showing the resection incision, the borders of the lateral fat flap to be used as well as the incision for the 
sentinel lymph node.
Figure 13. 
An intraoperative photo showing the status after remodeling of the breast and adaptation of the wound. The 
drawing of the mastopexy and the checking of the mastopexy limits using Backhaus towel clamps are shown in 
Figure 14a and b, respectively.
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the pectoral fascia (Figure 11f  ). The status after adaptation of the wound and postop-
erative result are shown in Figure 11g and h [28].
5.7 Case 7
5.7.1 Description of the case
In this case, we want to raise the attention on the importance of sparing every 
centimeter of fat tissue that could be used and mobilized when trying to fill the 
defect created after a wide breast excision.
After resection of the tumor, we can use an external fat flap that will be deepi-
thelialized and then mobilized internally to contribute to a better form of the 
remodeled breast (Figure 12). The flap is mobilized internally and then covered 
by both glandular pillars (superior and inferior) (Figure 13a). In the last step, the 
NAC is recentralized using mastopexy (Figure 13b). The postoperative result after 
2 weeks is as shown in Figure 14a and b.
6. Complications
Massive breast mobilization and recentralization of the nipple during onco-
plastic surgery cause tissue trauma, large wound surfaces, and surgical dead space, 
which may increase the risk of complications [29].
First, some complications are frequently seen after an oncoplastic surgery. 
Actually, the manipulation and mobilization of the breast may compromise the 
blood supply of flap tissue and make it prone to present fat necrosis in 5% of cases. 
Sometimes the fat necrosis may impair the ability to adequately screen for tumor 
recurrence and can be mistaken for a suspicious lesion or local recurrence which may 
require more tissue sampling procedures in order to rule out malignancy [30]. In 
addition, seroma formation is commonly seen after oncoplastic surgery. The presence 
of seroma may also delay the delivery of adjuvant therapy and may be seen in 8–10% of 
cases. Wound healing can also be protracted in patients receiving oncoplastic surgery 
in comparison to standard surgery especially in the case of smoking history. Moreover, 
Figure 14. 
Postoperative outcome after outer quadrant breast resection and reconstruction using oncoplastic technique.
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asymmetry can also be an issue after oncoplasty [31]. However, an adjustment of the 
contralateral side can always be offered especially when the size difference between the 
two sides is remarkable. Also, there is a risk of nipple malposition in the case of lack of 
mastopexy when needed. Loss of nipple sensitivity can occur and may be related not 
only to nipple-areolar complex manipulation but also to radiotherapy effect.
Second, other complications can occur after oncoplasty but may rarely be observed. 
For example, partial nipple necrosis or complete nipple loss can be a devastating 
complication for both the patient and surgeon in 0.5% of cases. That is why it is essential 
to select wisely the patients, the safest possible technique, and encourage them to reduce 
risk factors. In the case of very thin flaps, skin necrosis can be expected. The radiother-
apy after the oncoplastic surgery can occasionally lead to breast deformity especially 
in the case of mostly fatty very-low-density breasts. Patients with smoking history, 
uncontrolled diabetes, or postoperative infection are prone to develop breast fibrosis.
Last but not the least, special concern should be made when combining onco-
plastic surgery with intraoperative radiotherapy because these cases were associated 
with a high risk of fat necrosis in our patients collectively. Also, a particular atten-
tion should be given when operating slim women with small breasts. Due to the 
small available volume, the reshaping of the breast cannot be sufficient resulting in 
deformity and NAC malposition.
7. Conclusion
The introduction of oncoplastic surgery has helped to optimize esthetic out-
comes in breast cancer management without compromising oncological safety. 
Along with wider volume resection, this technique can also maintain breast shape 
and appearance. Indeed, an excellent postoperative outcome starts with a preopera-
tive planning done by an experienced surgeon who will take into consideration the 
breast volume, tumor size and location, breast density, and patient’s age and comor-
bidities. It is not a one technique fits all, but it is about the capability of blending art 
and science in every case individually based on the mentioned principles.
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Traditional breast conservative therapy (BCT) is lumpectomy, sentinel lymph 
node biopsy and possible axillary dissection, and radiation therapy. BCT is, as 
known and considered all over the world, is oncologically equivalent to mastectomy 
with regard to overall long-term survival rates. BCT is the recommended treat-
ment of choice for women with early stages breast cancer. The main philosophy 
of BCT is optimizing cosmetic goals and minimizing the psychological morbid-
ity of a mastectomy while ensuring low rates of local recurrence. Achieving an 
oncologically safe resection is maintained by tumor margin clearance. Ensuring 
an oncologic clearance with increasing tumor size requires extensive breast paren-
chyma resection. And this results in large volume resection and this requires volume 
replacement techniques. Depending on the amount of breast volume resected, an 
autologous tissue transfer may be required to achieve requirement of breast restora-
tion. Latissimus dorsi flap and TRAM flap are two autologous tissues mostly used 
to fulfill this restoration. This chapter focuses on the TRAM flap, one of the most 
commonly used autologous tissue in volume replacement reconstruction of the 
mastectomy defect.
Keywords: TRAM, flap, breast, reconstruction, pediculated, skin sparing, 
mastectomy, autologous, repair
1. Introduction
Breast reconstruction with transverse rectus abdominis myocutaneous (TRAM) 
flap has its own unique features and requirements. Not all cases require TRAM 
flap, and TRAM flap is not the best option for every case. That can be analyzed by 
comparing available treatment options of breast cancer (or breast deformities) and 
reconstruction.
Traditional breast conservative therapy (BCT) is lumpectomy, sentinel lymph 
node biopsy, possible axillary dissection, and radiation therapy. BCT, as known and 
considered all over the world, is oncologically equivalent to mastectomy with regard 
to overall long-term survival rates. BCT is the recommended treatment of choice 
for women with early stages of breast cancer [1, 2]. The main philosophy of BCT is 
optimizing cosmetic goals and minimizing the psychological morbidity of a mastec-
tomy while ensuring low rates of local recurrence.
Achieving an oncologically safe resection is maintained by tumor margin 
clearance [2]. Ensuring an oncologic clearance with increasing tumor size requires 
extensive breast parenchyma resection. And this results in large volume resection, 
and this requires volume replacement techniques. Depending on the amount of 
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breast volume resected, an autologous tissue transfer may be required to achieve 
requirement of breast restoration. Latissimus dorsi flap and TRAM flap are two 
autologous tissues mostly used to fulfill this restoration. Perforator flaps are also 
available within the last two decades, and some centers and surgeons began to use 
them as the procedure of choice. This chapter focuses on the TRAM flap, one of the 
most commonly used autologous tissue in volume replacement reconstruction of 
the mastectomy defect.
The results of breast reconstruction have improved dramatically over the past 
30 years. The main reason for this improvement is the experience that has grown 
from various techniques of flap surgery. Breast reconstruction entered the modern 
era with the introduction of the TRAM flap in 1982 by Hartrampf et al. [3]. This 
ingenious procedure reliably transfers autogenous tissue from the lower abdomen 
for breast reconstruction. This surgery has also the added benefit of abdominal 
rejuvenation.
2. Pertinent anatomy
The adult female breast lies with its footprint extending from the second to sixth 
ribs. The medial border is at the edge of the sternum, and the lateral border is at the 
anterior axillary line. The female breast has a circular shape except the upper outer 
quadrant, where the axillary tail of Spence extends to the armpit. The breast is a 
modified cutaneous gland. The mature breast demonstrates both a superficial and 
a deep fascia support system. From an embryological standpoint, the breast bud 
develops within the Scarpa’s fascia. This fascia splits to form anterior and posterior 
lamella. Anterior lamella serves as a dissection plane for surgeons when performing 
a mastectomy, while the posterior lamella separates the breasts from the underlying 
pectoralis major muscle. Breast duct network often extends more widely than this 
footprint. In about 15% of cases, breast tissue extends below the costal margin. 
It is critical when performing breast reconstruction that the inframammary fold 
(IMF) is maintained or at least identified and reconstructed if surgical removal of 
additional breast tissue below this fold is required [4–6]. The breast lobule is the 
basic unit of the breast. Each breast consists of roughly 20 lobules. The breast has its 
breast duct network starting from acini or alveoli, excretory duct, and lactiferous 
duct. A total of 15–20 lactiferous ducts drain the entire breast and dilate into the 
milk sinus beneath the areola. The stroma within the breast consists of connective 
tissue, nerves, blood vessels, and lymphatic channels.
Arterial supply: The blood supply of the breast is diffuse and comes from a 
variety of potential sources including internal mammary artery, lateral thoracic 
artery, branches from thoracoacromial artery, and intercostal arteries. The internal 
mammary artery system has both deep and superficial blood supplies and provides 
more than half of total breast blood flow by anterior and posterior perforating 
branches. The lateral thoracic vessels have both dermal and dermoglandular pedicles 
with adequate both arterial input and venous drainage [5]. Minor sources of arterial 
supply to the breast are posterior intercostal arteries (third, fourth, and fifth) and 
branches from the axillary artery, the thoracic artery, the subscapular artery, and 
the pectoralis branches of the thoracoacromial artery.
Venous drainage: The venous drainage of the breast is superficial and deep. The 
superficial system has transverse and longitudinal veins. The deep system empties 
into internal mammary vein, axillary vein, and perforating branches of posterior 
intercostal veins [5].
Arterial inflow is strong enough to support blood supply, but venous return is 
also a key in designing and avoiding congestion and increasing the security of the 
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perfusion of both breast parenchyma and skin envelopes. This is one of the key 
issues for the viable results in breast oncologic surgery and in breast reconstruction.
Lymphatic drainage: The lymphatic drainage of the breast is also diffuse and vari-
able. Traditionally recognized lymphatic basins include the axillary nodes as well as 
nodes along the internal mammary vessels.
Innervation: The innervation of the breast is also diffuse and variable. Multiple 
nerve branches from the lateral and anterior cutaneous branches of the second 
through the sixth intercostal nerves as well as the supraclavicular nerves enter and 
branch within the breast. The lateral branches are more significant than the smaller 
anterior branches.
2.1 Basic anatomy for tram flap
Rectus abdominis muscle: The rectus abdominis muscles are pairs of long, straight 
muscles that flex the spine and tighten the intra-abdominal wall. This muscle has its 
origin from the symphysis pubis and the pubic crest and inserts on the linea alba and 
the fifth, sixth, and seventh costal cartilages. Each muscle has two to five tendinous 
inscriptions. The most caudal inscription is at the level of umbilicus. These tendinous 
inscriptions are not adherent to the posterior sheath but to overlying anterior rectus 
sheath. Rectus sheath is thick and encloses the rectus abdominis muscle except for 
the posterior part below the arcuate line. The arcuate line is mostly located halfway 
between the umbilicus and symphysis pubis. The arcuate line is the transition point 
where the internal oblique aponeurosis stops to split and the aponeurosis of all three 
muscles pass ventral to the rectus abdominis muscle. Below the arcuate line, there is 
only the transversalis fascia where this is the region of weakness and it is the place 
potential herniation after flap dissection. The linea alba is the decussation of the 
fused aponeurosis in the midline. The linea alba is wider close to the xiphoid process 
and narrows to a fine a line below the umbilicus. The lateral border of the rectus 
muscle with its sheath is referred to as the linea semilunaris.
Blood supply: The blood supply to the rectus muscle and TRAM flap comes from 
the deep superior epigastric artery (DSEA), which arises from the internal thoracic 
(mammary) artery, and the deep inferior epigastric artery (DIEA), a branch of 
the external iliac artery. Both the deep superior and inferior epigastric arteries 
communicate within the rectus abdominis muscle and the overlying muscular and 
cutaneous tissue of the anterior abdominal wall. The DSEA and DIEA systems con-
nect above the umbilicus through a system of small-caliber vessels that Taylor and 
Palmer refer to as “choke” vessels [7]. The DIEA originates approximately 1 cm above 
the inguinal ligament and then pierces the transversalis fascia and enters the rectus 
sheath just below the arcuate line. The DIEA then ascends obliquely and medially 
between the rectus abdominis muscle and the posterior wall of the rectus sheath. 
The DIEA divides into two or three large branches below the level of the umbilicus. It 
shows certain type of arborization, extensive studies reported by Moon and Taylor. 
Based on their outcomes, there are three types of anastomosis between DIEA and 
DSEA. Most patients have two networks (57%), while there are three networks in 
14% of the people and only one major anastomosis in 29% of the people [8].
Perforators are key for the vascular supply of TRAM flap. These vessels are ter-
minal branches of the DIEA and deep inferior epigastric veins. Perforators extend 
from the vertical epigastric system and pass through the anterior rectus sheath, 
supplying the skin and subcutaneous tissue. Taylor and Palmer studies demon-
strated a rich connection between the DIEA system and the abdominal wall skin. 
The majority of perforators are between the umbilicus and the arcuate line, but the 
highest concentration of perforators is in the periumbilical area. Usually there are 
two parallel rows of perforators, a medial one and a lateral one. Incorporation of the 
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periumbilical perforators permits the harvesting of a skin flap with virtually any 
orientation from the midline [9, 10].
TRAM flap can be planned either unipedicled or bipedicled. The decision about 
pedicle depends on the requirement of the tissue pad to be transferred. If a surgeon 
needs almost up to 60% of the lower abdominal tissue, then unipedicle might be the 
right choice. If the requirement is more than that, then it would be better to go with 
bipedicled flap.
3. TRAM flap
Breast reconstruction with TRAM flap can be accomplished with a variety of 
lower abdomen flap and techniques such as pedicled TRAM flap (uni- or bipedicled), 
free TRAM flap, or DIEP flap. The scope of this chapter is pedicled TRAM flap.
Patient selection: The very first part of this procedure should be patient selection. 
The candidate should be evaluated as to the status of her disease and overall health. 
She should be emotionally stable. She should have a good motivation. All details 
regarding surgery, hospitalization, and recuperation need to be discussed in detail.
Who are candidates for TRAM flap breast reconstruction? In general speak-
ing, mastectomy defect needs to be evaluated before planning (Figure 1). The best 
candidates are as follows:
1. Patients with large and ptotic breasts where the contralateral breast needs to be 
altered for symmetry purpose.
2. Patients with big mastectomy defect and/or poor skin quality due to excessive 
dissection, skin slough, radiation effect, etc.
The best candidates for TRAM flap harvesting are the patients with well-padded 
lower abdominal soft tissue and loose upper abdominal soft tissue. Patient with 
excessive abdominal fat might not be a good candidate [11].
Who are not candidates for TRAM flap breast reconstruction? The scar on 
the abdomen is also a key to analyze patient eligibility for TRAM flap. A subcostal 
or transverse incision that divides the rectus abdominis muscle and its superior 
epigastric blood supply might be a contraindication for the use of a pedicled TRAM 
flap. Lower abdominal incision such as Pfannenstiel incision is not a contraindica-
tion for a TRAM flap, and contrary to fact, such an incision might play a “delay 
phenomena” effect. Patients ideally should be nonsmoker, or if they are smoker, 
Figure 1. 
Typical mastectomy defect and best candidates for breast reconstruction with TRAM flap are as seen in the picture.
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they need to stop smoking almost 1–2 months before surgery. If the patient is 
on chemotherapy, it would be better to wait at least 6 months more after the last 
cure of chemotherapy. If there is a history of radiation therapy, it would be better 
to postpone surgery for another 6 months to year after the last cure of radiation 
therapy. The last condition can be totally excluded based on the recipient area 
requirement such as radiation-induced soft tissue defect in the mastectomy area or 
other soft tissue defects due to the mastectomy.
3.1 Preoperative marking and patient positioning
All markings are made with the patient in an upright standing position.
Recipient area: The inframammary, parasternal, anterior axillary line of the 
contralateral breast is marked. The template of these lines is reflected to the recipi-
ent side on a mirror image. The footprint of the recipient side is also copied from the 
contralateral breast. The marking are also made for the future inframammary fold 
and the tunnel that the flap would pass through (Figure 2).
Donor area: The TRAM flap is marked as a horizontal ellipse on the lower 
abdomen. Perforators around the umbilicus and below it are marked with the aid 
of a handheld Doppler US. The whole ellipse is tried to fit with these perforators 
as much as possible. The inferior incision is placed in the low bikini area. The best 
inferior incision location would be suprapubic crease, but this might not be possible 
in each case. The excursion of the lower bikini area should be tested by pinching. 
The superior incision line is marked 1 cm above or below the umbilicus. A superior 
incision that is above the umbilicus is preferable as this has a higher chance to 
include as much periumbilical perforators as possible. But the ease of donor area 
closure is the key factor to place the superior incision line (Figure 2).
A TRAM flap is divided into four zones based on the reliability of perfusion. 
There are four zones for a unipedicled TRAM flap scenario. Zone 1 refers to the skin 
overlying each lateral rectus abdominis muscle. Zone 2 refers to the skin overly-
ing contralateral rectus abdominis muscle. The skin territory on each side of the 
Figure 2. 
Marking for the TRAM flap. All markings are made with the patient in an upright standing position. 
Recipient area: the inframammary, parasternal, anterior axillary line of the contralateral breast is marked. 
The template of these lines is reflected to the recipient side on a mirror image. Footprint of the recipient side is 
also copied from the contralateral breast. The marking are also made for the future inframammary crease and 
the tunnel that the flap would pass through.
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periumbilical perforators permits the harvesting of a skin flap with virtually any 
orientation from the midline [9, 10].
TRAM flap can be planned either unipedicled or bipedicled. The decision about 
pedicle depends on the requirement of the tissue pad to be transferred. If a surgeon 
needs almost up to 60% of the lower abdominal tissue, then unipedicle might be the 
right choice. If the requirement is more than that, then it would be better to go with 
bipedicled flap.
3. TRAM flap
Breast reconstruction with TRAM flap can be accomplished with a variety of 
lower abdomen flap and techniques such as pedicled TRAM flap (uni- or bipedicled), 
free TRAM flap, or DIEP flap. The scope of this chapter is pedicled TRAM flap.
Patient selection: The very first part of this procedure should be patient selection. 
The candidate should be evaluated as to the status of her disease and overall health. 
She should be emotionally stable. She should have a good motivation. All details 
regarding surgery, hospitalization, and recuperation need to be discussed in detail.
Who are candidates for TRAM flap breast reconstruction? In general speak-
ing, mastectomy defect needs to be evaluated before planning (Figure 1). The best 
candidates are as follows:
1. Patients with large and ptotic breasts where the contralateral breast needs to be 
altered for symmetry purpose.
2. Patients with big mastectomy defect and/or poor skin quality due to excessive 
dissection, skin slough, radiation effect, etc.
The best candidates for TRAM flap harvesting are the patients with well-padded 
lower abdominal soft tissue and loose upper abdominal soft tissue. Patient with 
excessive abdominal fat might not be a good candidate [11].
Who are not candidates for TRAM flap breast reconstruction? The scar on 
the abdomen is also a key to analyze patient eligibility for TRAM flap. A subcostal 
or transverse incision that divides the rectus abdominis muscle and its superior 
epigastric blood supply might be a contraindication for the use of a pedicled TRAM 
flap. Lower abdominal incision such as Pfannenstiel incision is not a contraindica-
tion for a TRAM flap, and contrary to fact, such an incision might play a “delay 
phenomena” effect. Patients ideally should be nonsmoker, or if they are smoker, 
Figure 1. 
Typical mastectomy defect and best candidates for breast reconstruction with TRAM flap are as seen in the picture.
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they need to stop smoking almost 1–2 months before surgery. If the patient is 
on chemotherapy, it would be better to wait at least 6 months more after the last 
cure of chemotherapy. If there is a history of radiation therapy, it would be better 
to postpone surgery for another 6 months to year after the last cure of radiation 
therapy. The last condition can be totally excluded based on the recipient area 
requirement such as radiation-induced soft tissue defect in the mastectomy area or 
other soft tissue defects due to the mastectomy.
3.1 Preoperative marking and patient positioning
All markings are made with the patient in an upright standing position.
Recipient area: The inframammary, parasternal, anterior axillary line of the 
contralateral breast is marked. The template of these lines is reflected to the recipi-
ent side on a mirror image. The footprint of the recipient side is also copied from the 
contralateral breast. The marking are also made for the future inframammary fold 
and the tunnel that the flap would pass through (Figure 2).
Donor area: The TRAM flap is marked as a horizontal ellipse on the lower 
abdomen. Perforators around the umbilicus and below it are marked with the aid 
of a handheld Doppler US. The whole ellipse is tried to fit with these perforators 
as much as possible. The inferior incision is placed in the low bikini area. The best 
inferior incision location would be suprapubic crease, but this might not be possible 
in each case. The excursion of the lower bikini area should be tested by pinching. 
The superior incision line is marked 1 cm above or below the umbilicus. A superior 
incision that is above the umbilicus is preferable as this has a higher chance to 
include as much periumbilical perforators as possible. But the ease of donor area 
closure is the key factor to place the superior incision line (Figure 2).
A TRAM flap is divided into four zones based on the reliability of perfusion. 
There are four zones for a unipedicled TRAM flap scenario. Zone 1 refers to the skin 
overlying each lateral rectus abdominis muscle. Zone 2 refers to the skin overly-
ing contralateral rectus abdominis muscle. The skin territory on each side of the 
Figure 2. 
Marking for the TRAM flap. All markings are made with the patient in an upright standing position. 
Recipient area: the inframammary, parasternal, anterior axillary line of the contralateral breast is marked. 
The template of these lines is reflected to the recipient side on a mirror image. Footprint of the recipient side is 
also copied from the contralateral breast. The marking are also made for the future inframammary crease and 
the tunnel that the flap would pass through.
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abdomen lateral to the linea semilunaris is referred to as zone 3, and the skin lateral 
to the opposite linea semilunaris is zone 4. The perfusion of zones 4 and 3 is less 
than zones 1 and 2 where zone 4 is the most tenuous.
Surgical technique: The mastectomy skin flap is elevated off the pectoralis major 
muscle inferiorly and superiorly based on the preoperative marking. Previous 
mastectomy scar is excised and sent for pathologic evaluation.
The superior TRAM flap incision is placed till anterior rectus fascia. The upper 
abdominal skin flap is elevated close to both inframammary folds (IMF). A tunnel 
is made to the mastectomy area.
The inferior incision is placed deep to the rectus muscle, and both superficial 
epigastric vessels are identified and preserved. Zones 3 and 4 are dissected off 
the external oblique fascia, and dissection continues medially with precaution 
while approaching the lateral border of the rectus abdominis fascia. At this 
point, preoperative markings for perforators are followed, and this dissection 
continues medially, stopping approximately 4–5 mm lateral to these perforators. 
The largest perforator is mostly found just lateral and inferior to the  
umbilicus. An incision is made on the rectus fascia just 1 cm lateral to the perfo-
rators. The inferior epigastrics are identified easily along the lateral edge of the 
rectus muscle. The vessels are identified close to the external iliac artery, and the 
DIEA is ligated. The rectus fascia is divided vertically, and the rectus muscle with 
TRAM flap attached elevated off the posterior rectus fascia. The umbilicus is 
circumferentially incised and isolated on its stalk medially. The eight intercostal 
nerves are identified and transected to help for the atrophy of the muscle pedicle 
while approaching close to the arcus costarum. TRAM flap is delivered through 
the tunnel to the mastectomy site.
Anterior rectus fascia is closed with 0 or 1\0 Prolene (or nylon suture). Inferior 
cuff of rectus muscle is integrated to the weak area below arcuate line (Figure 3). 
Closure is reinforced with an overlay Prolene mesh that lies from epigastric area 
to symphysis pubis. Care must be taken not to constrict the pedicle. Abdominal 
skin flap is closed in layers, and the umbilicus is delivered to its new location in the 
midline.
The TRAM flap is provisionally placed into the mastectomy defect, and the 
mastectomy flap is draped over the TRAM flap. The patient is placed in a sit-
ting position, and the TRAM flap is shaped into a breast mound. Care should be 
taken to shift breast mound superior and medial area to ensure adequate cleavage 
volume. Surely, volume distribution is important for each quadrant of breast 
mound (Figures 4 and 5).
Figure 3. 
Anterior rectus fascia is closed after the TRAM flap is transferred to the mastectomy site.
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Postoperative care: Wound care is essential, and routine wound care is needed. 
The flap is kept warm, and a fenestrated dressing might be a better option to 
observe flap perfusion. A support bra is used to maintain the position of the flap. 
The patient is placed in a flexed position by keeping head elevated 30° and legs 
elevated 20°. An abdominal girdle needs to be on at all time for 2 months. Patients 
are mostly hospitalized for 3 days. Patients are advised for resting for 15 days to a 
month after surgery.
3.2 Complications
Fat necrosis: Fat necrosis can be seen, and the reason is inadequate perfusion 
or limited perfusion to a certain part of the flap. Planning and surgical technique 
needs to be verified before and during surgery to minimize the possibility of inad-
equate perfusion. Planning and technique should be optimal perforator areas with 
limited perfusion, or question might be discarded during surgery. Zone 4 is always 
an area of question and must be discarded before transposing the flap.
Partial flap loss: Partial flap loss is also can be seen due to inadequate perfusion. 
Likewise, areas with question need to be discarded; planning and technique should 
be optimal to include as much perforators as possible.
Abdominal hernia: Hernia or bulging can be seen as one of the major complica-
tion. Fascial closure needs to be dome tension-free, and mesh needs to be used if 
indicated. Patients should be placed in abdominal girdle and told to avoid strenuous 
exercise till the sixth month after surgery [12]. The incidence of abdominal bulges 
Figure 4. 
Pre- and postoperative view of a mastectomy patient that is reconstructed with bipedicled TRAM flap. The 
patient is 56 years old. Follow-up picture was taken 6 month after nipple and areola complex reconstruction.
Figure 5. 
Pre- and postoperative view of a mastectomy patient that is reconstructed with bipedicled TRAM flap. The 
patient is 48 years old.
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was reported 3.8%, while hernia was reported 2.6% [13]. It is also reported that 
abdominal strength, as measured by the ability do sit-ups, is influenced signifi-
cantly by TRAM flap.
Revisional surgeries for TRAM flap: All complications need to be revised as 
needed. Partial flap loss should be addressed within the first 2 weeks after surgery. 
Meticulous wound care is essential meanwhile.
Breast reconstruction with TRAM flap is a two-stage procedure. The goal of the 
first step is to reconstruct the breast mound as close as to the contralateral breast 
mound. The goal of the second stage is to get symmetry as much as possible and 
reconstruction of nipple areola complex (NAC). Surgical intervention might be 
needed for the contralateral breast (i.e., lifting and reduction) during the second 
stage. The following procedures might be done during the second stage: removal of 
fat necrosis, breast mound revision, IMF revision, medial cleavage revision (with 
flap transposition or fat grafting), donor site liposuction for feathering touch, and 
NAC reconstruction.
NAC reconstruction: NAC reconstruction can be done with various techniques. 
Some of the mostly used techniques are CV flap, skate flap, star flap, etc. Areola 
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Immediate Breast Reconstruction 
with Free Autologous Tissue 
Transfer
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Abstract
Immediate breast reconstruction in the United States is increasing with the 
majority of patients undergoing implant-based reconstruction. The use of pedicled 
autologous tissues has also been used, but due to significant donor site morbidity, 
free autologous tissue transfer has largely replaced it. The gold standard currently 
for breast reconstruction is free autologous tissue transfer from the abdomen if no 
contraindications exist. However, not all hospitals have the expertise available to 
perform free autologous tissue transfers for breast reconstruction. Other donor sites 
available for free autologous tissue transfer include the thigh and gluteal areas. With 
advances in free tissue transfer techniques, the donor site morbidity and flap failure 
rates are minimal. The ultimate goal for any breast reconstruction patient is to 
achieve the appropriate size, shape, symmetry, softness, and sensation. The goal of 
this chapter is to assist in achieving these goals in the immediate breast reconstruc-
tion patient through the use of free autologous tissue transfers.
Keywords: breast reconstruction, autologous tissue, free flaps, deep inferior epigastric 
perforator, transverse rectus abdominis myocutaneous, transverse upper gracilis, 
profunda artery perforator, superior gluteal artery perforator,inferior gluteal artery 
perforator, breast ptosis, mastopexy, nipple devascularization, re-innervation, 
autologous with implant
1. Introduction
The incidence of mastectomy for breast cancer over the last couple decades has 
been increasing leading to more patients desiring breast reconstruction. While most 
of these patients undergo implant-based reconstruction there is a significant number 
of patients that have autologous reconstructions performed [1, 2]. Implant-based 
reconstruction is technically easier and can have good esthetic appearance but 
should not be used in all patients. Ideal candidates for implant-based reconstruction 
are those who are not obese, a non-smoker, require no radiation, and have healthy 
vascularized mastectomy skin flaps. Not all breast reconstruction patients meet these 
characteristics nor do all patients want to be subjected to secondary affects of having 
a foreign body used for reconstruction. More recently patients are also concerned 
about breast implant associated anaplastic large cell lymphoma (BIA-ALCL) [3].
The use of pedicled autologous tissue to reconstruct the breast started with the trans-
verse rectus abdominis myocutaneous (TRAM) flap by Hartrampf in 1982 [4]. With 
improved understanding about perforator vascular anatomy and surgical technique, the 
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perforator flap concept was developed. About a decade after the TRAM, the deep inferior 
epigastric perforator (DIEP) flap by Allen was developed, which addressed donor site 
morbidity by preserving muscle and fascia [5]. Another abdominal flap that uses the 
same skin incision and utilizes the identical skin and fat for reconstruction as the TRAM/
DIEP is the superficial inferior epigastric artery (SIEA) flap but this flap requires no 
fascial incision. Abdominally based free flaps are the gold standard for breast reconstruc-
tion but not all patients are candidates. Patients that do not desire a scar from hip to hip or 
have had previous abdominoplasty, abdominal liposuction, or other significant abdomi-
nal procedures should not undergo free flaps from the abdomen for breast reconstruc-
tion. Other potential sources for autologous tissue include the thigh and gluteal areas.
The purpose of this chapter is to review the common free flaps for breast recon-
struction starting from pre-operative workup to flap in-setting along with ptosis 
management and adjunctive intraoperative procedures.
2. Preoperative workup and flap selection
Patients that desire breast reconstruction must undergo a multidisciplinary 
approach utilizing a breast oncologist and plastic surgeon from a surgical stand-
point and possible radiation oncologist and genetic counselor as indicated. The 
majority of patients undergo breast reconstruction secondary to breast cancer 
ablation. However, more recently there is an increase in breast reconstruction for 
patients desiring prophylactic mastectomies secondary to specific genetic mutations 
(i.e. BRCA) and/or increased risk of developing breast cancer in the future [2].
After a patient decides that she would like a mastectomy for breast cancer treat-
ment or risk reduction, the patient will be referred to a plastic surgeon who should 
perform a thorough history and physical examination. The surgeon should not only 
discuss the risks and benefits of surgery but other alternatives to free tissue transfer 
breast reconstruction, which should include no reconstruction, tissue expander or 
implant-based reconstruction, and pedicled flap reconstruction. Possible revisional 
surgery should also be discussed.
The ideal breast reconstruction would involve free tissue transfer from the 
abdomen. Most patients in the United States have sufficient lower abdominal tissue 
to reconstruct a similar size breast. For thin patients with a small abdominal pan-
nus, other sites such as the thigh or gluteal area can be used, but these are typically 
smaller than the abdominal tissue. In these cases other adjunctive procedures such 
as fat grafting, free flap stacking, and implant placement can be performed.
Most patients that undergo free tissue transfer for breast reconstruction utilize a 
DIEP or TRAM flap. There are various algorithms that have been proposed based on 
perforator size/number and flap size [6, 7]. In general, a DIEP flap can be per-
formed for smaller flaps (<1000 g) that have adequate perforator size (>1.5 mm). 
Conversely, a TRAM flap is considered for larger flaps with smaller, less dominant 
perforators. Another abdominal flap that is used in the minority of patients is the 
SIEA flap. The ideal candidate for an SIEA flap is reconstruction of a small breast 
with a sizeable/palpable SIEA [8].
Patients that have contraindications to using the abdomen as a free tissue trans-
fer source or who do not want the morbidity associated with these flaps can use the 
thigh or gluteal areas as donor sites. These flaps include the transverse upper gracilis 
(TUG), profunda artery perforator (PAP), and superior/inferior gluteal artery 
perforator (SGAP/IGAP) flaps. The benefit of these flaps is that they can be har-
vested unilaterally so the contralateral side can be used for later use in the future. 
The downfall to these flaps is that they are typically smaller than the abdominally 
based flaps and positioning in the operating room can be more difficult.
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Some absolute contraindications to free tissue transfer breast reconstruction 
include the inability to undergo a lengthy procedure under general anesthesia sec-
ondary to cardiovascular/pulmonary compromise, patient desire for a less complex 
procedure or unwillingness to have a long donor site scar, vascular compromise of 
the intended flap secondary to scarring or previous surgery, and coagulopathy that 
cannot be controlled with medical management. Other more common relative con-
traindications include severe obesity [9], smoking, diabetes, end stage renal disease 
[10], and hemophilia/venous thromboembolism [11]. These comorbidities should be 
optimized prior to breast reconstruction surgery to minimize morbidity/mortality.
3. Preoperative imaging
The standard for immediate breast reconstruction is perforator flaps from 
the abdomen. To aid in preoperative planning and surgical technique the use of 
preoperative imaging has been developed. The various forms of imaging modali-
ties to identify perforators include duplex ultrasound, computed tomographic 
(CT) angiography, and magnetic resonance (MR) angiography. The use of duplex 
ultrasound can identify the location, size, flow, and velocity of perforators from the 
deep inferior epigastric artery. Other benefits of duplex ultrasound are ease of use, 
reduced cost, and no radiation exposure when compared to CT angiography [12].
A superior imaging technique to identify perforators is the use of CT angi-
ography, which can identify perforator size, location, and intramuscular course 
(Figure 1a). The use of CT angiography has shown to reduce operative times, 
improve the perfusion of flaps, and minimize donor site morbidity. Patients 
with previous abdominal surgeries resulting in a paramedian scar would benefit 
from CT angiography to assess patency of the deep inferior epigastric artery 
and associated perforators [12]. The ideal perforators would be large, centrally 
located in the flap, and have a short traverse muscular and subfascial course [13]. 
The sensitivity and positive predictive value of CT angiography is near 100% 
for locating and mapping out the course of deep inferior epigastric perforators. 
For patient who do not want to undergo radiation they can elect to undergo MR 
angiography, which can help map out the perforators but the spatial resolution is 
inferior to CT angiography [14].
Figure 1. 
(a) CT angiogram of deep inferior epigastric artery and perforators and (b) 3D model of deep inferior 
epigastric artery and perforators.
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perforator flap concept was developed. About a decade after the TRAM, the deep inferior 
epigastric perforator (DIEP) flap by Allen was developed, which addressed donor site 
morbidity by preserving muscle and fascia [5]. Another abdominal flap that uses the 
same skin incision and utilizes the identical skin and fat for reconstruction as the TRAM/
DIEP is the superficial inferior epigastric artery (SIEA) flap but this flap requires no 
fascial incision. Abdominally based free flaps are the gold standard for breast reconstruc-
tion but not all patients are candidates. Patients that do not desire a scar from hip to hip or 
have had previous abdominoplasty, abdominal liposuction, or other significant abdomi-
nal procedures should not undergo free flaps from the abdomen for breast reconstruc-
tion. Other potential sources for autologous tissue include the thigh and gluteal areas.
The purpose of this chapter is to review the common free flaps for breast recon-
struction starting from pre-operative workup to flap in-setting along with ptosis 
management and adjunctive intraoperative procedures.
2. Preoperative workup and flap selection
Patients that desire breast reconstruction must undergo a multidisciplinary 
approach utilizing a breast oncologist and plastic surgeon from a surgical stand-
point and possible radiation oncologist and genetic counselor as indicated. The 
majority of patients undergo breast reconstruction secondary to breast cancer 
ablation. However, more recently there is an increase in breast reconstruction for 
patients desiring prophylactic mastectomies secondary to specific genetic mutations 
(i.e. BRCA) and/or increased risk of developing breast cancer in the future [2].
After a patient decides that she would like a mastectomy for breast cancer treat-
ment or risk reduction, the patient will be referred to a plastic surgeon who should 
perform a thorough history and physical examination. The surgeon should not only 
discuss the risks and benefits of surgery but other alternatives to free tissue transfer 
breast reconstruction, which should include no reconstruction, tissue expander or 
implant-based reconstruction, and pedicled flap reconstruction. Possible revisional 
surgery should also be discussed.
The ideal breast reconstruction would involve free tissue transfer from the 
abdomen. Most patients in the United States have sufficient lower abdominal tissue 
to reconstruct a similar size breast. For thin patients with a small abdominal pan-
nus, other sites such as the thigh or gluteal area can be used, but these are typically 
smaller than the abdominal tissue. In these cases other adjunctive procedures such 
as fat grafting, free flap stacking, and implant placement can be performed.
Most patients that undergo free tissue transfer for breast reconstruction utilize a 
DIEP or TRAM flap. There are various algorithms that have been proposed based on 
perforator size/number and flap size [6, 7]. In general, a DIEP flap can be per-
formed for smaller flaps (<1000 g) that have adequate perforator size (>1.5 mm). 
Conversely, a TRAM flap is considered for larger flaps with smaller, less dominant 
perforators. Another abdominal flap that is used in the minority of patients is the 
SIEA flap. The ideal candidate for an SIEA flap is reconstruction of a small breast 
with a sizeable/palpable SIEA [8].
Patients that have contraindications to using the abdomen as a free tissue trans-
fer source or who do not want the morbidity associated with these flaps can use the 
thigh or gluteal areas as donor sites. These flaps include the transverse upper gracilis 
(TUG), profunda artery perforator (PAP), and superior/inferior gluteal artery 
perforator (SGAP/IGAP) flaps. The benefit of these flaps is that they can be har-
vested unilaterally so the contralateral side can be used for later use in the future. 
The downfall to these flaps is that they are typically smaller than the abdominally 
based flaps and positioning in the operating room can be more difficult.
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Some absolute contraindications to free tissue transfer breast reconstruction 
include the inability to undergo a lengthy procedure under general anesthesia sec-
ondary to cardiovascular/pulmonary compromise, patient desire for a less complex 
procedure or unwillingness to have a long donor site scar, vascular compromise of 
the intended flap secondary to scarring or previous surgery, and coagulopathy that 
cannot be controlled with medical management. Other more common relative con-
traindications include severe obesity [9], smoking, diabetes, end stage renal disease 
[10], and hemophilia/venous thromboembolism [11]. These comorbidities should be 
optimized prior to breast reconstruction surgery to minimize morbidity/mortality.
3. Preoperative imaging
The standard for immediate breast reconstruction is perforator flaps from 
the abdomen. To aid in preoperative planning and surgical technique the use of 
preoperative imaging has been developed. The various forms of imaging modali-
ties to identify perforators include duplex ultrasound, computed tomographic 
(CT) angiography, and magnetic resonance (MR) angiography. The use of duplex 
ultrasound can identify the location, size, flow, and velocity of perforators from the 
deep inferior epigastric artery. Other benefits of duplex ultrasound are ease of use, 
reduced cost, and no radiation exposure when compared to CT angiography [12].
A superior imaging technique to identify perforators is the use of CT angi-
ography, which can identify perforator size, location, and intramuscular course 
(Figure 1a). The use of CT angiography has shown to reduce operative times, 
improve the perfusion of flaps, and minimize donor site morbidity. Patients 
with previous abdominal surgeries resulting in a paramedian scar would benefit 
from CT angiography to assess patency of the deep inferior epigastric artery 
and associated perforators [12]. The ideal perforators would be large, centrally 
located in the flap, and have a short traverse muscular and subfascial course [13]. 
The sensitivity and positive predictive value of CT angiography is near 100% 
for locating and mapping out the course of deep inferior epigastric perforators. 
For patient who do not want to undergo radiation they can elect to undergo MR 
angiography, which can help map out the perforators but the spatial resolution is 
inferior to CT angiography [14].
Figure 1. 
(a) CT angiogram of deep inferior epigastric artery and perforators and (b) 3D model of deep inferior 
epigastric artery and perforators.
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Figure 3. 
TRAM flap utilizing periareolar incision with lateral extension before and after surgery.
Our institution has developed 3D printed models of the deep inferior epigastric 
artery and perforators from CT angiography imaging to further aid intraopera-
tive decision making (Figure 1b). The 3D printed models can be sterilized and aid 
in locating the larger (>1 mm) perforators in relation to the umbilicus and their 
course through the rectus abdominis muscle to the deep inferior epigastric artery. 
A limitation of the 3D printed models is their poor sensitivity to identify smaller 
perforators.
4. Mastectomy incisions
Surgical exposure for immediate breast reconstruction is not only dependent 
on flap characteristics and setup but also the choice of mastectomy incisions used. 
As breast cancer treatment has changed over the decades from modified radi-
cal mastectomy to nipple/skin sparing mastectomy, so have the incision choices. 
Traditionally, a wide elliptical incision around the NAC was performed in a trans-
verse or oblique fashion for modified radical mastectomies. To preserve native 
breast skin, a circumareolar incision with or without a lateral or vertical extension 
can be performed resulting in a lollipop incision. A vertical extension (Figure 2) 
of a circumareolar incision is preferred over a lateral extension (Figure 3) as the 
incision can be incorporated into a mastopexy incision. Other types of mastectomy 
Figure 2. 
TRAM flap utilizing circumareolar incision with vertical extension before and after surgery.
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incisions that can be used with the aid of a plastic surgeon is a wise (Figure 4) or 
vertical pattern, similar to breast reduction or mastopexy incisions. These incisions 
allow for removal of excess skin that can be seen in ptotic patients. Additional ben-
efits include reshaping of the breast mound and to allow for a smaller skin envelope 
for patients that desire a reduction in breast size.
With advances in breast cancer treatment the ability to preserve the nipple 
areolar complex is now possible. This not only allows for improved cosmesis 
but also quality of life for patients. The ideal patient for preservation of the 
nipple areolar complex would have a small breast, minimal ptosis (<grade 2), 
non-obese (BMI < 30 kg/m2), and be a non-smoker [15]. There are techniques 
that will be described later in the chapter to allow for nipple areolar preserva-
tion in larger ptotic patients. From a cancer standpoint, patients that have NAC 
involvement seen on MRI, inflammatory breast cancer, extensive skin involve-
ment, or bloody nipple discharge are not candidates for nipple sparing mastec-
tomies [16].
5. Flaps
Free tissue transfers from an abdominal donor site is most commonly used 
for breast reconstruction. The TRAM, DIEP, and SIEA flaps all result in similar 
abdominal donor scars and include the lower abdominal skin/subcutaneous tissue 
between the umbilicus and the pubis in the flap. The deep inferior epigastric artery 
supplies the TRAM and DIEP flaps so various amounts of fascia, muscle, and nerve 
preservation is performed to allow for perforator harvest. In contrary, the SIEA 
flap is based on the superficial inferior epigastric artery so fascial violation does 
not occur. The majority of patients have small or absent superficial systems so SIEA 
flaps are only performed in a minority of patients [8].
An algorithm was developed by Lindsey in 2007 based on perforator anatomy to 
aid in selection of the appropriate abdominal flap [7]. Evaluation of the lateral row 
perforators proceeds the medial row perforators. If a large (>3 mm) centrally located 
perforator is seen from the deep inferior epigastric artery, then a single perforator 
DIEP can be performed. If moderate (1.5–3 mm) perforators are present, then more 
than one perforator should be included in the DIEP. When small (<1.5 mm) perfora-
tors are present then evaluation of the medial row perforators should be performed. 
Figure 4. 
TRAM flap utilizing wise pattern incision before and after surgery.
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Figure 3. 
TRAM flap utilizing periareolar incision with lateral extension before and after surgery.
Our institution has developed 3D printed models of the deep inferior epigastric 
artery and perforators from CT angiography imaging to further aid intraopera-
tive decision making (Figure 1b). The 3D printed models can be sterilized and aid 
in locating the larger (>1 mm) perforators in relation to the umbilicus and their 
course through the rectus abdominis muscle to the deep inferior epigastric artery. 
A limitation of the 3D printed models is their poor sensitivity to identify smaller 
perforators.
4. Mastectomy incisions
Surgical exposure for immediate breast reconstruction is not only dependent 
on flap characteristics and setup but also the choice of mastectomy incisions used. 
As breast cancer treatment has changed over the decades from modified radi-
cal mastectomy to nipple/skin sparing mastectomy, so have the incision choices. 
Traditionally, a wide elliptical incision around the NAC was performed in a trans-
verse or oblique fashion for modified radical mastectomies. To preserve native 
breast skin, a circumareolar incision with or without a lateral or vertical extension 
can be performed resulting in a lollipop incision. A vertical extension (Figure 2) 
of a circumareolar incision is preferred over a lateral extension (Figure 3) as the 
incision can be incorporated into a mastopexy incision. Other types of mastectomy 
Figure 2. 
TRAM flap utilizing circumareolar incision with vertical extension before and after surgery.
115
Immediate Breast Reconstruction with Free Autologous Tissue Transfer
DOI: http://dx.doi.org/10.5772/intechopen.85652
incisions that can be used with the aid of a plastic surgeon is a wise (Figure 4) or 
vertical pattern, similar to breast reduction or mastopexy incisions. These incisions 
allow for removal of excess skin that can be seen in ptotic patients. Additional ben-
efits include reshaping of the breast mound and to allow for a smaller skin envelope 
for patients that desire a reduction in breast size.
With advances in breast cancer treatment the ability to preserve the nipple 
areolar complex is now possible. This not only allows for improved cosmesis 
but also quality of life for patients. The ideal patient for preservation of the 
nipple areolar complex would have a small breast, minimal ptosis (<grade 2), 
non-obese (BMI < 30 kg/m2), and be a non-smoker [15]. There are techniques 
that will be described later in the chapter to allow for nipple areolar preserva-
tion in larger ptotic patients. From a cancer standpoint, patients that have NAC 
involvement seen on MRI, inflammatory breast cancer, extensive skin involve-
ment, or bloody nipple discharge are not candidates for nipple sparing mastec-
tomies [16].
5. Flaps
Free tissue transfers from an abdominal donor site is most commonly used 
for breast reconstruction. The TRAM, DIEP, and SIEA flaps all result in similar 
abdominal donor scars and include the lower abdominal skin/subcutaneous tissue 
between the umbilicus and the pubis in the flap. The deep inferior epigastric artery 
supplies the TRAM and DIEP flaps so various amounts of fascia, muscle, and nerve 
preservation is performed to allow for perforator harvest. In contrary, the SIEA 
flap is based on the superficial inferior epigastric artery so fascial violation does 
not occur. The majority of patients have small or absent superficial systems so SIEA 
flaps are only performed in a minority of patients [8].
An algorithm was developed by Lindsey in 2007 based on perforator anatomy to 
aid in selection of the appropriate abdominal flap [7]. Evaluation of the lateral row 
perforators proceeds the medial row perforators. If a large (>3 mm) centrally located 
perforator is seen from the deep inferior epigastric artery, then a single perforator 
DIEP can be performed. If moderate (1.5–3 mm) perforators are present, then more 
than one perforator should be included in the DIEP. When small (<1.5 mm) perfora-
tors are present then evaluation of the medial row perforators should be performed. 
Figure 4. 
TRAM flap utilizing wise pattern incision before and after surgery.




If the medial row perforators are also small (<1.5 mm) then a muscle sparing (MS) 
TRAM should be selected [7]. An SIEA flap can be considered if the vessel is large 
(>1.5 mm) and palpable but should be limited to smaller flaps [6].
If the abdomen is not available to use as a donor site then the thigh and gluteal 
areas can be used but require more difficult positioning in the operating room and 
the flaps tend to be smaller in size compared to abdominally based flaps.
5.1 Transverse rectus abdominis myocutaneous (TRAM)
The first abdominally based free and pedicled flaps for breast reconstruction 
were performed by Hartrampf and Holmstrom nearly 4 decades ago [4, 17]. To 
minimize donor site morbidity and vascular complications combined with the 
refinements in microsurgical technique, the free TRAM increased in popular-
ity among surgeons. Even though the TRAM flap is a Mathes and Nahai type III 
muscle (two dominant vessels), it has a more robust blood supply based on the 
deep inferior epigastric artery compared to the internal thoracic artery [18]. The 
free TRAM is now the flap of choice for breast reconstruction in the majority of 
breast centers.
The TRAM flaps can spare various amounts of muscle to minimize abdominal 
wall morbidity so a classification system was developed by Nahabedian in 2002. 
A MS-0 TRAM involves the full width of the rectus abdominis muscle, MS-1 
preserves the lateral or medial segment of muscle, MS-2 preserves the lateral and 
medial segment of muscle, and MS-3 (DIEP) preserves the entire muscle [19].
5.1.1 Marking
For any breast reconstruction patient, the markings for the breast should be in 
the standing position. The midline (sternal notch to pubis), inframammary folds 
(IMFs), anterior axillary lines, and the breast footprints are marked (Figure 5). 
If one of the IMF’s are not apparent then the contralateral IMF can be used as a 
guide. A mastopexy incision marking can also be performed as needed. In a patient 
with a unilateral reconstruction, a symmetry procedure can be performed on the 
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contralateral side, which should also be marked at this time. It is important to put 
the nipple-areolar complex on the symmetry side to match the reconstructed breast 
and not at the level of the native IMF, as is done in routine breast reductions.
For the abdominal marking, the patient is in standing position to identify and 
mark the lower abdominal fold, which will hide the placement of the incision. In 
the midline, this incision should be at least 6 cm from the vulvar commissure to 
prevent urinary stream dysfunction post-operatively. The lower incision is typically 
extended laterally distal to the anterior superior iliac spine (ASIS) to remove any 
Burow’s triangles. The upper incision is marked about the level of the umbilicus and 
then extended laterally to meet the lower incision endpoint (Figure 5). A pinch test 
must be used to confirm the location of the upper incision mark to ensure proper 
abdominal wall closure at the end of the case. It is also helpful to keep the length 
of the upper and lower incision limbs a similar length to prevent scalloping of the 
incision upon skin closure.
5.1.2 Flap dissection
The lower skin incision is made first followed by dissection of the SIEA/SIEV for 
a few centimeters to allow for superficial vascular supply as needed. The SIEA/SIEV 
can then be clipped and divided if they are not to be used for a SIEA flap. Dissection 
then proceeds all the way down to the muscular fascia but care should be taken to 
leave some fat around the ASIS to prevent injury to the lateral femoral cutaneous 
nerve, which is medial to the ASIS. After confirming the upper incision mark with 
a pinch test the upper incision can be made, including release of the umbilicus. The 
upper incision is taken down to the muscular fascia. The upper abdominal flap is 
then elevated above the muscular fascia in the midline to the xiphoid and costal 
margins as needed to aid in abdominal wall closure.
The dissection then continues from lateral to medial above the level of the muscu-
lar fascia until the lateral row perforators are encountered going through  
the anterior rectus fascia and into the flap (Figure 6). It is imperative to turn down 
the bovie or bipolar once you start to dissect the perforators. If a bilateral reconstruc-
tion is being performed, then the vertical midline incision can be made to separate 
the two flaps (Figure 7). Dissection then proceeds from medial to lateral above the 
level of the muscular fascia until the medial row perforators are encountered. If a 
unilateral reconstruction is being performed, then the vertical midline incision is 
Figure 6. 
Lateral to medial dissection of TRAM flap above muscular fascia to lateral row perforators.




If the medial row perforators are also small (<1.5 mm) then a muscle sparing (MS) 
TRAM should be selected [7]. An SIEA flap can be considered if the vessel is large 
(>1.5 mm) and palpable but should be limited to smaller flaps [6].
If the abdomen is not available to use as a donor site then the thigh and gluteal 
areas can be used but require more difficult positioning in the operating room and 
the flaps tend to be smaller in size compared to abdominally based flaps.
5.1 Transverse rectus abdominis myocutaneous (TRAM)
The first abdominally based free and pedicled flaps for breast reconstruction 
were performed by Hartrampf and Holmstrom nearly 4 decades ago [4, 17]. To 
minimize donor site morbidity and vascular complications combined with the 
refinements in microsurgical technique, the free TRAM increased in popular-
ity among surgeons. Even though the TRAM flap is a Mathes and Nahai type III 
muscle (two dominant vessels), it has a more robust blood supply based on the 
deep inferior epigastric artery compared to the internal thoracic artery [18]. The 
free TRAM is now the flap of choice for breast reconstruction in the majority of 
breast centers.
The TRAM flaps can spare various amounts of muscle to minimize abdominal 
wall morbidity so a classification system was developed by Nahabedian in 2002. 
A MS-0 TRAM involves the full width of the rectus abdominis muscle, MS-1 
preserves the lateral or medial segment of muscle, MS-2 preserves the lateral and 
medial segment of muscle, and MS-3 (DIEP) preserves the entire muscle [19].
5.1.1 Marking
For any breast reconstruction patient, the markings for the breast should be in 
the standing position. The midline (sternal notch to pubis), inframammary folds 
(IMFs), anterior axillary lines, and the breast footprints are marked (Figure 5). 
If one of the IMF’s are not apparent then the contralateral IMF can be used as a 
guide. A mastopexy incision marking can also be performed as needed. In a patient 
with a unilateral reconstruction, a symmetry procedure can be performed on the 
117
Immediate Breast Reconstruction with Free Autologous Tissue Transfer
DOI: http://dx.doi.org/10.5772/intechopen.85652
contralateral side, which should also be marked at this time. It is important to put 
the nipple-areolar complex on the symmetry side to match the reconstructed breast 
and not at the level of the native IMF, as is done in routine breast reductions.
For the abdominal marking, the patient is in standing position to identify and 
mark the lower abdominal fold, which will hide the placement of the incision. In 
the midline, this incision should be at least 6 cm from the vulvar commissure to 
prevent urinary stream dysfunction post-operatively. The lower incision is typically 
extended laterally distal to the anterior superior iliac spine (ASIS) to remove any 
Burow’s triangles. The upper incision is marked about the level of the umbilicus and 
then extended laterally to meet the lower incision endpoint (Figure 5). A pinch test 
must be used to confirm the location of the upper incision mark to ensure proper 
abdominal wall closure at the end of the case. It is also helpful to keep the length 
of the upper and lower incision limbs a similar length to prevent scalloping of the 
incision upon skin closure.
5.1.2 Flap dissection
The lower skin incision is made first followed by dissection of the SIEA/SIEV for 
a few centimeters to allow for superficial vascular supply as needed. The SIEA/SIEV 
can then be clipped and divided if they are not to be used for a SIEA flap. Dissection 
then proceeds all the way down to the muscular fascia but care should be taken to 
leave some fat around the ASIS to prevent injury to the lateral femoral cutaneous 
nerve, which is medial to the ASIS. After confirming the upper incision mark with 
a pinch test the upper incision can be made, including release of the umbilicus. The 
upper incision is taken down to the muscular fascia. The upper abdominal flap is 
then elevated above the muscular fascia in the midline to the xiphoid and costal 
margins as needed to aid in abdominal wall closure.
The dissection then continues from lateral to medial above the level of the muscu-
lar fascia until the lateral row perforators are encountered going through  
the anterior rectus fascia and into the flap (Figure 6). It is imperative to turn down 
the bovie or bipolar once you start to dissect the perforators. If a bilateral reconstruc-
tion is being performed, then the vertical midline incision can be made to separate 
the two flaps (Figure 7). Dissection then proceeds from medial to lateral above the 
level of the muscular fascia until the medial row perforators are encountered. If a 
unilateral reconstruction is being performed, then the vertical midline incision is 
Figure 6. 
Lateral to medial dissection of TRAM flap above muscular fascia to lateral row perforators.
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not performed. Dissection in this case then proceeds in the midline at the level of 
the muscular fascia until the medial row perforators are visualized. After visual 
inspection of all perforators, a Doppler can be used to see which perforators are more 
dominant. A decision is made (based on the above algorithm) about taking the lateral, 
medial, or both row perforators. Further dissection between the perforators along 
the muscular fascia occurs to help preserve fascia for the abdominal wall closure. A 
marking pen is used to design the planned longitudinal incision in the anterior rectus 
sheath, which is then extended to the lateral edge of the rectus inferiorly to aid in 
pedicle dissection. Various amount of anterior rectus sheath are incorporated into the 
flap depending on the number and location of the perforators. The anterior rectus 
sheath is incised and the lateral aspect of the sheath elevated off of the rectus abdomi-
nis muscle (Figure 8). The deep inferior epigastric artery/vein is then identified deep 
and lateral to the rectus abdominis muscle. The pedicle is then dissected all the way to 
the external iliac vessels and then separated near their origins (Figure 9). The pedicle 
is then dissected superiorly to identify the perforators going into the flap. Care should 
be taken to preserve the vascular and nerve supply to the rectus abdominis muscle. 
The rectus abdominis muscle is then split longitudinally between the perforators and 
the rectus abdominis muscle that will remain in-situ (Figure 10). If a MS-2 TRAM is 
being performed then a second longitudinal spit is made in the rectus abdominis mus-
cle on the other side of the perforators. Once the pedicle is cleared posteriorly from 
the posterior rectus sheath, then the pedicle can be dissected away from the rectus 
abdominis muscle inferior to the takeoff of the first perforator. The rectus abdominis 
muscle can then be divided with cautery inferiorly with care taken to protect the 
pedicle. Attention is then turned to identify the superior epigastric vessels, which are 
then temporarily clamped. The Doppler is used to identify perforators on the skin, 
which can then be marked with a 5-0 prolene suture. After confirming the vascular 
supply to the flap, the superior rectus abdominis muscle and the superior epigastric 
vessels can be divided (Figure 11). The deep inferior epigastric vessels should not be 
divided until the recipient vessels are identified.
Figure 7. 
Vertical midline incision separating bilateral TRAM flaps.
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5.1.3 Recipient vessel harvest
After completion of the mastectomy attention is then turned to the chest to har-
vest recipient vessels, typically the internal mammary vessels or the thoracodorsal 
vessels. The internal mammary vessels at our institution are preferred because the 
thoracodorsal vessels can be damaged during the mastectomy or lymph node dissec-
tion and require a long pedicle to allow for medialization of the flap. Some prefer 
the thoracodorsal vessels because of easier dissection but either recipient vessel has 
the same outcomes and are proven to be safe and reliable [20].
Figure 8. 
Lateral anterior rectus sheath elevated after fascial incision.
Figure 9. 
TRAM flap pedicle dissection to external iliac vessels.
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not performed. Dissection in this case then proceeds in the midline at the level of 
the muscular fascia until the medial row perforators are visualized. After visual 
inspection of all perforators, a Doppler can be used to see which perforators are more 
dominant. A decision is made (based on the above algorithm) about taking the lateral, 
medial, or both row perforators. Further dissection between the perforators along 
the muscular fascia occurs to help preserve fascia for the abdominal wall closure. A 
marking pen is used to design the planned longitudinal incision in the anterior rectus 
sheath, which is then extended to the lateral edge of the rectus inferiorly to aid in 
pedicle dissection. Various amount of anterior rectus sheath are incorporated into the 
flap depending on the number and location of the perforators. The anterior rectus 
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Figure 7. 
Vertical midline incision separating bilateral TRAM flaps.
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5.1.3 Recipient vessel harvest
After completion of the mastectomy attention is then turned to the chest to har-
vest recipient vessels, typically the internal mammary vessels or the thoracodorsal 
vessels. The internal mammary vessels at our institution are preferred because the 
thoracodorsal vessels can be damaged during the mastectomy or lymph node dissec-
tion and require a long pedicle to allow for medialization of the flap. Some prefer 
the thoracodorsal vessels because of easier dissection but either recipient vessel has 
the same outcomes and are proven to be safe and reliable [20].
Figure 8. 
Lateral anterior rectus sheath elevated after fascial incision.
Figure 9. 
TRAM flap pedicle dissection to external iliac vessels.
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To expose the internal mammary vessels, the mastectomy skin is gently retracted 
and then the pectoralis major muscle is split over the third costal cartilage. A 
Weitlaner retractor is placed between the split pectoralis major muscle for expo-
sure. The third costal cartilage perichondrium is incised anteriorly from the sternal 
attachment then 2–3 cm laterally. A freer elevator is used to elevate the perichon-
drium anteriorly then posteriorly off of the third costal cartilage. The third costal 
cartilage segment can be incised sharply laterally with use of a Doyen rib raspatory 
to protect the pleura posteriorly. The third costal cartilage is then removed in piece-
meal fashion using a rongeur until the sternal edge is encountered. Some prefer 
not to use the Doyen rib raspatory and only use the rongeur. Bipolar is then used to 
remove the third costal cartilage perichondrium along with some of the adjacent 
intercostal muscles. As the internal mammary vessels are encountered about 1 cm 
lateral to the sternal edge, it is important to clip any small branches from the vessels 
entering the posterior perichondrium. Care is taken to preserve the anterior branch 
of the third intercostal nerve if flap re-innervation is desired. The internal mam-
mary vessels can be dissected as needed to obtain length. If one is struggling with 
the vessels dissection it is important to finish further dissection with increased 
loupe magnification or the microscope. An internal mammary lymph node is often 
encountered along the artery, which can be sent for permanent pathology to aid 
in oncologic staging. A neurosurgical patty and microsurgery background sheet is 
Figure 10. 
TRAM flap after longitudinal split of rectus muscle with exposed pedicle.
Figure 11. 
TRAM flap in-situ after division of rectus muscle.
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then placed posterior to the internal mammary vessels (Figure 12). Vasodilating 
agents such as lidocaine 4% or papaverine can be injected around the vessels per 
surgeon preference and then covered with a warm moist RayTec sponge. The retrac-
tion on the mastectomy flaps should be released to allow for improved perfusion 
until the microsurgical anastomosis will be performed.
For exposure of the thoracodorsal vessels, the mastectomy skin is gently 
retracted to allow for visualization of the anterior border of the latissimus dorsi 
muscle. Once identified, the anterior border of the latissimus dorsi muscle is fol-
lowed superiorly to the axillary vein. The thoracodorsal vessels will then be located 
between the chest wall and the latissimus dorsi muscle. The vessels are dissected 
until the appropriate length and caliber is obtained. Another option for recipient 
vessels that are less commonly used are the thoracoacromial vessels. These vessels 
are identified in the midclavicular area by using a Doppler. The pectoralis major 
muscle is then split and dissection of the thoracoacromial vessels occurs. The axil-
lary vessels and the scapular circumflex vessels can also be used if the above recipi-
ent sites are not available. Additional venous drainage can occur via cephalic vein or 
external jugular vein transposition [21].
5.1.4 Anastomosis
Once the recipient vessels are dissected and the TRAM flap elevated, the flap 
pedicle can be clipped and divided. The artery should be clipped prior to the vein so 
the flap does not get engorged with blood. The flap is placed on an iced lap sponge 
and then transferred to the contralateral chest. The flap is rotated 90° so the pedicle 
lies adjacent to the recipient vessels. Care is taken to make sure the flap pedicle is 
laying in its natural orientation without twisting. The flap is secured to the chest 
wall using sutures and/or staples. A microscope is then brought into the field if 
loupe magnification is not preferred and centered over the recipient vessels. The 
pedicle vessels are further dissected until enough length is obtained and the vessel 
ends are cleared of fat and adventitia. Attention is then turned to the recipient ves-
sels, which are dissected in a similar fashion. An Acland clamp is placed proximally 
on the recipient artery and vein and then the distal ends clipped and divided. The 
recipient vessels should be irrigated with heparinized saline (100 units per ml) until 
the lumen is clear. The flap should also be flushed with heparinized saline through 
the artery until the venous output is clear. After the recipient and pedicle vessels 
are prepared, the vessels ends are approximated in a way to ensure no kinking or 
twisting of the vessels. The first anastomosis performed is the vessel which will 
be more posterior after the artery and venous anastomoses are completed. For the 
Figure 12. 
Internal mammary vessel preparation.
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artery, the double apposing Acland clamp can be used to approximate the arterial 
ends if needed. 8-0 or 9-0 nylon is used in an interrupted fashion for the arterial 
anastomosis. The venous anastomosis is performed using a venous coupler after 
the diameters of the veins are measured. The use of the venous coupler has been 
shown to reduce operating room times and take-backs to the operating room [22]. 
The venous followed by the arterial Acland clamps are released and the vessels 
checked for leakage and patency. We routinely use indocyanine green angiography 
to evaluate anastomotic patency [23, 24] (Figure 13). A study by Holm showed that 
the intrinsic transit time (ITT) or the time it takes for the indocyanine green dye to 
travel from the arterial to the venous anastomosis can help predict flap compromise 
and early re-exploration. An ITT greater than 50 s was significantly associated with 
these negative outcomes [24].
5.2 Deep inferior epigastric perforator (DIEP)
As techniques in microsurgery developed along with the need to reduce the 
amount of donor muscle sacrifice, the DIEP flap was developed and first performed 
by Allen in 1994 [5]. Some consider the DIEP flap the gold standard for autologous 
breast reconstruction but there can be higher fat necrosis rates compared to the 
TRAM flap if only a few perforators are included in the flap [6].
Similar to the TRAM flap, the DIEP flap can preserve various amounts of muscle 
and nerves. Based on the Nahabedian classification, DIEP flaps are considered MS-3 
TRAM flaps because they preserve the entire rectus muscle [19]. Lee in 2010 devel-
oped a DIEP classification because not all DIEP flap harvests are the same as they 
vary with how much muscle and nerves are transected. A DIEP-1 has one perforator 
and preserves all muscle and nerves. A DIEP-2 has two or more perforators in the 
same row requiring segmental nerve sacrifice but the muscle is preserved. A DIEP-3 
has perforators in different rows so both muscle and nerve are sacrificed. When 
comparing the DIEP-1 to DIEP-3 flaps, the DIEP-1 flaps had a significantly higher 
fat necrosis rate (19.8 vs. 9.2%) [6].
5.2.1 Flap dissection
The breast and abdomen markings pre-operatively are the same as for the TRAM 
flap above (Figure 5). The lower and upper abdominal incisions are made with 
dissection/preservation of the superficial inferior epigastric vessels. The lateral 
and medial row perforators are identified in standard fashion. The surgeon then 
determines which perforators to include in the flap. A DIEP-1 can be performed if 
the perforator is greater than 3 mm. If the perforators are between 1.5 and 3 mm, 
a DIEP-2 or DIEP 3 can be performed. However, if no perforators are greater 
than 1.5 mm, a TRAM should be considered [6, 7]. Usually if there are multiple 
Figure 13. 
Internal mammary vessel anastomosis and ICG angiography.
123
Immediate Breast Reconstruction with Free Autologous Tissue Transfer
DOI: http://dx.doi.org/10.5772/intechopen.85652
perforators in the same row, they will all be included in the DIEP flap. In order to 
preserve more fascia and muscle dissection certain perforators can be temporarily 
clamped so the flap can be assessed based on desired perforators. The ideal perfora-
tors should not only be large but also centrally located to allow for centric perfusion. 
Once the perforators are selected the anterior rectus sheath is incised, the pedicle 
identified, and the rectus muscle split longitudinally adjacent to the perforators 
(Figure 14). The perforators are dissected circumferentially from the pedicle 
to the fascia. A small fascial cuff around the perforators can be left intact if the 
perforators are tiny or if the surgeons prefers. Once the perforators and pedicle are 
dissected, the flap should be assessed for perfusion after the extraneous perforators 
and superior epigastric vessels are temporarily clamped. The extraneous perfora-
tors and superior epigastric vessels can then be clipped and divided (Figure 15). In 
a unilateral reconstruction, the contralateral perforators should be left intact as a 
backup if needed. Once the recipient vessels are prepared the DIEP flap pedicle can 
be clipped and divided (Figure 16).
5.3 Superficial inferior epigastric artery (SIEA)
In 1991, Grotting was the first person to use a free SIEA flap for breast recon-
struction [25]. Compared to the TRAM and DIEP flaps, the SIEA flap minimizes 
donor site morbidity because it does not violate the rectus fascia. Therefore, the risks 
Figure 14. 
Longitudinal rectus muscle longitudinal split during DIEP flap harvest.
Figure 15. 
DIEP flap based on three perforators.
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perforators in the same row, they will all be included in the DIEP flap. In order to 
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tors should not only be large but also centrally located to allow for centric perfusion. 
Once the perforators are selected the anterior rectus sheath is incised, the pedicle 
identified, and the rectus muscle split longitudinally adjacent to the perforators 
(Figure 14). The perforators are dissected circumferentially from the pedicle 
to the fascia. A small fascial cuff around the perforators can be left intact if the 
perforators are tiny or if the surgeons prefers. Once the perforators and pedicle are 
dissected, the flap should be assessed for perfusion after the extraneous perforators 
and superior epigastric vessels are temporarily clamped. The extraneous perfora-
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backup if needed. Once the recipient vessels are prepared the DIEP flap pedicle can 
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of hernia, bulging, and abdominal wall weakness are reduced. Other benefits of the 
SIEA flap is that it can reduce patient discomfort and hospital stay [8]. The SIEA flap 
is performed in the minority of patients because 35–51% of patients do not have an 
SIEA [8, 26]. Other disadvantages of the SIEA flap is it can only perfuse zones I and 
II, has a short pedicle length (5–8 cm), and the pedicle exits the flap just below the 
skin. The use of the SIEA flap should be performed if the vessel is palpable with a 
diameter that is at least 1.5 mm [8, 27]. If the SIEA is absent or small then one should 
proceed to evaluating the deep inferior epigastric perforators as discussed above.
5.3.1 Flap dissection
The breast and abdomen markings for the SIEA flap is the same as the TRAM 
and DIEP flaps (Figure 5). The lower abdominal incision is made and then the SIEA 
is identified. The SIEA is usually one third of the distance from the pubic tubercle 
to the ASIS. A couple techniques to help identify the SIEA is the use of Doppler or to 
apply traction on both sides of the lower incision with your fingers to help separate 
the fat from the SIEA. The SIEA and SIEV can be dissected to their origin on the 
superficial circumflex iliac vessels or less commonly the femoral vessels. If one is 
not confident that the SIEA will perfuse the flap, the deep inferior epigastric perfo-
rators can be dissected suprafascial and then temporarily clamped so the perfusion 
of the flap can be assessed. Once perfusion of the flap is confirmed, then the deep 
perforators can be transected and the pedicle clipped/divided. The flap needs to be 
placed medially to allow the short pedicle to reach the internal mammary vessels. 
Hence, the ipsilateral SIEA flap is preferred.
5.4 Transverse upper gracilis (TUG)
For patients that have contraindications to using abdominal tissue for breast 
reconstruction or who do not want a scar from hip to hip they can use their thigh 
tissue. Another benefit of using thigh tissue as a donor site is that it can result in a 
thigh lift and the scar is usually inconspicuous. The transverse upper gracilis (TUG) 
flap was modified by Yousif in 1992 to allow for improved skin paddle survival 
[28]. It was not until 2002 when Arnez performed the first free TUG flap for breast 
reconstruction [29].
The TUG flap is a Mathes and Nahai type II flap with the dominant vascular supply 
from the ascending branch of the medial circumflex femoral artery [18]. The pedicle is 
around 6 cm in length and enters the gracilis muscle on its medial side about 8–10 cm 
inferior to the pubic tubercle [29, 30]. There are one or two minor pedicles from the 
superficial femoral artery that enter the distal aspect of the gracilis muscle [29].
Figure 16. 
Anterior and posterior surfaces of the DIEP flap with visible superficial inferior epigastric vein.
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5.4.1 Marking
The breast markings are performed in the standard fashion (Figure 5). The 
patient is then frogged legged with the thigh abducted and externally rotated. The 
adductor longus is marked from the pubis to the medial femoral condyle. The graci-
lis muscle is located 2–3 cm posterior to this line. A doppler is used to identity the 
perforator for the TUG flap 8–10 cm inferior to the pubic tubercle over the gracilis 
muscle. The skin paddle is centered over the perforator and the vertical height of 
the flap determined by a pinch test (Figure 17). Primary closure can occur with a 
width of 10–12 cm. The proximal incision marking is at or 1 fingerbreadth below 
the groin crease and extends from just lateral to the adductor longus to the midline 
of the posterior thigh along the gluteal crease. The distal incision marking is then 
drawn to form a semilunar skin paddle that can have a length up to 25 cm [31, 32].
5.4.2 Flap dissection
The patient is placed in the supine position with the thigh abducted and the knee 
flexed. The anterior part of the flap is raised first above the level of the muscular 
fascia. Care is taken to preserve the saphenous vein but the posterior branch can be 
included in the flap. Once the medial aspect of the adductor longus is reached, the 
muscular fascia is incised. The interval between the adductor longus and gracilis 
is entered so the pedicle can be identified entering the medial aspect of the gracilis 
muscle. The ascending branch of the medial circumflex femoral artery is dissected 
all the way to the profunda femoris artery, which can allow for a pedicle length 
of 5–6 cm [29, 31]. After the pedicle is dissected, the posterior aspect of the flap 
can be raised above the muscular fascia. At the posterior aspect of the gracilis, the 
dissection becomes subfascial. The gracilis muscle is then transected 3 cm above 
and below the entrance of the pedicle. The obturator nerve branch to the gracilis is 
clipped and divided followed by the pedicle. In contrast to the abdominal flaps, the 
TUG flap needs to be coned by approximating the superior edges of the two wings 
Figure 17. 
TUG flap and perforator markings.
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dissection becomes subfascial. The gracilis muscle is then transected 3 cm above 
and below the entrance of the pedicle. The obturator nerve branch to the gracilis is 
clipped and divided followed by the pedicle. In contrast to the abdominal flaps, the 
TUG flap needs to be coned by approximating the superior edges of the two wings 
Figure 17. 
TUG flap and perforator markings.
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of the flap. The apex of the coned flap can then be used to reconstruct a nipple areo-
lar complex (NAC). The post-operative results of a patient that underwent bilateral 
TUG flaps for breast reconstruction is shown in Figure 18.
5.5 Profunda artery perforator (PAP)
Another thigh-based flap for patients with contraindications to abdominal 
donor tissue is the profunda artery perforator (PAP) flap, which was first per-
formed by Allen and Haddock in 2010 for breast reconstruction [33, 34]. Prior to 
this in 2000, Angrigiani developed the PAP flap based on the first medial branch of 
the profunda femoris artery [35]. Suitable patients for a PAP flap would have excess 
tissue in the posterior medial thigh and small to moderate sized breasts [34].
The PAP flap is a fasciocutaneous flap that is based on the second or third 
perforator from the profunda femoris artery. The pedicle length can be up to 13 cm 
and can be septocutaneous or go through the adductor magnus muscle [36]. The 
benefits of the PAP flap over the TUG flap is it has a larger volume, longer pedicle, 
requires no muscle sacrifice, and less anterior thigh scar. The PAP flap can also be 
converted to a TUG or IGAP flap if needed intra-operatively [36].
5.5.1 Marking
The breast markings are made in standard fashion (Figure 5) then the patient 
is placed in the supine position with the thigh abducted and knee flexed. The 
gracilis muscle is identified just posterior to the adductor longus muscle. A mark is 
made 2 cm posterior to the gracilis muscle and 8 cm inferior to the groin crease. A 
Doppler is used to confirm the perforator around this location [35]. There are also 
other posterior or lateral thigh perforators from the profunda femoris artery that 
Figure 18. 
Bilateral breast reconstruction using TUG flaps.
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are seen on preoperative CTA or MRA that can be used but the medial perforators 
are preferred because of ease of positioning and size of the medial perforators 
[34]. The flap is designed in an ellipse shape with the superior border of the flap 
at or 1 cm below the gluteal crease and the inferior border around 7 cm below the 
superior marking (Figure 19). A pinch test can also be performed to increase the 
vertical height of the flap if needed. Care is taken to make sure the flap is centered 
on the marked perforator(s). The length of the flap can be up to 35 cm, which 
extends from the posterior lateral thigh to the medial thigh. If the TUG flap is being 
considered as a bailout plan then the medial incision should be carried to the adduc-
tor longus [37]. If more posterior perforators are being considered the patient can 
be in the prone position.
5.5.2 Flap dissection
Similar to the TUG flap, the PAP flap is performed in the supine position with 
the thigh abducted and knee flexed. The anterior medial aspect of the flap is raised 
above the level of the muscular fascia until the posterior border of the adductor 
longus is reached. A subfascial plane is dissected between the adductor longus and 
gracilis muscles. The perforator to the PAP flap can be identified along the adduc-
tor magnus muscle as you dissect posteriorly. If no perforator is seen then the flap 
can be converted to a TUG flap. After confirming the perforator to the PAP flap the 
gracilis muscle can be retracted anteriorly to aid in further perforator dissection. If 
further pedicle length is needed then the pedicle can be dissected to the profunda 
femoris artery (Figure 20). The posterior lateral aspect of the flap can then be 
dissected in the suprafascial plane and then below the fascia once the perforator is 
nearby. To increase volume in the flap and improve lateral thigh contour, the flap 
can be beveled in the lateral thigh [34]. The pedicle to the flap can be clipped and 
divided after the flap is elevated. The PAP flap is coned in the same fashion as the 
TUG flap with the apex of the flap able to reconstruct the NAC as needed.
Figure 19. 
PAP flap and perforator markings.
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of the flap. The apex of the coned flap can then be used to reconstruct a nipple areo-
lar complex (NAC). The post-operative results of a patient that underwent bilateral 
TUG flaps for breast reconstruction is shown in Figure 18.
5.5 Profunda artery perforator (PAP)
Another thigh-based flap for patients with contraindications to abdominal 
donor tissue is the profunda artery perforator (PAP) flap, which was first per-
formed by Allen and Haddock in 2010 for breast reconstruction [33, 34]. Prior to 
this in 2000, Angrigiani developed the PAP flap based on the first medial branch of 
the profunda femoris artery [35]. Suitable patients for a PAP flap would have excess 
tissue in the posterior medial thigh and small to moderate sized breasts [34].
The PAP flap is a fasciocutaneous flap that is based on the second or third 
perforator from the profunda femoris artery. The pedicle length can be up to 13 cm 
and can be septocutaneous or go through the adductor magnus muscle [36]. The 
benefits of the PAP flap over the TUG flap is it has a larger volume, longer pedicle, 
requires no muscle sacrifice, and less anterior thigh scar. The PAP flap can also be 
converted to a TUG or IGAP flap if needed intra-operatively [36].
5.5.1 Marking
The breast markings are made in standard fashion (Figure 5) then the patient 
is placed in the supine position with the thigh abducted and knee flexed. The 
gracilis muscle is identified just posterior to the adductor longus muscle. A mark is 
made 2 cm posterior to the gracilis muscle and 8 cm inferior to the groin crease. A 
Doppler is used to confirm the perforator around this location [35]. There are also 
other posterior or lateral thigh perforators from the profunda femoris artery that 
Figure 18. 
Bilateral breast reconstruction using TUG flaps.
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are seen on preoperative CTA or MRA that can be used but the medial perforators 
are preferred because of ease of positioning and size of the medial perforators 
[34]. The flap is designed in an ellipse shape with the superior border of the flap 
at or 1 cm below the gluteal crease and the inferior border around 7 cm below the 
superior marking (Figure 19). A pinch test can also be performed to increase the 
vertical height of the flap if needed. Care is taken to make sure the flap is centered 
on the marked perforator(s). The length of the flap can be up to 35 cm, which 
extends from the posterior lateral thigh to the medial thigh. If the TUG flap is being 
considered as a bailout plan then the medial incision should be carried to the adduc-
tor longus [37]. If more posterior perforators are being considered the patient can 
be in the prone position.
5.5.2 Flap dissection
Similar to the TUG flap, the PAP flap is performed in the supine position with 
the thigh abducted and knee flexed. The anterior medial aspect of the flap is raised 
above the level of the muscular fascia until the posterior border of the adductor 
longus is reached. A subfascial plane is dissected between the adductor longus and 
gracilis muscles. The perforator to the PAP flap can be identified along the adduc-
tor magnus muscle as you dissect posteriorly. If no perforator is seen then the flap 
can be converted to a TUG flap. After confirming the perforator to the PAP flap the 
gracilis muscle can be retracted anteriorly to aid in further perforator dissection. If 
further pedicle length is needed then the pedicle can be dissected to the profunda 
femoris artery (Figure 20). The posterior lateral aspect of the flap can then be 
dissected in the suprafascial plane and then below the fascia once the perforator is 
nearby. To increase volume in the flap and improve lateral thigh contour, the flap 
can be beveled in the lateral thigh [34]. The pedicle to the flap can be clipped and 
divided after the flap is elevated. The PAP flap is coned in the same fashion as the 
TUG flap with the apex of the flap able to reconstruct the NAC as needed.
Figure 19. 
PAP flap and perforator markings.
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5.6 Superior gluteal artery perforator (SGAP)
Breast reconstruction can be performed by utilizing gluteal tissue if the 
abdomen and thighs are not usable as donor sites. The first superior gluteal 
artery myocutaneous flap for breast reconstruction was by Fujino in 1975 [38]. 
With the development of perforator flaps, Allen in 1993 developed the superior 
gluteal artery perforator (SGAP) flap to allow for a longer vascular pedicle 
and gluteus maximus muscle preservation [39, 40]. The use of the SGAP is not 
considered the first option for breast reconstruction because of a tedious flap 
dissection, change in positioning in the operating room, smaller volume flap, 
and gluteal scarring [40].
The SGAP flap is based on the superior gluteal artery, which is a branch of the 
internal iliac artery. The superior gluteal artery leaves the pelvis above the pirifor-
mis muscle and then divides into a deep and superficial branch. The superficial 
branch transverses the gluteal muscles and gives off perforators to the skin [30]. 
The use of CTA or MRA preoperatively can be used to aid in identification of the 
SGAP perforators.
5.6.1 Marking
To aid in intra-operative positioning, the patient is placed in the lateral decubi-
tus position and the ipsilateral flap is used so a two team approach can be utilized 
for the chest and gluteal areas. If bilateral gluteal flaps are needed then the patient 
will have to be in the prone position for flap harvest after the mastectomies and 
recipient vessels are harvested. The posterior superior iliac spine (PSIS), ante-
rior superior iliac spine (ASIS), greater trochanter, and coccyx are marked. The 
perforators are identified one third of the distance from the PSIS to the greater 
trochanter, which is confirmed with Doppler. There can be more lateral perfora-
tors located between the gluteus maximus and gluteus medius muscles that can 
allow for a longer pedicle length, which can be included in the flap. The flap is 
then centered on a line from the coccyx to the ASIS. It is desirable to have a less 
centric but more laterally placed perforator, which will allow for a longer pedicle. 
The height of the flap can vary from 7 to 14 cm but must be confirmed with the 
pinch test to allow for appropriate closure (Figure 21). The length of the flap can 
also vary from 18 to 30 cm [30, 40].
Figure 20. 
PAP flap pedicle dissected through adductor magnus muscle to the profunda femoris artery.
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5.6.2 Flap dissection
The SGAP flap skin incisions are made and then beveled outward once past the 
superficial fascia to increase flap volume and to improve the transition onto the chest 
wall. The gluteus maximus fascia is incised and then the dissection proceeds in this 
plane above the muscle from lateral to medial until the perforators are identified. Similar 
to DIEP flap dissection, the dominant perforators are identified and preserved. Usually 
one large perforator is selected but two perforators in the same muscle fiber plane can 
also be dissected together. The selected perforators are dissected vertically between 
the gluteus maximus muscle fibers and through the deep gluteal fascia until a fat pad is 
seen. Once the pedicle is of the appropriate size and length the dissection can cease. In a 
unilateral reconstruction in the lateral decubitus position, the pedicle to the flap can be 
clipped and divided followed by the microvascular anastomoses. If a bilateral recon-
struction is performed in the prone position, the flaps should be placed in a bag on an 
ice saline bath. The patient is then flipped supine so the anastomoses can be performed. 
The internal mammary vessels are the main recipient vessels for the SGAP flap. If the 
SGAP flap has two perforators then one can be connected in an antegrade fashion and 
the other in a retrograde fashion to the internal mammary vessels. After confirming flap 
perfusion, the flap can be coned or the tips excised to improve flap contour [30, 40].
5.7 Inferior gluteal artery perforator (IGAP)
The inferior gluteal artery perforator (IGAP) flap is another gluteal based free 
flap for breast reconstruction. The first IGAP free flap for breast reconstruction was 
performed by LeQuang in 1978 [41]. The ideal patient will have excess tissue in the 
inferior buttock or a saddlebag deformity. The benefit of the IGAP flap over the SGAP 
flap is the scar can be hidden in the gluteal crease and it does not leave a hollowing 
in the superior gluteal area [42]. However, the IGAP flap tends to be smaller than the 
SGAP and can lead to increased patient discomfort if the sciatic nerve is exposed [27].
The IGAP flap is based on the inferior gluteal artery, which is a branch of the 
internal iliac artery. The inferior gluteal artery leaves the pelvis below the piriformis 
muscle and is soon accompanied by the sciatic nerve, posterior femoral cutaneous 
nerve, and the internal pudendal vessels [32]. The IGAP can also be neurotized if 
Figure 21. 
SGAP (right) and IGAP (left) flap and perforator markings.
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5.6 Superior gluteal artery perforator (SGAP)
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With the development of perforator flaps, Allen in 1993 developed the superior 
gluteal artery perforator (SGAP) flap to allow for a longer vascular pedicle 
and gluteus maximus muscle preservation [39, 40]. The use of the SGAP is not 
considered the first option for breast reconstruction because of a tedious flap 
dissection, change in positioning in the operating room, smaller volume flap, 
and gluteal scarring [40].
The SGAP flap is based on the superior gluteal artery, which is a branch of the 
internal iliac artery. The superior gluteal artery leaves the pelvis above the pirifor-
mis muscle and then divides into a deep and superficial branch. The superficial 
branch transverses the gluteal muscles and gives off perforators to the skin [30]. 
The use of CTA or MRA preoperatively can be used to aid in identification of the 
SGAP perforators.
5.6.1 Marking
To aid in intra-operative positioning, the patient is placed in the lateral decubi-
tus position and the ipsilateral flap is used so a two team approach can be utilized 
for the chest and gluteal areas. If bilateral gluteal flaps are needed then the patient 
will have to be in the prone position for flap harvest after the mastectomies and 
recipient vessels are harvested. The posterior superior iliac spine (PSIS), ante-
rior superior iliac spine (ASIS), greater trochanter, and coccyx are marked. The 
perforators are identified one third of the distance from the PSIS to the greater 
trochanter, which is confirmed with Doppler. There can be more lateral perfora-
tors located between the gluteus maximus and gluteus medius muscles that can 
allow for a longer pedicle length, which can be included in the flap. The flap is 
then centered on a line from the coccyx to the ASIS. It is desirable to have a less 
centric but more laterally placed perforator, which will allow for a longer pedicle. 
The height of the flap can vary from 7 to 14 cm but must be confirmed with the 
pinch test to allow for appropriate closure (Figure 21). The length of the flap can 
also vary from 18 to 30 cm [30, 40].
Figure 20. 
PAP flap pedicle dissected through adductor magnus muscle to the profunda femoris artery.
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5.6.2 Flap dissection
The SGAP flap skin incisions are made and then beveled outward once past the 
superficial fascia to increase flap volume and to improve the transition onto the chest 
wall. The gluteus maximus fascia is incised and then the dissection proceeds in this 
plane above the muscle from lateral to medial until the perforators are identified. Similar 
to DIEP flap dissection, the dominant perforators are identified and preserved. Usually 
one large perforator is selected but two perforators in the same muscle fiber plane can 
also be dissected together. The selected perforators are dissected vertically between 
the gluteus maximus muscle fibers and through the deep gluteal fascia until a fat pad is 
seen. Once the pedicle is of the appropriate size and length the dissection can cease. In a 
unilateral reconstruction in the lateral decubitus position, the pedicle to the flap can be 
clipped and divided followed by the microvascular anastomoses. If a bilateral recon-
struction is performed in the prone position, the flaps should be placed in a bag on an 
ice saline bath. The patient is then flipped supine so the anastomoses can be performed. 
The internal mammary vessels are the main recipient vessels for the SGAP flap. If the 
SGAP flap has two perforators then one can be connected in an antegrade fashion and 
the other in a retrograde fashion to the internal mammary vessels. After confirming flap 
perfusion, the flap can be coned or the tips excised to improve flap contour [30, 40].
5.7 Inferior gluteal artery perforator (IGAP)
The inferior gluteal artery perforator (IGAP) flap is another gluteal based free 
flap for breast reconstruction. The first IGAP free flap for breast reconstruction was 
performed by LeQuang in 1978 [41]. The ideal patient will have excess tissue in the 
inferior buttock or a saddlebag deformity. The benefit of the IGAP flap over the SGAP 
flap is the scar can be hidden in the gluteal crease and it does not leave a hollowing 
in the superior gluteal area [42]. However, the IGAP flap tends to be smaller than the 
SGAP and can lead to increased patient discomfort if the sciatic nerve is exposed [27].
The IGAP flap is based on the inferior gluteal artery, which is a branch of the 
internal iliac artery. The inferior gluteal artery leaves the pelvis below the piriformis 
muscle and is soon accompanied by the sciatic nerve, posterior femoral cutaneous 
nerve, and the internal pudendal vessels [32]. The IGAP can also be neurotized if 
Figure 21. 
SGAP (right) and IGAP (left) flap and perforator markings.
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the inferior gluteal nerve is preserved. Similar to other perforator flaps, preopera-
tive CTA or MRA can be used to aid in identification of the IGAP perforators.
5.7.1 Marking
The gluteal crease is marked in the standing position. The positioning of the 
patient for the IGAP flap is the same as for the SGAP flap. Lateral decubitus for a 
unilateral reconstruction and prone for a bilateral reconstruction. The PSIS and 
ischial tuberosity are marked. The inferior gluteal perforators are identified two third 
of the distance from the PSIS to the outer aspect of the ischial tuberosity. The inferior 
border of the flap is marked at or 1 cm inferior to the gluteal crease. After confirming 
the location of the IGAP perforators with a doppler, the superior border of the flap is 
marked to form an ellipse that is parallel to the gluteal crease [42]. The height of the 
flap is usually around 7–8 cm but must be confirmed with a pinch test (Figure 21). 
The length of the flap is around 18 cm. The flap can be designed to include the saddle 
bag deformity laterally. Care must be taken to leave tissue over the ischial tuberosity to 
prevent patient discomfort and wound dehiscence when in the sitting position [30].
5.7.2 Flap dissection
The IGAP flap skin incisions are made and then continued just distal to the 
gluteus maximus fascia. Beveling of the flap can occur to increase flap volume or to 
remove tissue in the saddle bag area. The dissection proceeds in this plane above the 
muscle from lateral to medial until the inferior gluteal artery perforators are identi-
fied. Typically, two to four perforators from the inferior gluteal artery can be identi-
fied but the dominant perforators are preserved [42]. Usually one perforator that is 
greater than 1 mm is selected but two perforators in the same muscle fiber plane can 
also be dissected together. The selected perforators are dissected vertically between 
the gluteus maximus muscle fibers and through the deep gluteal fascia. Once the 
pedicle is of the appropriate size and length the dissection can cease. Similar to the 
SGAP harvest, a unilateral reconstruction in the lateral decubitus position can then 
proceed with pedicle clipping and dividing followed by the microvascular anas-
tomoses. If a bilateral reconstruction is performed in the prone position, the flaps 
should be placed in a bag on an ice saline bath. The patient is then flipped supine so 
the anastomoses can be performed. The recipient vessels for the IGAP flap are the 
internal mammary vessels but they can also reach the thoracodorsal vessels since 
the pedicle length is around 8–11 cm. The elliptical IGAP flap is coned or the tips 
trimmed after the microvascular anastomoses [30, 42].
6. Insetting
After the arterial and venous anastomoses are deemed to be patent by using 
various techniques such as the strip test, uplift test, checking for dermal bleeding, 
and SPY-angiography, the flap should be placed into the breast pocket gently as to 
not avulse the anastomosis. If an abdominal flap is performed, the contralateral flap 
is usually chosen and rotated 90° so the corner of the flap with the umbilical carve 
out is placed inferior laterally. Therefore the vertical height of the flap will represent 
the width of the reconstructed breast. If the thoracodorsal vessels are preferred, 
then an ipsilateral flap should be used and rotated 90° so the pedicle vessels exit the 
flap laterally. A limitation to using the thoracodorsal vessels include the inability to 
medialize the flap that can result in a narrow breast. The rotation of the flaps can 
also be modified to increase or decrease the new breast mound width and/or height.
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The shape of the neo-breast mound can be over looked and is a critical proponent 
to breast reconstruction from an esthetic standpoint. The first step to aid in shaping of 
the breast is to trim the flap to the desired breast footprint. Often it is necessary to trim 
and tapper the most lateral aspect of the flap or zone 4 to improve the contour of the 
upper pole of the breast. The projection of the flap can also be easily modified by folding 
the flap on itself or coning. In unilateral breast reconstructions, stacked or bipedicled 
abdominal free flap can be performed to increase volume as needed [43]. Once the shape 
of the flap is optimal, the flap should circumferentially be sutured down to the chest 
wall using 2-0 absorbable suture. Usually the medial aspect of the flap is sutured first to 
insure medial fullness of the neo-breast mound. The superficial fascia and/or dermis of 
the flap can be sutured to the deep fascia and inframammary fold (IMF) of the chest.
7. Mastectomy flap assessment and skin closure
Upon completion of flap in-setting, the viability of the mastectomy skin 
should be performed. Clear areas of devascularized mastectomy skin should be 
sharply excised. For areas of the mastectomy skin that are not so obvious, indo-
cyanine green (ICG) angiography can be used to assess perfusion (Figure 22). 
Figure 22. 
Mastectomy skin, NAC, and flap perfusion assessment using ICG angiography. (a and b) First stage bilateral 
breast reduction before and after and (c) second stage bilateral NSM and TRAM flaps.
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the inferior gluteal nerve is preserved. Similar to other perforator flaps, preopera-
tive CTA or MRA can be used to aid in identification of the IGAP perforators.
5.7.1 Marking
The gluteal crease is marked in the standing position. The positioning of the 
patient for the IGAP flap is the same as for the SGAP flap. Lateral decubitus for a 
unilateral reconstruction and prone for a bilateral reconstruction. The PSIS and 
ischial tuberosity are marked. The inferior gluteal perforators are identified two third 
of the distance from the PSIS to the outer aspect of the ischial tuberosity. The inferior 
border of the flap is marked at or 1 cm inferior to the gluteal crease. After confirming 
the location of the IGAP perforators with a doppler, the superior border of the flap is 
marked to form an ellipse that is parallel to the gluteal crease [42]. The height of the 
flap is usually around 7–8 cm but must be confirmed with a pinch test (Figure 21). 
The length of the flap is around 18 cm. The flap can be designed to include the saddle 
bag deformity laterally. Care must be taken to leave tissue over the ischial tuberosity to 
prevent patient discomfort and wound dehiscence when in the sitting position [30].
5.7.2 Flap dissection
The IGAP flap skin incisions are made and then continued just distal to the 
gluteus maximus fascia. Beveling of the flap can occur to increase flap volume or to 
remove tissue in the saddle bag area. The dissection proceeds in this plane above the 
muscle from lateral to medial until the inferior gluteal artery perforators are identi-
fied. Typically, two to four perforators from the inferior gluteal artery can be identi-
fied but the dominant perforators are preserved [42]. Usually one perforator that is 
greater than 1 mm is selected but two perforators in the same muscle fiber plane can 
also be dissected together. The selected perforators are dissected vertically between 
the gluteus maximus muscle fibers and through the deep gluteal fascia. Once the 
pedicle is of the appropriate size and length the dissection can cease. Similar to the 
SGAP harvest, a unilateral reconstruction in the lateral decubitus position can then 
proceed with pedicle clipping and dividing followed by the microvascular anas-
tomoses. If a bilateral reconstruction is performed in the prone position, the flaps 
should be placed in a bag on an ice saline bath. The patient is then flipped supine so 
the anastomoses can be performed. The recipient vessels for the IGAP flap are the 
internal mammary vessels but they can also reach the thoracodorsal vessels since 
the pedicle length is around 8–11 cm. The elliptical IGAP flap is coned or the tips 
trimmed after the microvascular anastomoses [30, 42].
6. Insetting
After the arterial and venous anastomoses are deemed to be patent by using 
various techniques such as the strip test, uplift test, checking for dermal bleeding, 
and SPY-angiography, the flap should be placed into the breast pocket gently as to 
not avulse the anastomosis. If an abdominal flap is performed, the contralateral flap 
is usually chosen and rotated 90° so the corner of the flap with the umbilical carve 
out is placed inferior laterally. Therefore the vertical height of the flap will represent 
the width of the reconstructed breast. If the thoracodorsal vessels are preferred, 
then an ipsilateral flap should be used and rotated 90° so the pedicle vessels exit the 
flap laterally. A limitation to using the thoracodorsal vessels include the inability to 
medialize the flap that can result in a narrow breast. The rotation of the flaps can 
also be modified to increase or decrease the new breast mound width and/or height.
131
Immediate Breast Reconstruction with Free Autologous Tissue Transfer
DOI: http://dx.doi.org/10.5772/intechopen.85652
The shape of the neo-breast mound can be over looked and is a critical proponent 
to breast reconstruction from an esthetic standpoint. The first step to aid in shaping of 
the breast is to trim the flap to the desired breast footprint. Often it is necessary to trim 
and tapper the most lateral aspect of the flap or zone 4 to improve the contour of the 
upper pole of the breast. The projection of the flap can also be easily modified by folding 
the flap on itself or coning. In unilateral breast reconstructions, stacked or bipedicled 
abdominal free flap can be performed to increase volume as needed [43]. Once the shape 
of the flap is optimal, the flap should circumferentially be sutured down to the chest 
wall using 2-0 absorbable suture. Usually the medial aspect of the flap is sutured first to 
insure medial fullness of the neo-breast mound. The superficial fascia and/or dermis of 
the flap can be sutured to the deep fascia and inframammary fold (IMF) of the chest.
7. Mastectomy flap assessment and skin closure
Upon completion of flap in-setting, the viability of the mastectomy skin 
should be performed. Clear areas of devascularized mastectomy skin should be 
sharply excised. For areas of the mastectomy skin that are not so obvious, indo-
cyanine green (ICG) angiography can be used to assess perfusion (Figure 22). 
Figure 22. 
Mastectomy skin, NAC, and flap perfusion assessment using ICG angiography. (a and b) First stage bilateral 
breast reduction before and after and (c) second stage bilateral NSM and TRAM flaps.
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The trimming of mastectomy skin with the use of ICG imaging reduces the need 
for future operations secondary to deep skin necrosis [44]. Another alternative if 
a large or critical area of mastectomy skin is concerning for poor perfusion, the 
flap can be buried and then a second look procedure in 72 h can be performed to 
re-assess the mastectomy skin [45]. Aside from excising devascularized mastectomy 
skin, areas with significant radiation changes, scarring, and/or tethering need to be 
excised to allow for optimal outcomes. If the mastectomy skin is constricted causing 
pin cushioning of the flap, a superior lateral incision in the mastectomy skin can 
allow for release of the constricted mastectomy skin.
Once the mastectomy skin defect is known, the skin paddle on the flap can 
be designed. The excess skin on the outside of the skin paddle is then de-epithe-
lialized using Gorney scissors or a scalpel. It is important to preserve the dermis 
in order to protect the subdermal plexus of the flap. However, from an esthetic 
standpoint to prevent an indentation along the flap suture line it is necessary to 
score the dermis about 1–2 mm away from the skin paddle. Prior to skin closure, 
hemostasis in the breast pocket and along the de-epithelized flap need to be 
confirmed. A 15F round channel drain is placed along the axilla and IMF then 
exits the skin inferior to the IMF along the anterior axillary line. The dermis is 
then approximated using 2-0 or 3-0 absorbable suture followed by 4-0 running 
subcuticular for the skin. The Doppler signal on the skin paddle should be con-
firmed and marked with a 5-0 prolene suture. Our preferred dressings for the flap 
incision is antibiotic ointment and xeroform then coverage with abdomen battle 
dressing (ABD) pads.
8. Ptosis management
Nipple-sparing mastectomy (NSM) has increased overtime with refinements in 
oncologic techniques and protocols, allowing for improved patient satisfaction and 
esthetics [46]. Patients with large or ptotic breasts were traditionally contraindi-
cated to have nipple preservation over concerns of poor mastectomy skin and nipple 
perfusion. Some techniques that have been developed to increase nipple perfusion 
in ptotic patients include mastopexy or reduction (Figure 22a–c) before NSM, 
mastopexy during the time of the NSM, and nipple devascularization [47–49].
Figure 23. 
Single stage bilateral NSM, de-epithelization wise pattern mastopexy, and TRAM flaps.
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The use of mastectomy or reduction with a minimum of 3–4 weeks prior to 
nipple sparing mastectomy was performed by Spear in fifteen patients. No reports 
of total nipple-areola complex necrosis occurred and 13% had partial nipple-areola 
complex necrosis [47]. It is important to note that the majority of patients in this 
study underwent prophylactic NSM’s because by adding an additional procedure 
can delay oncologic treatment of cancer patients. Another technique is to perform 
the mastopexy at the time of the nipple sparing mastectomy, which can be in a 
peri-areolar, vertical, or wise fashion [48]. Nguyen described an approach of skin 
reduction with deepithelization and tissue infolding that preserves dermal plexus 
perfusion and promotes nipple and skin flap survival in immediate breast recon-
struction after skin sparing and NSM [49] (Figure 23).
Staged devascularization of the NAC can also be performed 1–3 weeks prior 
to NSM [50, 51]. This is performed by using a pre-existing incision or making a 
vertical or radial lateral incision then undermining the NAC and the adjacent skin 
for 4–5 cm in the mastectomy plane. During this time a biopsy of the subnipple is 
performed to confirm absence of tumor. The staged devascularization of the NAC 
in a study by Jensen in 20 patients resulted in 100% NAC survival after the NSM 
[50]. A follow up study by Nguyen a few years later also support the use of staged 
devascularization of the NAC in high risk women that  
undergo NSM [51, 52].
9. Adjunctive procedures
9.1 Neurotization
The ideal reconstructed breast should not only take into consideration size, shape, 
symmetry, and softness but also sensibility. The presence of sensation in the recon-
structed breast has shown to improve patient satisfaction and quality of life [53]. The 
neurotization of abdominally based free tissue transfers have shown to have signifi-
cantly increased sensory recovery [53, 54]. Coaptation of the flap nerve is typically 
performed to the anterior branch of the third intercostal nerve (Figure 24). This donor 
nerve can be found just below the third rib and crosses just anterior to the internal 
mammary vessels. The benefits of using the anterior branch of the third intercostal 
nerve is minimal dissection needed and it is in the vicinity of the vascular anastomo-
ses. A less commonly used donor nerve is the lateral cutaneous branch of the third or 
fourth intercostal nerve because it can be damaged with the mastectomy procedure 
and is far away from the flap pedicle [54]. If primary coaptation of the nerves is not 
possible, a nerve conduit or graft can be used to improve sensibility. A meta-analysis 
Figure 24. 
TRAM flap neurotized to the anterior branch of the third intercostal nerve.
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The trimming of mastectomy skin with the use of ICG imaging reduces the need 
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of 37 articles on neurotization of breast reconstruction showed that sensation returns 
spontaneously but neurotization can lead to earlier return of sensation and increased 
magnitude [55]. Beside neurotization of the flap, the NAC can be neurotized with the 
aid of a nerve graft to the lateral branch of the fourth intercostal nerve (Figure 25).
9.2 Autologous with implant
Another adjunctive procedure for patients that need flap skin for their breast recon-
struction but do not have enough donor tissue volume to reconstruct a larger size breast is 
the addition of an implant or tissue expander at the time of free tissue transfer [56–60]. 
This was first reported in 5 patients who had combined TRAM flaps with implants 
placed by Miller in 1996 [56]. In this study no flap compromise or implant complication 
Figure 26. 
Bilateral TRAM flap breast reconstruction combined with immediate implant.
Figure 25. 
NAC neurotization to lateral branch of fourth intercostal nerve using nerve graft and tunneled through TRAM 
flap.
135
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Immediate Breast Reconstruction with Free Autologous Tissue Transfer
DOI: http://dx.doi.org/10.5772/intechopen.85652
Author details
Justin Zelones, Suzanne Inchauste and Dung Nguyen*
Stanford University, Palo Alto, California, USA
*Address all correspondence to: nguyendh@stanford.edu
was reported. Others have shown that immediate expander/implant placement at the 
time of the free tissue transfer is associated with higher late (>30 days) implant related 
complications such as infection, implant rupture, implant malposition, rippling, and 
capsular contracture [58]. These could be secondary to a longer procedure with unrecog-
nized contamination of the implant and difficulty with forming an appropriate implant 
pocket [58]. A more recent study by Momeni in 2018 demonstrated that no implant 
infection, implant malposition, and flap loss occurred in 23 patients that underwent 
autologous reconstruction with simultaneous prepectoral silicone implant placement 
[59]. In patients that have undergone neoadjuvant irradiation, the use of TRAM flap 
combined with an implant significantly lowers the implant loss rate (5 vs. 30%) and 
reconstruction failures (10 vs. 42%) when compared to expander/implant only recon-
structions [60]. Often patients that undergo immediate autologous reconstruction with 
implant placement have increased esthetic appearance with more breast fullness and less 
ptosis when compared to their breasts prior to their mastectomies (Figure 26).
10. Conclusion
Free autologous tissue transfer from the abdomen is the ideal reconstruction option 
for the majority of breast cancer patients. The use of autologous tissue can result in a 
natural appearing breast that is soft, symmetric, and sensate. With improvements in 
microsurgical techniques, the donor site morbidity and flap complications are mini-
mal allowing for free tissue transfers to be performed in most breast reconstruction 
patients. Although the abdomen is the preferred donor site, there are other areas that 
can be utilized for reconstruction. This chapter reviews some of the common free autol-
ogous tissue transfers for breast reconstruction along with some adjunctive procedures.
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The use of biological matrices in immediate implant-based breast reconstruc-
tion arose with the need to reinforce the lower pole of the breast and to cover the 
implant to reduce the risk of implant exposure. Synthetic mesh appears to be a 
lower cost alternative to biological matrices. This literature review aims to assess the 
usefulness of the use of synthetic meshes in breast reconstruction compared with 
the traditional techniques and whether outcomes and complications of synthetic 
meshes and biological matrices are comparable. The positioning of the implants and 
meshes, either submuscular or subcutaneous, has also been considered.
Keywords: breast cancer, breast reconstruction, synthetic breast meshes,  
biological breast meshes, complications of breast reconstruction
1. Introduction
Breast cancer is a life-changing diagnosis. Presently, breast conserving therapy 
can be performed in 70–80% of all breast cancer patients, but in about 20–30% of 
them mastectomy is indicated as the primary therapeutic management [1–3]. As 
mastectomy can profoundly affect body image and self-esteem, breast reconstruc-
tion should be offered to improve quality of life. Reconstruction may be immediate 
or delayed, performed with implants or autologous tissue. Immediate reconstruc-
tion has several advantages: it provides a psychological benefit, reducing emotional 
stress and helping to preserve a positive body image [4, 5].
Numerous surgical techniques have been developed, including the use of 
autologous tissue flaps or silicone implants with or without prior insertion of a 
tissue expander [1]. Implant-based breast reconstruction (IBBR) accounts for 
approximately 40–60% of all breast reconstructions in Europe and around 75% 
in the United States [6]. The American Society of Plastic Surgeons documented 
a 4% increase in these techniques from 2014 to 2015 and a 35% increase over the 
last 15 years. A similar trend has also been shown in the United Kingdom, where 
the rate of IBBR has doubled over the period 1996–2012 [7]. As the number of 
autologous procedures remains approximately the same, the increased number 
of immediate procedures can be primarily attributed to an increase in implant/
expander reconstructions. This number has substantially increased since skin- and 
nipple-sparing mastectomies (SSM/NSM) have proven to be oncologically safe 
procedures.
In IBBR, complete implant coverage has been the mainstay target of surgeons 
in order to reduce the risk of implant exposure [8]. In the last years, biological 
and synthetic meshes have emerged as a useful adjunct to breast reconstruction, 
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although the decision to add some mesh to an alloplastic reconstruction is contro-
versial. However, there is no high-quality evidence comparing clinical and patient-
reported outcomes with mesh-assisted IBBR and traditional IBBR [9]. Finally, the 
decision for using mesh or not and a particular type of matrix or mesh depends 
predominately on the surgeons’ experience [3, 10].
2. Methods
A literature search has been performed in PubMed, Cochrane, and Embase 
databases using the keywords “Breast” and “Reconstruction” and “Mesh” and 
“Synthetic” which rendered 80, 3, and 107 articles, respectively. No date limits 
were set.
Papers written in English reporting on the complications and/or outcome of 
IBBR in women aged 18 years or over, either with expander or implants, as a single- 
or two-stage procedure, either immediate or delayed, both in submuscular and in 
prepectoral position in which synthetic meshes had been used, were selected for 
inclusion. Authors screened these articles discarding duplicates, those reporting less 
than 10 cases, and those unrelated to the subject, leaving a total of 49 papers. The 
reference list of the retrieved studies was searched manually looking for potentially 
relevant reports.
3. Synthetic meshes
Usually, the term “matrices” are used for biological materials and the term 
“meshes” for synthetic materials. There are numerous studies explaining the pros 
and cons of the matrices, but minimal data are available regarding the synthetic 
meshes.
Biological meshes or matrices are flexible sheets of tissue that have been stripped 
of their antigenic cells through a specialised procedure, resulting in decellularisa-
tion but leaving the extracellular matrix intact. They provide a scaffold of tissue 
that the patient’s own cells can repopulate and revascularise.
The acellular dermal matrix (ADM), introduced in 1994 [11], is a plate of 
dermis produced from cadaveric human (Alloderm, Allured, Allomax, Flex HD, 
Dermacell, Dermamatrix, NeoForm), porcine (Strattice, Permacol, Protexa, 
XenMartix, XCM), or bovine (SurgiMend) dermis. Other biological meshes 
come from bovine pericardium (Veritas, Tutopatch, Periguard, Esaflex), porcine 
peritoneum (Meso Biomatrix), bovine intestine (Surgisis), or fish skin (Kerecis 
Omega 3 Pectus) [3]. Their utility has been demonstrated in various reconstructive 
techniques, particularly in burn, abdominal wall repair, and breast reconstruction 
[11–13].
With the introduction of these meshes, the indications for IBBR became 
extended, since they provided surgeons with alternative means of obtaining suffi-
cient vascularized soft tissue to cover the implant. Breuing first reported the use of 
human acellular dermis in IBBR in 2005 [14]. Increased filling volumes of expand-
ers and improved aesthetic outcomes have been reported since then by several 
authors [4, 15–17]. As new data become available, the use of biological meshes in 
IBBR will evolve in the following years.
Synthetic meshes are flexible sheets made of plastic-like material that may play 
a similar role to biological ones in breast reconstruction, becoming an alternative 
with low cost. The tensile strength of most of these materials is enough to support 
the physiological demand, although an excessive strength increases inflammation 
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and decreases elasticity. The size of their pores directly impacts on the incorpora-
tion of the mesh into the surrounding tissues. Small pores generate a strong inflam-
matory response that can reduce tissue ingrowth; larger pores allow more ingrowth, 
preserving elasticity, but promoting more fibrous tissue. Moreover, the mesh can be 
constructed by knitting or weaving the material. Knitted meshes are generally more 
porous and flexible than woven meshes that, because of the increased fibre density, 
are generally stronger and are a poor skeleton for fibrous ingrowth [18].
Besides that, these meshes may be absorbable or non-absorbable. The former are 
made of polyglycolic acid (Dexon), polyglactin (Vicryl)—both of them are resorbed 
within a few months—a copolymer of glycolide, lactide and trimethylene carbonate 
(TIGR Matrix), silk protein (SERI Surgical Scaffold), or a poly-4-hydroxybutyrate 
polymer (Galatea Scaffold) which is long-term resorbable. Non-absorbable meshes 
are composed of polypropylene (PP), polyester, (Mersilene), or expanded polytet-
rafluoroethylene, though just the first material has been used in breast reconstruc-
tion (TiLOOP Bra, ULTRAPRO, SERAGYN BR).
3.1 Vicryl
Vicryl mesh is comprised of polyglactin 910 and is a cheap, ready-to-use, 
and widely available mesh. It causes minimal inflammatory reaction and is non-
allergenic and resistant to bacteria biofilm formation. However, because of its rapid 
resorption, it does not provide a long-lasting tissue reinforcing advantage.
3.2 TiLOOP
This mesh is made of non-resorbable, titanised, lightweight PP with a mono-
filament structure and was initially invented for hernia repair, showing a good 
biocompatibility. Production involves introducing titanium in gaseous form so 
that it reaches all parts of the mesh, forming covalent bonds with the plastic 
surface. Cellular reactions like proliferation and apoptosis were at the lowest level 
when using this material compared to not titanium-coated mesh (pure PP), pure 
lightweight PP mesh, or PP mesh incorporating resorbable polyglactic acid, thus 
reducing the inflammatory reaction and causing significantly less shrinkage [10]. 
Clinical studies show that 2 1/2 months after their use, the mesh fibres have been 
well embedded in the surrounding tissue.
TiLOOP® Bra is intended for extension of the pectoralis major, in the case of 
subpectoral, implant-based (permanent implant or expander) breast reconstruc-
tion. It covers and fixes the caudal pole of the breast implant (Figure 1). TiLOOP 
Bra Pocket is designed to cover a prepectoral implant, providing tissue supporting 
and preventing displacement.
3.3 SERAGYN BR
The SERAGYN BR mesh is a tightly woven, partially resorbable mesh made 
of polyglycolic acid-caprolactone and PP. The resorbable part is absorbed within 
90–120 days while the non-resorbable part remains in place for additional support. 
Its biocompatibility is similar to that of the TiLOOP Bra, although surgeons have 
reported more difficult intraoperative handling due to its firmer characteristics [10].
3.4 ULTRAPRO mesh
ULTRAPRO is manufactured from approximately equal parts of absorbable 
poliglecaprone-25 monofilament fibre and non-absorbable PP monofilament fibre. 
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although the decision to add some mesh to an alloplastic reconstruction is contro-
versial. However, there is no high-quality evidence comparing clinical and patient-
reported outcomes with mesh-assisted IBBR and traditional IBBR [9]. Finally, the 
decision for using mesh or not and a particular type of matrix or mesh depends 
predominately on the surgeons’ experience [3, 10].
2. Methods
A literature search has been performed in PubMed, Cochrane, and Embase 
databases using the keywords “Breast” and “Reconstruction” and “Mesh” and 
“Synthetic” which rendered 80, 3, and 107 articles, respectively. No date limits 
were set.
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IBBR in women aged 18 years or over, either with expander or implants, as a single- 
or two-stage procedure, either immediate or delayed, both in submuscular and in 
prepectoral position in which synthetic meshes had been used, were selected for 
inclusion. Authors screened these articles discarding duplicates, those reporting less 
than 10 cases, and those unrelated to the subject, leaving a total of 49 papers. The 
reference list of the retrieved studies was searched manually looking for potentially 
relevant reports.
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dermis produced from cadaveric human (Alloderm, Allured, Allomax, Flex HD, 
Dermacell, Dermamatrix, NeoForm), porcine (Strattice, Permacol, Protexa, 
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With the introduction of these meshes, the indications for IBBR became 
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cient vascularized soft tissue to cover the implant. Breuing first reported the use of 
human acellular dermis in IBBR in 2005 [14]. Increased filling volumes of expand-
ers and improved aesthetic outcomes have been reported since then by several 
authors [4, 15–17]. As new data become available, the use of biological meshes in 
IBBR will evolve in the following years.
Synthetic meshes are flexible sheets made of plastic-like material that may play 
a similar role to biological ones in breast reconstruction, becoming an alternative 
with low cost. The tensile strength of most of these materials is enough to support 
the physiological demand, although an excessive strength increases inflammation 
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are generally stronger and are a poor skeleton for fibrous ingrowth [18].
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made of polyglycolic acid (Dexon), polyglactin (Vicryl)—both of them are resorbed 
within a few months—a copolymer of glycolide, lactide and trimethylene carbonate 
(TIGR Matrix), silk protein (SERI Surgical Scaffold), or a poly-4-hydroxybutyrate 
polymer (Galatea Scaffold) which is long-term resorbable. Non-absorbable meshes 
are composed of polypropylene (PP), polyester, (Mersilene), or expanded polytet-
rafluoroethylene, though just the first material has been used in breast reconstruc-
tion (TiLOOP Bra, ULTRAPRO, SERAGYN BR).
3.1 Vicryl
Vicryl mesh is comprised of polyglactin 910 and is a cheap, ready-to-use, 
and widely available mesh. It causes minimal inflammatory reaction and is non-
allergenic and resistant to bacteria biofilm formation. However, because of its rapid 
resorption, it does not provide a long-lasting tissue reinforcing advantage.
3.2 TiLOOP
This mesh is made of non-resorbable, titanised, lightweight PP with a mono-
filament structure and was initially invented for hernia repair, showing a good 
biocompatibility. Production involves introducing titanium in gaseous form so 
that it reaches all parts of the mesh, forming covalent bonds with the plastic 
surface. Cellular reactions like proliferation and apoptosis were at the lowest level 
when using this material compared to not titanium-coated mesh (pure PP), pure 
lightweight PP mesh, or PP mesh incorporating resorbable polyglactic acid, thus 
reducing the inflammatory reaction and causing significantly less shrinkage [10]. 
Clinical studies show that 2 1/2 months after their use, the mesh fibres have been 
well embedded in the surrounding tissue.
TiLOOP® Bra is intended for extension of the pectoralis major, in the case of 
subpectoral, implant-based (permanent implant or expander) breast reconstruc-
tion. It covers and fixes the caudal pole of the breast implant (Figure 1). TiLOOP 
Bra Pocket is designed to cover a prepectoral implant, providing tissue supporting 
and preventing displacement.
3.3 SERAGYN BR
The SERAGYN BR mesh is a tightly woven, partially resorbable mesh made 
of polyglycolic acid-caprolactone and PP. The resorbable part is absorbed within 
90–120 days while the non-resorbable part remains in place for additional support. 
Its biocompatibility is similar to that of the TiLOOP Bra, although surgeons have 
reported more difficult intraoperative handling due to its firmer characteristics [10].
3.4 ULTRAPRO mesh
ULTRAPRO is manufactured from approximately equal parts of absorbable 
poliglecaprone-25 monofilament fibre and non-absorbable PP monofilament fibre. 
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The absorbable poliglecaprone part of the mesh helps keep the PP structure rigid, 
thus making intraoperative manipulation and positioning of the mesh easier. The 
poliglecaprone-25 copolymer is essentially absorbed at 84 days after implantation, 
remaining only the PP component. Due to the wide pore construction of the mesh, 
a strong, three-dimensional collagen fibre network is formed [19].
3.5 SERI surgical scaffold
This bioengineered mesh is derived from silk purified to result in ultrapure 
fibroin (one of the two proteins of the silk). It is a knitted, multifilament, macropo-
rous, and long-term bioresorbable mesh (more than 24 months) intended to resorb 
slowly, while neovascularization and tissue ingrowth occur. Accordingly, it behaves 
more like an ADM mesh since it is not just absorbed but accompanied by new tissue 
generation so that its strength is transferred to the newly ingrown tissue [20].
3.6 TIGR matrix
TIGR Matrix is a long-term resorbable synthetic mesh. The fast-resorbing fibre 
is a copolymer of lactide, glycolide, and trimethylene carbonate, while the slow-
resorbing part is a copolymer of lactide and trimethylene carbonate, completely 
absorbed after 3 years. Despite its description “matrix” (a term generally used to 
refer to biological products), the mesh is manufactured synthetically. After implan-
tation, the synthetic fibres degrade at different rates by bulk hydrolysis. It provides 
additional support in the first 6 months, and complete resorption is achieved after 
3 years. In vivo investigations revealed good biocompatibility with the formation 
of blood vessels and well-structured collagen fibres. The largest series using these 
meshes is reported by Becker and Lind [21].
3.7 Galatea scaffold
This mesh is made of a poly-4-hydroxybutyrate (P4HB) polymer, which 
degrades primarily by bulk hydrolysis into a natural metabolite (4HP) that is rapidly 
metabolised via the Krebs cycle and eliminated as carbon dioxide and water. The 
mesh is a knitted macroporous scaffold intended to elevate, reinforce, and repair 
soft tissue. It acts as a lattice for new tissue growth, which is rapidly vascularised 
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of its strength at 16 weeks in vivo and provides a gradual transfer of strength to host 
tissue over the course of 52 weeks. It is essentially fully resorbed by 18–24 months, 
allowing the formation of mature strong healthy collagen to support the repair. Its 
use in breast surgery has recently been described [22].
4. Surgical technique
Primary candidates for mesh reconstruction are patients suited for heterolo-
gous breast reconstruction with a small, mid-sized breast and moderate ptosis. 
Preoperative planning is necessary. Markings must be performed on the day with 
the patients in an upright position and including the middle and parasternal lines, 
inframammary folds, and the incision site [23]. There are some possibilities con-
cerning the type of incision technique; in most of the cases, surgeons chose infra-
mammary fold, inverted T, or periareolar.
Prosthetic submuscular IBBR is the most frequent type of reconstruction 
technique performed nowadays. Placing the implant under the muscular plane 
traditionally had less major complications than the subcutaneous technique, not-
withstanding its burden of pain, limited expansion, implant dislocation, and breast 
animation. However, adding a mesh to the prepectoral prosthesis allows a complete 
implant envelope, confers an extra cover, acts as an internal “bra” to relieve pres-
sure on the skin, and defines the implant pocket, preventing lateral displacement. 
The acceptable complication rate reported in the published studies using this 
procedure, although with short-term follow-up, has revived this technique [7] 
(Figure 2).
In the submuscular IBBR, after completion of the mastectomy flaps, the 
inferomedial pectoralis major muscle is elevated for implant placement, serving as 
a cover towards the maximal thinned out mastectomy flap. Usually, this coverage 
can often be achieved only for the upper and lower medial quadrant, which can 
lead to increased implant palpability, with a lack of support and subsequent skin 
erosion. Although additional coverage can be obtained by mobilising the serratus or 
the anterior layer of the rectus muscle, this approach involves even more trauma to 
native tissue and may not be technically possible, particularly in thin patients.
The mesh is fixed to the inferior border of the released pectoral major muscle 
using running or interrupted resorbable sutures. After placing the implant under 
the muscle, the mesh is spread over the implant and fixed to the inframammary 
fold either by single sutures or by wrapping around the implant to gain control of 
the lower pole [3, 24]. Otherwise, sutures may be given in the opposite order. Mesh 
Figure 2. 
Recommended implantation procedure in prepectoral reconstruction.
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of its strength at 16 weeks in vivo and provides a gradual transfer of strength to host 
tissue over the course of 52 weeks. It is essentially fully resorbed by 18–24 months, 
allowing the formation of mature strong healthy collagen to support the repair. Its 
use in breast surgery has recently been described [22].
4. Surgical technique
Primary candidates for mesh reconstruction are patients suited for heterolo-
gous breast reconstruction with a small, mid-sized breast and moderate ptosis. 
Preoperative planning is necessary. Markings must be performed on the day with 
the patients in an upright position and including the middle and parasternal lines, 
inframammary folds, and the incision site [23]. There are some possibilities con-
cerning the type of incision technique; in most of the cases, surgeons chose infra-
mammary fold, inverted T, or periareolar.
Prosthetic submuscular IBBR is the most frequent type of reconstruction 
technique performed nowadays. Placing the implant under the muscular plane 
traditionally had less major complications than the subcutaneous technique, not-
withstanding its burden of pain, limited expansion, implant dislocation, and breast 
animation. However, adding a mesh to the prepectoral prosthesis allows a complete 
implant envelope, confers an extra cover, acts as an internal “bra” to relieve pres-
sure on the skin, and defines the implant pocket, preventing lateral displacement. 
The acceptable complication rate reported in the published studies using this 
procedure, although with short-term follow-up, has revived this technique [7] 
(Figure 2).
In the submuscular IBBR, after completion of the mastectomy flaps, the 
inferomedial pectoralis major muscle is elevated for implant placement, serving as 
a cover towards the maximal thinned out mastectomy flap. Usually, this coverage 
can often be achieved only for the upper and lower medial quadrant, which can 
lead to increased implant palpability, with a lack of support and subsequent skin 
erosion. Although additional coverage can be obtained by mobilising the serratus or 
the anterior layer of the rectus muscle, this approach involves even more trauma to 
native tissue and may not be technically possible, particularly in thin patients.
The mesh is fixed to the inferior border of the released pectoral major muscle 
using running or interrupted resorbable sutures. After placing the implant under 
the muscle, the mesh is spread over the implant and fixed to the inframammary 
fold either by single sutures or by wrapping around the implant to gain control of 
the lower pole [3, 24]. Otherwise, sutures may be given in the opposite order. Mesh 
Figure 2. 
Recommended implantation procedure in prepectoral reconstruction.
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allows to create a more spacious pocket with a natural inframammary fold, bridging 
the gap between the muscle and chest wall fascia [3, 7] and protecting the pectoralis 
major from cranial movement.
In the prepectoral IBBR, the mesh or matrix is folded onto itself to create a 
pocket for the implant or the expander (filled with its final expansion volume and 
then deflated), and this pocket is sutured to the pectoral major fascia with at least 
three stitches, apical, medial, and lateral [25]. Advantages of this approach include 
less tissue dissection, less postoperative pain, better filling of the medial breast, 
avoidance of lateral fallout, and absence of hyperanimation deformity. This tech-
nique is frequently used in combination with new technologies such as autologous 
fat grafting and perfusion analysis of the skin flaps.
5. Complications
Mesh use in breast reconstruction is associated with many complications. 
Infection, seroma, hematoma, capsular contracture, skin flap necrosis, explantation 
or implant loss are the most commonly reported. Of course, some characteristics of 
patients are associated with increased complication rates, with or without use of a 
mesh. These include age (older than 65 years), large breasts (more than 600 g), obe-
sity (BMI greater than 30), smoking, diabetes, hypertension, long drain removal 
time, previous radiotherapy to the ipsilateral breast, and receipt of neoadjuvant 
chemotherapy [1, 2].
Infection is one of the most common complications seen in both biological and 
synthetic mesh use, which often leads to tissue necrosis and may result in explanta-
tion, revision, or even complete loss of implant [1, 26]. Ellis et al. reported rates of 
infection shifting between 0.2 and 35.8%, the higher numbers seen after ADM use 
[1, 2]. A high-throughput assay comparing synthetic meshes (Prolene and Vicryl) 
and biological matrices (Alloderm and Flex HD) as substrates for bacterial adhesion 
concluded that Staphylococcus aureus adhered more readily to ADMs than to meshes, 
therefore showing a greater potential propensity for biofilm development [27].
Seroma and haematoma are commonly occurring complications and can both 
lead to an increased risk of infection and tissue necrosis, particularly when large 
enough to require drain insertion. Haematoma formation is thought to occur in the 
immediate postoperative period as a result of trauma during surgery—although the 
use of electrocautery has significantly reduced its incidence—or as a late compli-
cation due to small tears in the capsule formed around the implant, often after 
physical trauma [1]. There seems to be different seroma formation rates between the 
two types of meshes. Matrices have smooth surfaces, allowing increased fluctuation 
between the matrix and the subcutaneous tissue and resulting in the development 
of seromas. Meshes have rougher surfaces and thus a potentially faster interaction 
with the subcutaneous tissue, lesser fluctuation, and a consequent decrease in 
seroma formation [10]. Rates are between 0 and 5.7% for meshes and between 1.5 
and 24.3 for ADM [1].
Capsular contracture is described as the formation of a fibrous capsule around 
the implant that thickens progressively and may contract, compressing the implant 
and resulting in a hard breast with deformed contouring of the surrounding skin. 
This may also cause severe pain due to nerve entrapment or muscle mobility inter-
ference. Although the aetiology is unclear, some believe that it is initiated by blood 
products like haematomas, while others consider infection and chronic inflam-
mation to be most likely the cause, either by bacteria colonisation from within the 
ductal breast tissue or from the skin [1, 28]. Studies have reported significantly 
lower rates of capsular contracture with the use of ADM than without it, but the 
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length of the follow-up is short [20]. Although no high-quality study has directly 
compared the incidence of capsular contracture between synthetic and biological 
matrices IBBR, rates are similar for both types (1.3–8.6% for meshes and 0.4–8.1% 
for matrices) [1, 3, 28, 29]. Dieterich et al. [30] reported a histological analysis with 
mild inflammation using TiLOOP, suggesting a low risk of capsular contracture.
Loss of vascular supply to the overlying mastectomy skin flap is the reason 
of skin necrosis after ischaemic changes. This is a multifactorial event: patient 
comorbidities, thin mastectomy skin flaps, or over expansion may contribute [1]. 
Regarding the surgical technique, rates of skin necrosis up to 30% have been associ-
ated with the use of inverted T-incision, especially at the T-junction [24].
Rates of 1.8–4.3% for meshes and 1.4–24.3% for matrices have been published [1].
All of the above complications, if severe enough, may lead to implant explan-
tation, often resulting in complete implant loss. Most of the studies showed 
comparable rates of implantation loss using matrices or synthetic meshes 
(between 0 and 8.7%), although some reports explantation rates as high as 
33.3% for ADM [1, 29].
6. Discussion
Reconstructive breast techniques with expander or implant without biologic or 
synthetic meshes can have disadvantages. In the short run, they may present with a 
thin or insufficient coverage of the implant, a risky stress of the inferior pole along 
with a decreased skin perfusion with a too early or too extensive expansion, and a 
herniation and sequential skin erosion towards the lateral border of the pectoralis 
major muscle or the inferior pole. In the medium and long term, a high-riding 
implant due to muscle stiffness, a restricted expansion of the inferior pole, or a 
loss of definition of the inframammary fold may appear. By using these meshes to 
support and cover these weak points, these disadvantages can be diminished or even 
resolved [30].
Benefits of their use include improved coverage over the device, lengthening and 
support of the pectoralis muscle, support for the lower pole, more rapid expansion, 
improved definition of the breast boundaries and folds, and possible modifica-
tion of capsule formation. Disadvantages include added risk of infection, seroma 
formation, risk of flap necrosis and implant exposure, added surgical time, and 
increased cost [31, 32]. These complications may be higher than traditional implant 
reconstruction, and there is no yet evidence on long-term outcomes of these mesh 
procedures, including the need for further surgery over time [33].
Although the choice of using a mesh or a matrix is controversial and depends 
basically on individual surgeon preference, there are indications where matrices 
may be advisable, such as in revisional breast surgery or after irradiation, since 
reported data suggest a better blood flow to the irradiated skin and, for some 
author, a decreased rate of capsular contracture compared with meshes [24]. 
Published guidelines, though largely based on poor-quality evidence and expert 
opinion, offer sensible advice regarding current best practice. The American Society 
of Plastic Surgeons recommends using mesh on a per patient basis. The United 
Kingdom professional associations (Association of Breast Surgery and the British 
Association of Plastic, Reconstructive, and Aesthetic Surgeons) advocate careful 
patient selection and employing mesh-assisted IBBR with caution in high-risk 
groups (current smokers, previous breast radiotherapy, high BMI) [21, 34]. A joint 
consensus guide on prepectoral IBBR from European and US surgeons has been 
recently published [35]. After a systematic review, Cabalag et al. offer a summary of 
recommendations for ADM use [36].
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immediate postoperative period as a result of trauma during surgery—although the 
use of electrocautery has significantly reduced its incidence—or as a late compli-
cation due to small tears in the capsule formed around the implant, often after 
physical trauma [1]. There seems to be different seroma formation rates between the 
two types of meshes. Matrices have smooth surfaces, allowing increased fluctuation 
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of seromas. Meshes have rougher surfaces and thus a potentially faster interaction 
with the subcutaneous tissue, lesser fluctuation, and a consequent decrease in 
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and 24.3 for ADM [1].
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the implant that thickens progressively and may contract, compressing the implant 
and resulting in a hard breast with deformed contouring of the surrounding skin. 
This may also cause severe pain due to nerve entrapment or muscle mobility inter-
ference. Although the aetiology is unclear, some believe that it is initiated by blood 
products like haematomas, while others consider infection and chronic inflam-
mation to be most likely the cause, either by bacteria colonisation from within the 
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length of the follow-up is short [20]. Although no high-quality study has directly 
compared the incidence of capsular contracture between synthetic and biological 
matrices IBBR, rates are similar for both types (1.3–8.6% for meshes and 0.4–8.1% 
for matrices) [1, 3, 28, 29]. Dieterich et al. [30] reported a histological analysis with 
mild inflammation using TiLOOP, suggesting a low risk of capsular contracture.
Loss of vascular supply to the overlying mastectomy skin flap is the reason 
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Regarding the surgical technique, rates of skin necrosis up to 30% have been associ-
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Rates of 1.8–4.3% for meshes and 1.4–24.3% for matrices have been published [1].
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tation, often resulting in complete implant loss. Most of the studies showed 
comparable rates of implantation loss using matrices or synthetic meshes 
(between 0 and 8.7%), although some reports explantation rates as high as 
33.3% for ADM [1, 29].
6. Discussion
Reconstructive breast techniques with expander or implant without biologic or 
synthetic meshes can have disadvantages. In the short run, they may present with a 
thin or insufficient coverage of the implant, a risky stress of the inferior pole along 
with a decreased skin perfusion with a too early or too extensive expansion, and a 
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Benefits of their use include improved coverage over the device, lengthening and 
support of the pectoralis muscle, support for the lower pole, more rapid expansion, 
improved definition of the breast boundaries and folds, and possible modifica-
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basically on individual surgeon preference, there are indications where matrices 
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Published guidelines, though largely based on poor-quality evidence and expert 
opinion, offer sensible advice regarding current best practice. The American Society 
of Plastic Surgeons recommends using mesh on a per patient basis. The United 
Kingdom professional associations (Association of Breast Surgery and the British 
Association of Plastic, Reconstructive, and Aesthetic Surgeons) advocate careful 
patient selection and employing mesh-assisted IBBR with caution in high-risk 
groups (current smokers, previous breast radiotherapy, high BMI) [21, 34]. A joint 
consensus guide on prepectoral IBBR from European and US surgeons has been 
recently published [35]. After a systematic review, Cabalag et al. offer a summary of 
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noted a higher rate of infection with mesh-assisted IBBR than traditional IBBR, but 
the quality of evidence is low [37]. Improved cosmetic results have been advocated 
for the use of matrices, although the outcomes of the reported studies are of limited 
value [20, 29]. Sigalove et al. found less than 5% of aesthetic complications (capsu-
lar contracture, implant malposition, and rippling) after prepectoral reconstruction 
with ADM. Their complication rate was 9.1%: 4.5% infections, 2.0% seromas, and 
2.5% necrosis [38]. Obtaining data from 14,249 patients, Pannucci et al. reported 
a significant increased risk of 0.7% (1.85 vs. 2.58%) expander/implant loss when 
ADM was used [39].
Salibian et al. showed 85.2% of patients as having very good or good results 
with prepectoral expander/implant without any additional material (together with 
infection in 2.4%, necrosis in 6.8%, capsular contracture Baker grade III or IV in 
7.6%, and rippling in 3.6% of the patients) [40].
In a small pilot randomised controlled trial comparing biological and synthetic 
meshes, Gschwantler-Kaulich et al. [24] found no statistically significant differ-
ences in cosmetic outcome and overall complications between the groups, but 
patients in the ADM group experienced substantially higher rates of implant loss 
than those undergoing IBBR with synthetic mesh (although the first group was 
more exposed to radiotherapy). Nevertheless, this study is insufficiently designed 
to look at the target difference between the treatment groups and is of very low-
quality evidence.
A recent cohort study reported no differences in satisfaction and quality of life 
between the use of matrix (Surgisis) or mesh (TIGR) in IBBR [41]. Reitsemer et al. 
reported low complication rates after 200 prepectoral reconstructions with the use 
of ADM or TIGR mesh, but with no comparison between both [42]. A systematic 
review comparing subcutaneous IBBR using ADM or meshes (without any infor-
mation about the types of meshes) concluded that short-term complication rates 
are low and similar but refers that statistical analysis was not possible given dif-
fering study designs, confounding variables, and lack of comparative data in each 
study [43].
In a retrospective cohort study comparing the benefits of mesh (TiLOOP) 
versus non-mesh reconstructions, there was no statistical significance either in 
complications or in patient-reported outcomes [3]. In a large retrospective mul-
ticenter study of 231 procedures using synthetic mesh (TiLOOP Bra), Dieterich 
revealed major complications (those needing additional surgery) occurring in 
13.4%, minor complications (requiring just conservative measures) in 15.6%, and 
implant loss in 8.7% of patients. The overall infection rate was 6.1% of which only 
1.7% needed revision, and the seroma rate was 4.8%. In this chapter, risk factors 
for postoperative complications included a bilateral procedure or a previous skin 
expansion. The authors concluded that these were acceptable complication rates, 
that the mesh should only be used in primary cases, and that, when adhering to the 
proposed indications, it was a safe and convenient option in implant-based breast 
reconstruction [26].
Low complication rates (6.6%, including implant loss of 1.3%) and good aes-
thetic results have also been reported by Tessler et al. with the use of Vicryl meshes, 
which add to their economic advantage over matrices, but again with insufficient 
power to obtain clear-cut conclusions [44].
Hallberg et al. noticed complications in 23% of the patients with IBBR using 
TIGR Matrix, including two implant losses. Reported risk factors were age over 
51 years, BMI over 24.5 kg/m2, large resection weight, and a Wise pattern excision 
of the skin [45]. A similar rate of complications with the same material was stated 
by Pompei et al., with 11.6% of the patients requiring revisional surgery but with 
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removal of the mesh only in 3.3% of them. These authors found that this mesh 
caused low seroma (3.6%) and infection rates (1.6%) when compared with other 
nonreabsorbable or semiresorbable synthetic meshes, but also this study has a low 
quality of evidence [46]. A recent abstract reports on 34 patients reconstructed 
with TIGR Matrix encountered 9% cases with infections, 9% with necrosis, 5.9% 
with seromas, and 3% with reoperations [47]. Schrenk et al. found just one case of 
seroma and another of skin necrosis, needing reoperation, after 37 IBBR with the 
same mesh [48]. Irwin et al. had 11 implant losses out of 94 cases with the same 
material [49].
In a prospective study with 187 patients treated with prepectoral expander and 
TiLOOP Bra mesh and with a mean follow-up of 36.5 months, Casella et al. found 
complications requiring a second operation in 6.7% of the cases, with implant loss 
in half of them. Capsular contracture, implant malposition, and, above all, rippling 
appeared in 16.4%. Patients scored a high level of satisfaction [50].
In a study comparing reconstruction with a prepectoral titanium mesh wrap to 
subpectoral titanium sling, there was only one implant failure in the prepectoral 
cohort. There were no significant differences between the two groups with any 
complication, including infection, implant loss, skin necrosis, hematoma, or 
reoperation at 1-year follow-up [51]. Two-year follow-up demonstrated no capsular 
contracture in the prepectoral cohort and 12% in the partial subpectoral cohort 
[52]. Other paper by Casella et al. on 250 cases of prepectoral implant immedi-
ate reconstruction and TiLOOP recounts complications in 2.4% of the cases, but 
aesthetic complications are brought to reoperations in 19.5% of the breasts [53].
A reported side effect of titanium-coated permanent mesh in IBBR is the for-
mation of granulomas in the inframammary fold, probably in the area where the 
mesh had been folded or fixed, mimicking a local recurrence [54]. Other papers 
state good cosmetic results and/or a low rate of complications with the use of this 
mesh [3, 55, 56].
A retrospective analysis of 320 cases comparing TiLOOP Bra mesh with 
SERAGYN mesh reported no differences in complication rates (and no differences 
in performance when compared to ADM) [58, 59]. A similar report about 131 
patients with SERAGYN showed a rate of complication comparable to the use of 
other meshes or matrices (seroma in 25.7%, reconstructive failure in 11.5%, wound 
healing issues in 13.5%, wound infections in 10.8%), without severe complications 
in 83.8% of operations [60]. Other retrospective study with 102 patients and 174 
IBBR using ULTRAPRO, which included 45.1% patients with previous radiotherapy 
and pre-existing scars, recorded complications in 18.3%, (6.9% minor and 11.4% 
major, requiring revision) [19]. A similar report with 70 cases of reconstructed 
breast using SURGIMESH found no statistical significances in outcomes compared 
with standard IBBR without meshes [61]. Another paper about the use of polyester 
mesh (Mersilene) in 73 patients reported an explantation rate of 4.1%, although 
the surgical technique included an abdominal advancement flap [62]. One abstract 
reported similar results with polyester mesh, titanium mesh, and ADM in 104 
cases, with excellent results in 67.3% of them [63].
The best report till the date is a prospective, multicentre cohort study in the 
United Kingdom, where 2108 patients were recruited to establish the short-term 
safety of immediate IBBR performed with and without mesh, either biological or 
synthetic, in prepectoral or submuscular pockets. After 3 months of surgery, 9% of 
the patients suffered implant loss, 18% required readmission, 18% needed a second 
surgery because of the complications, and 25% had treatment for an infection, 
with no differences regarding mesh use or type [2]. This analysis also identified 
an association between infection and previous radiotherapy. Ages, neoadjuvant 
chemotherapy, bilateral surgery, indication for surgery, nipple-sparing procedure, 
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fixed-volume implant, and type of reconstruction were not significant risk factors. 
A summary of all these data is shown in Table 1. A number of studies are currently 
underway in Europe [64].
It is well known that radiotherapy has a significantly detrimental effect on 
most breast reconstruction outcomes, whether given pre- or postoperatively (but 
without differences in complication rates between both) [65], since it impedes 
neovascularisation and mesh incorporation into the host [1]. Most published studies 
identify radiotherapy as adversely affecting the cosmetic outcome by precipitat-
ing the inflammatory reaction of the implant to the surrounding tissues. Becker 
described frequent complications in patients that received radiotherapy and were 
reconstructed with TIGR mesh [21]. Similar results were reported by Dieterich 
et al. using TiLOOP mesh [26] and by others using ADM [1, 4, 66–68]. On the other 
hand, some protective effects of matrices against radiotherapy, compared with 
those patients without them, have been reported, since biological meshes appear to 
limit the elastosis and chronic inflammation seen in irradiated IBBR [69, 70].
To sum up, the literature on this subject is difficult to interpret because there 
is neither high-quality evidence comparing outcomes of mesh-assisted IBBR with 
traditional IBBR or comparing matrices with meshes. Most studies in this area are 
small, single-centre, retrospective cohort studies and case series with methodologi-
cal limitations: different surgical techniques, with different meshes and matrices, 
differing in sizes and positions, with very disparate ways of reporting complications 
(in fact, it is often unclear what complications have been included and how they 
have been diagnosed and how and when capsular contracture and aesthetic out-
come have been evaluated), thus carrying a low level of evidence [37]. Randomised 
clinical trials with sufficient periods of follow-up should be carried out to determine 
whether the cost of these products is justified in terms of the benefits provided [71].
7. Conclusions
Although it is still unclear whether mesh procedures are a safe alternative to 
traditional IBBR regarding patient-reported outcomes, matrices and meshes have 
proven to wear valuable advantages. Moreover, there is not even a consensus on 
which of the two types produces the best outcomes, although there is a trend to 
consider that meshes bring comparable aesthetic outcomes to matrices, with lower 
costs and complication rates. Regarding the uncertainty about the best position for 
the implant, either submuscular or subcutaneous, the prepectoral position is gain-
ing ground quickly among surgeons and patients.
Most of the literature have focused on the complication and safety profiles of 
these meshes, but, given that the purpose of breast reconstruction is to improve 
body image and psychosocial function, it is equally important that cosmesis 
and patient satisfaction are also included when evaluating the results of these 
techniques.
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L-Shaped Nipple Reconstruction: 




Nipple reconstruction is the final stage of breast reconstruction and performed 
after acceptable breast mound shape and symmetry has been achieved. The objectives 
of this study are to describe an original technique of nipple reconstruction, using 
a combination of random flap (for new nipple) and dermal graft (for new areola), 
and also measure patient satisfaction outcomes. Thirty-one patients underwent the 
L-shaped nipple reconstruction (2011-2016) at Liverpool Breast Unit and completed 
satisfaction survey of this technique. This cohort was compared to 59 patients who 
underwent traditional CV flap during the same period, in our Breast Unit. The  
study analysed the combined data of 90 patients (L flap N = 31 and CV flap N = 59). 
“L”-shaped flap is a random local skin flap to create new nipple and dermal graft 
is used to create new areola. There was no statistically significant difference in 
 complication rates between traditional CV flap (9.7%) and L-shaped (13.6%) nipple 
reconstructions (Fishers exact test p = 0.74). In our L flap cohort, 94% were pleased 
and 93% would recommend it to a friend. Thus L flap is a viable alternative to CV flap 
in suitable patients and has positive patient satisfaction outcomes.
Keywords: L flap, nipple reconstruction, novel technique, patient satisfaction, 
areolar graft
1. Introduction
Reconstruction of nipple-areolar complex has been shown to have a positive 
influence on the overall recovery process of women undergoing post mastectomy 
breast reconstruction and hence helps to restore body image more completely. This 
clearly underscores the well-known concept that, part of the reconstruction of an 
aesthetically pleasing breast, is a high-quality nipple-areolar reconstruction [1].
Over the last 30 years, many different techniques have been described to accom-
plish this task. The goals for this nipple-areola reconstruction include appropriate 
nipple projection, areolar colour, and areolar texture. A number of reconstructive 
techniques have been described for nipple reconstruction including skin grafts, 
composite grafts, and various local flaps. Numerous techniques, using a variety of 
geometric designs, have been reported and reviewed [2–9]. Each of these techniques 
aims to achieve a natural shape with maintenance of projection over time, and 
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1. Introduction
Reconstruction of nipple-areolar complex has been shown to have a positive 
influence on the overall recovery process of women undergoing post mastectomy 
breast reconstruction and hence helps to restore body image more completely. This 
clearly underscores the well-known concept that, part of the reconstruction of an 
aesthetically pleasing breast, is a high-quality nipple-areolar reconstruction [1].
Over the last 30 years, many different techniques have been described to accom-
plish this task. The goals for this nipple-areola reconstruction include appropriate 
nipple projection, areolar colour, and areolar texture. A number of reconstructive 
techniques have been described for nipple reconstruction including skin grafts, 
composite grafts, and various local flaps. Numerous techniques, using a variety of 
geometric designs, have been reported and reviewed [2–9]. Each of these techniques 
aims to achieve a natural shape with maintenance of projection over time, and 
minimal donor site morbidity. The most popular techniques benefit from simplicity, 
reliability and reproducibility.
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Presented in this article is an original and novel technique, L shaped nipple 
reconstruction; which achieves these goals by providing an alternative to traditional 
techniques such as CV flap [9]. This has proven to be a suitable alternative option 
when previous mastectomy scars preclude optimum nipple positioning.
In this chapter, we share our institution’s experience with the L flap nipple 
areolar reconstruction. Here, an earnest attempt is made to describe the indications 
for its use, flap design and surgical technique, and outcomes and complications 
associated with its use.
2. Patients and methods
Thirty-one patients underwent L shaped nipple reconstruction following breast 
reconstruction between 2011 and 2016, at Liverpool Breast Unit, Linda McCartney 
Centre. The study cohort were identified from prospectively collected data and ana-
lysed. All patients with transversely placed mastectomy scar, considered otherwise 
unsuitable for traditional CV flap reconstruction, were included in this study.
Once the patients were identified, their case notes were reviewed to record 
patient’s age, body mass index, and position of previous mastectomy scar, type 
of breast reconstruction, chemotherapy, medical history, and smoking history. 
Complications explored included haematoma, postoperative wound healing prob-
lems, nipple-areola complex necrosis (partial and complete), infection, discharge, 
pain, fat necrosis and hypertrophic scarring.
Of the 31 patients, 17 patients (55%) had implant based reconstruction and 
12 patients (39%) had latissimus dorsi (LD) with implant reconstruction and 2 
patients (6%) had LD flap autologous breast shape reconstruction.
The timing of L flap reconstruction ranged from 6 months to 2 years after their 
initial cancer surgery or breast reconstruction, with an average time of 15 months.
Each patient was sent an outcome questionnaire, using validated Likert scoring 
scales (scale of 1–5), relating specifically to their nipple reconstruction. The ques-
tionnaire using Likert Scales was developed to evaluate overall patient satisfaction 
with cosmetic result, and addressed key issues, such as perceived match to contra-
lateral nipple, confidence in clothing and reported complications.
3. Surgical technique
L-flap nipple reconstruction is a random skin flap, containing dermal and 
adipose tissue. It has a pedicle with long and short arms which resemble the letter L 
and hence the terminology. The L-flap was used on all our patients with transverse 
mastectomy scars, which would otherwise preclude the use of traditional flap, such 
as CV flap (Figure 1).
The traditional CV flap marked in Figure 1, would produce unsatisfactory neo-
nipple position, i.e., above or below the mastectomy scar. Whereas, the alternate L 
shaped flap offers optimal neo-nipple position.
Preoperative marking was performed with patient standing to achieve ideal and 
closest natural nipple position. Marking with patient stood up would further ensure 
to centre the nipple symmetrically to the opposite side (natural or reconstructed 
nipple). The important markings included the patient’s breast meridian, infra-
mammary fold, and new nipple-areolar position (Figure 2).
The skin incision is made using no. 11 blade with depth of incision extending 
to pectoral fascia or onto subcutaneous tissue in event of autologous tissue breast 
shape reconstruction (Figure 3). The base of the L pedicle is measured to be equal 
to the nipple diameter to be created. The short arm lies opposite to the pedicle 
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(Figure 3). The long arm of the L flap is based on a laterally based random flap 
and is one and half to two times the diameter of the nipple. The marked long arm 
is raised and rotated through 180°, and sutured (Figure 4) with absorbable 4–0 
monocryl (poliglecaprone 25, Ethicon) sutures. The short arm is then sutured to the 
upper border of long arm to create the summit of the neo-nipple and hence fash-
ioned to create a projecting neo-nipple (Figure 4).
The area surrounding the reconstructed nipple site is de-epithelialised to match 
the areola on the native breast and this forms the first step in preparing the areolar 
base (Figure 5).
The next step involves harvesting and preparing the areolar graft from abdomen 
or from skin envelope of the opposite breast. The skin graft is then fashioned and 
placed over the raw surface to reconstruct the neo-areola (Figure 6), using absorb-
able 4–0 monocryl.
Figure 1. 
Transverse mastectomy scar with mark up of L flap and CV flap (depicted with arrows).
Figure 2. 
Pre-operative markings for L flap nipple and areola.
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The full thickness graft is fenestrated to facilitate drainage of serous collection 
or blood, which would ensure very low infection rates. The additional value of 
designing small openings in the graft is that it eventually generates the appearance 
of Montgomery tubercles over the neo-areola (Figure 7).
An interrupted 4–0 monocryl suture is used to secure the skin to the graft. Once 
the graft is secured, the entire neo-nipple/areolar complex is covered with Mepitel 
or Jelonet, covered with surgical gauze with a central button hole; all held together 
with clear Tegaderm hydrocolloid dressings. Tegaderm backing allows the patient 
to shower, easy to use and can be applied one-handed. The dressing is left intact for 
Figure 4. 




Details of raising the L flap.
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10 days until the outpatient clinic review, wherein all 31 patients were reviewed by 
the Surgeon.
Prophylactic antibiotics are administered, with Co-amoxiclav (500 mg/125 mg) 
being our antibiotic of choice. In patients with allergies to penicillin, we found 
macrolide antibiotics such as erythromycin or clarithromycin helpful.
4. Statistical analysis
The data of complications from concurrently performed traditional CV flap was 
compared with the novel L-flap technique.
The categorical data were summarised using frequencies, percentages, cross 
tabulation and bar chart and analysed by Fisher’s exact test. All statistics and 
analyses were produced using IBM SPSS version 20.
5. Results
A total of 31 patients met inclusion criteria (previous transverse mastectomy 
scar and not deemed suitable for CV flap nipple-areola reconstruction) and were 
evaluated. The mean age of patients identified was 44 years (range, 33–64 years) 
and the mean body mass index was 28 (range, 24–32). Patients displayed minimal 
medical co-morbidities, and there were no patients who were actively smoking at 
the time of surgery.
Figure 6. 
Full thickness skin graft to create neo-areola.
Figure 7. 
A per op view of neo-nipple and neo-areola with typical fenestrations.
Breast Cancer and Breast Reconstruction
164
The full thickness graft is fenestrated to facilitate drainage of serous collection 
or blood, which would ensure very low infection rates. The additional value of 
designing small openings in the graft is that it eventually generates the appearance 
of Montgomery tubercles over the neo-areola (Figure 7).
An interrupted 4–0 monocryl suture is used to secure the skin to the graft. Once 
the graft is secured, the entire neo-nipple/areolar complex is covered with Mepitel 
or Jelonet, covered with surgical gauze with a central button hole; all held together 
with clear Tegaderm hydrocolloid dressings. Tegaderm backing allows the patient 
to shower, easy to use and can be applied one-handed. The dressing is left intact for 
Figure 4. 




Details of raising the L flap.
165
L-Shaped Nipple Reconstruction: A Novel Technique to Improve Patient Satisfaction Outcomes
DOI: http://dx.doi.org/10.5772/intechopen.86068
10 days until the outpatient clinic review, wherein all 31 patients were reviewed by 
the Surgeon.
Prophylactic antibiotics are administered, with Co-amoxiclav (500 mg/125 mg) 
being our antibiotic of choice. In patients with allergies to penicillin, we found 
macrolide antibiotics such as erythromycin or clarithromycin helpful.
4. Statistical analysis
The data of complications from concurrently performed traditional CV flap was 
compared with the novel L-flap technique.
The categorical data were summarised using frequencies, percentages, cross 
tabulation and bar chart and analysed by Fisher’s exact test. All statistics and 
analyses were produced using IBM SPSS version 20.
5. Results
A total of 31 patients met inclusion criteria (previous transverse mastectomy 
scar and not deemed suitable for CV flap nipple-areola reconstruction) and were 
evaluated. The mean age of patients identified was 44 years (range, 33–64 years) 
and the mean body mass index was 28 (range, 24–32). Patients displayed minimal 
medical co-morbidities, and there were no patients who were actively smoking at 
the time of surgery.
Figure 6. 
Full thickness skin graft to create neo-areola.
Figure 7. 
A per op view of neo-nipple and neo-areola with typical fenestrations.
Breast Cancer and Breast Reconstruction
166
All patients had undergone total mastectomy and had well healed transversely 
placed chest wall scars. Twelve patients (38.7%) were treated with chemotherapy 
(Adriamycin with or without Paclitaxel) and none of the 31 patients underwent 
external beam irradiation.
Intra-operatively, all patients underwent L-shaped flap nipple reconstruction 
with areolar skin graft from abdomen or contralateral breast, with technique as 
described above.
As depicted in Table 1; the incidence of any complications, including infec-
tion, discharge, pain, bleeding, partial or total nipple loss; as compared with 
traditional CV flap were similar and no statistically significant difference (Fisher’s 
exact test).
Table 2 summarises the patients’ undergoing L flap showed good cosmetic 
outcomes in comparison with patients’ undergoing CV flap in the same breast Unit 
during the same period of time as the study cohort.
Table 3 shows that nipple projection in the study cohort of L flap compared 
favourably with patients’ undergoing traditional CV flap, over 6 and 24 months.
6. Discussion
Nipple reconstruction and patient satisfaction outcomes study seem to be an 
area of very limited research and hence lack of evidence based scientific literature. 
While nipple reconstruction is considered a minor procedure, its profound implica-
tions on patient satisfaction after post-mastectomy breast reconstruction have been 
clearly demonstrated [9, 10].




P-value (Fisher’s exact test)
Superficial nipple tip necrosis 3 (10%) 6 (10%) P = 1.0
Cellulitis 2 (6%) 3 (5%) P = 1.0
Pain 2 (6%) 5 (8%) P = 1.0
Bleeding/haematoma 1 (3%) 3 (5%) P = 1.0
Partial nipple loss 2 (6%) 2 (3%) P = 0.60
Surgical revision 2 (6%) 3 (5%) P = 1.0
Table 1. 






Overall cosmetic outcome—satisfied/very satisfied 90% (n = 28) 86% (n = 51) P = 0.74
Wearing daily clothes—confident/very confident 81% (n = 25) 69% (n = 41) P = 0.32
Wearing swim clothes—confident/very confident 77% (n = 24) 63% (n = 37) P = 0.24
Wearing night clothes—confident/very confident 71% (n = 22) 63% (n = 37) P = 0.49




PROMs (patient reported outcome measures) in each of the techniques.
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A vast majority of contributions related to nipple reconstruction merely focus 
on surgical techniques. Literature review has shown a major emphasis of articles 
has been on ways to prevent the inevitable loss of nipple projection [11–16]. This is 
in contrast to the limited number of studies analysing risk factors and complication 
rates after nipple reconstruction [13, 17].
It is prudent, however, to not only concentrate on preservation of nipple projec-
tion but also analyse and identify factors that predict poor outcome, as complica-
tions after nipple reconstruction can have devastating consequences for patients.
It is reasonable for the patient undergoing breast shape reconstruction to 
expect the same high standards of nipple-areolar reconstruction as the breast 
mound itself [18]. Hence it would be prudent to give the greatest consideration 
to the position of the new nipple-areola complex and to the symmetry on the 
other side. It is important to assert that nipple-areola reconstruction represents 
the final stage of breast reconstruction, whereby a reconstructed breast mound 
is transformed into a breast facsimile that more closely resembles the original 
breast. Shestak et al. in their salient review of Assessment of Long-Term Nipple 
Projection—A Comparison of Three Techniques, using either a bell flap, a modi-
fied star flap, or a skate flap and full-thickness skin graft for areola reconstruc-
tion; note that loss of nipple and areola projection was quite remarkable using 
the bell flap and hence would discourage its use in virtually all patients requiring 
nipple-areola reconstructions [19]. They find the other two techniques reviewed, 
i.e., modified star flap and skate flap with full-thickness skin graft for areolar 
reconstruction, to be more suitable in a variety of situations to maintain long term 
nipple projections [19].
The complexity and outcomes of the creation of a new nipple areola following 
cancer surgery is succinctly demonstrated by Sisti et al. [20] In their seminal review 
of literature, the authors having thoroughly analysed 75 papers published over 
69 years, and have observed that flaps have held the “test of time” in nipple recon-
structions. Overcorrection of nipple projection (up to 50%), in suitable patients, 
to prevent long term loss of nipple projection is an interesting observation in this 
review. In this context, being informed and sharing decision making with patients, 
helps patient empowerment and improves overall satisfaction. This concept could 
support future studies involving techniques, outcomes and influence patient 
confidence which would all further enhance patient safety.
This novel L-flap nipple reconstruction was devised and developed at Liverpool 
Breast Unit, to provide a viable and robust alternative to traditional flaps and 
keeping with patient’s expectations and interest. This technique seems a very useful 
resource considering several criteria it should fulfil to near match contralateral 
native nipple areolar complex or a previously reconstructed neo-nipple. Our clinical 
observation over the years of an unsatisfactory nipple position with traditional CV 
flap, in people with transversely placed mastectomy scar, has led us to develop this 
innovative L flap. The outcomes of PROMs (patient reported outcome measures), 
in addition to our clinical observation of a better and satisfactory nipple position 
achieved with L flap have supported our journey to develop this L flap.
Nipple projection L flap CV flap
Immediate post-op 4–5 mm (4.5 mm) 5–6 mm (5.5 mm)
6 months follow-up 3–5 mm (4 mm) 4–5 mm (4.5 mm)
24 months follow-up 2–4 mm (3 mm) 2–4 mm (3 mm)
Table 3. 
Comparison of nipple projection between two cohorts.
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All patients had undergone total mastectomy and had well healed transversely 
placed chest wall scars. Twelve patients (38.7%) were treated with chemotherapy 
(Adriamycin with or without Paclitaxel) and none of the 31 patients underwent 
external beam irradiation.
Intra-operatively, all patients underwent L-shaped flap nipple reconstruction 
with areolar skin graft from abdomen or contralateral breast, with technique as 
described above.
As depicted in Table 1; the incidence of any complications, including infec-
tion, discharge, pain, bleeding, partial or total nipple loss; as compared with 
traditional CV flap were similar and no statistically significant difference (Fisher’s 
exact test).
Table 2 summarises the patients’ undergoing L flap showed good cosmetic 
outcomes in comparison with patients’ undergoing CV flap in the same breast Unit 
during the same period of time as the study cohort.
Table 3 shows that nipple projection in the study cohort of L flap compared 
favourably with patients’ undergoing traditional CV flap, over 6 and 24 months.
6. Discussion
Nipple reconstruction and patient satisfaction outcomes study seem to be an 
area of very limited research and hence lack of evidence based scientific literature. 
While nipple reconstruction is considered a minor procedure, its profound implica-
tions on patient satisfaction after post-mastectomy breast reconstruction have been 
clearly demonstrated [9, 10].




P-value (Fisher’s exact test)
Superficial nipple tip necrosis 3 (10%) 6 (10%) P = 1.0
Cellulitis 2 (6%) 3 (5%) P = 1.0
Pain 2 (6%) 5 (8%) P = 1.0
Bleeding/haematoma 1 (3%) 3 (5%) P = 1.0
Partial nipple loss 2 (6%) 2 (3%) P = 0.60
Surgical revision 2 (6%) 3 (5%) P = 1.0
Table 1. 






Overall cosmetic outcome—satisfied/very satisfied 90% (n = 28) 86% (n = 51) P = 0.74
Wearing daily clothes—confident/very confident 81% (n = 25) 69% (n = 41) P = 0.32
Wearing swim clothes—confident/very confident 77% (n = 24) 63% (n = 37) P = 0.24
Wearing night clothes—confident/very confident 71% (n = 22) 63% (n = 37) P = 0.49




PROMs (patient reported outcome measures) in each of the techniques.
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A vast majority of contributions related to nipple reconstruction merely focus 
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in contrast to the limited number of studies analysing risk factors and complication 
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tion but also analyse and identify factors that predict poor outcome, as complica-
tions after nipple reconstruction can have devastating consequences for patients.
It is reasonable for the patient undergoing breast shape reconstruction to 
expect the same high standards of nipple-areolar reconstruction as the breast 
mound itself [18]. Hence it would be prudent to give the greatest consideration 
to the position of the new nipple-areola complex and to the symmetry on the 
other side. It is important to assert that nipple-areola reconstruction represents 
the final stage of breast reconstruction, whereby a reconstructed breast mound 
is transformed into a breast facsimile that more closely resembles the original 
breast. Shestak et al. in their salient review of Assessment of Long-Term Nipple 
Projection—A Comparison of Three Techniques, using either a bell flap, a modi-
fied star flap, or a skate flap and full-thickness skin graft for areola reconstruc-
tion; note that loss of nipple and areola projection was quite remarkable using 
the bell flap and hence would discourage its use in virtually all patients requiring 
nipple-areola reconstructions [19]. They find the other two techniques reviewed, 
i.e., modified star flap and skate flap with full-thickness skin graft for areolar 
reconstruction, to be more suitable in a variety of situations to maintain long term 
nipple projections [19].
The complexity and outcomes of the creation of a new nipple areola following 
cancer surgery is succinctly demonstrated by Sisti et al. [20] In their seminal review 
of literature, the authors having thoroughly analysed 75 papers published over 
69 years, and have observed that flaps have held the “test of time” in nipple recon-
structions. Overcorrection of nipple projection (up to 50%), in suitable patients, 
to prevent long term loss of nipple projection is an interesting observation in this 
review. In this context, being informed and sharing decision making with patients, 
helps patient empowerment and improves overall satisfaction. This concept could 
support future studies involving techniques, outcomes and influence patient 
confidence which would all further enhance patient safety.
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Breast Unit, to provide a viable and robust alternative to traditional flaps and 
keeping with patient’s expectations and interest. This technique seems a very useful 
resource considering several criteria it should fulfil to near match contralateral 
native nipple areolar complex or a previously reconstructed neo-nipple. Our clinical 
observation over the years of an unsatisfactory nipple position with traditional CV 
flap, in people with transversely placed mastectomy scar, has led us to develop this 
innovative L flap. The outcomes of PROMs (patient reported outcome measures), 
in addition to our clinical observation of a better and satisfactory nipple position 
achieved with L flap have supported our journey to develop this L flap.
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Our choice of creating neo-areola by means of a full-thickness graft has resulted 
in a better colour match and projection compared with other techniques, such as 
tattooing.
In this study we have noted complication rates in all our L-shaped flaps are not 
significantly different from the traditional and well established CV flap. There was 
no statistically significant difference in complication rates between both types of 
nipple reconstruction, although perceived clinical difference should be individually 
addressed. These outcomes support our nascent work of developing a technique to 
enhance patient satisfaction.
We acknowledge the study limitations being small population sizes and inter-
mediate follow up period. A larger group of patients and a longer follow up will help 
us draw conclusions, with particular attention to nipple projection. Analysing the 
patient feedback and reflecting on the overall outcomes, we are pleased that we have 
developed and presented a novel technique to enhance patient care and safety. This 
provides further stimulus to our on-going service improvement project keeping In 
line with modern National Health Services, “patient centred care”.
7. Conclusions
This novel design for nipple-areola complex reconstruction can be used in either 
primary or secondary nipple reconstruction. Of particular and distinct advantage is 
that all the scars are contained within the peripheral peri-areolar incision and thus 
can be completely camouflaged by an intra-dermal tattoo. Nipple projection has 
been consistently maintained and outcomes are reasonable and are similar to that 
of a CV flap. The creative use of patient’s own tissue expands the utility of the L flap 
beyond its current application in poorly placed transverse mastectomy scars.
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